

***ATTACHMENT 2:***  
***TECHNICAL SPECIFICATIONS***

## Adult BMI Assessment (ABA)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Added CPT codes 99341–99345, 99347–99350 to Table ABA-A.

Added ICD-9-CM Diagnosis codes 678, 679 to Table ABA-C.

#### Description

The percentage of members 18–74 years of age who had an outpatient visit and who had their body mass index (BMI) documented during the measurement year or the year prior the measurement year.

#### Definitions

<b>BMI</b>	Body mass index. A statistical measure of the weight of a person scaled according to height.
<b>BMI percentile</b>	The percentile ranking based on the Centers for Disease Control and Prevention's (CDC) BMI-for-age growth charts, which indicates the relative position of the patient's BMI number among those of the same sex and age.

#### Eligible Population

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	18 years as of January 1 of the year prior to the measurement year to 74 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year and the year prior to the measurement year.
<b>Allowable gap</b>	No more than one gap in continuous enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	None.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	Members who had an outpatient visit (Table ABA-A) during the measurement year or the year prior to the measurement year.

**Table ABA-A: Codes to Identify Outpatient Visits**

CPT	HCPCS	ICD-9-CM Diagnosis	UB Revenue
99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99385-99387, 99395-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456	G0344	V70.0, V70.3, V70.5, V70.6, V70.8, V70.9	051x, 0520-0523, 0526-0529, 077x, 0982, 0983

**Administrative Specification**

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	BMI (Table ABA-B) during the measurement year or year prior to the measurement year.

**Table ABA-B: Codes to Identify BMI**

HCPCS	ICD-9-CM Diagnosis
G8417-G8420	V85.0-V85.5

**Exclusions (optional)**

Members who have a diagnosis of pregnancy (Table ABA-C) during the measurement year or the year prior to the measurement year.

**Table ABA-C: Codes to Identify Exclusions**

Description	ICD-9-CM Diagnosis
Pregnancy	630-679, V22, V23, V28

**Hybrid Specification**

<b>Denominator</b>	A systematic sample drawn from the eligible population. The organization may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate. Refer to the <i>Guidelines for Calculations and Sampling</i> for information on reducing the sample size.
<b>Numerator</b>	BMI during the measurement year or year prior to the measurement year as documented through either administrative data or medical record review.
<b>Administrative</b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from the administrative data.
<b>Medical record</b>	Documentation in the medical record must indicate the date of the BMI and the BMI value.  For members younger than 19 years on the date of service, documentation of BMI percentile also meets criteria:  BMI percentile documented as a value (e.g., 85th percentile)  BMI percentile plotted on an age-growth chart.

---

## Exclusions (optional)

---

Refer to *Administrative Specification* for exclusion criteria. Exclusionary evidence in the medical record must include a note indicating a diagnosis of pregnancy. The diagnosis must have occurred during the measurement year or the year prior to the measurement year.

### Note

---

The following notations or examples of documentation are considered “negative findings” and do not count as numerator compliant.

*No BMI or BMI percentile documented in medical record or plotted on age-growth chart*

*Notation of height and weight only*

*BMI or BMI percentile noted before the look-back period or after the measurement year*

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table ABA-1/2/3: Data Elements for Adult BMI Assessment**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		✓
Current year’s administrative rate (before exclusions)		✓
Minimum required sample size (MRSS) or other sample size		✓
Oversampling rate		✓
Final sample size (FSS)		✓
Number of numerator events by administrative data in FSS		✓
Administrative rate on FSS		✓
Number of original sample records excluded because of valid data errors		✓
Number of administrative data records excluded		✓
Number of medical records excluded		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	✓	✓
Numerator events by medical records		✓
Reported rate	✓	✓
Lower 95% confidence interval	✓	✓
Upper 95% confidence interval	✓	✓

---

## Breast Cancer Screening (BCS)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

No changes to this measure.

#### Description

The percentage of women 40–69 years of age who had a mammogram to screen for breast cancer.

#### Eligible Population

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	Women 42–69 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year and the year prior to the measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage during each year of continuous enrollment.
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

#### Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	One or more mammograms during the measurement year or the year prior to the measurement year. A woman had a mammogram if a submitted claim/encounter contains any code in Table BCS-A.

**Table BCS-A: Codes to Identify Breast Cancer Screening**

CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure	UB Revenue
76090-76092, 77055-77057	G0202, G0204, G0206	V76.11, V76.12	87.36, 87.37	0401, 0403

---

## Exclusion (optional)

---

Women who had a bilateral mastectomy. Look for evidence of a bilateral mastectomy as far back as possible in the member's history through December 31 of the measurement year. Exclude members for whom there is evidence of two unilateral mastectomies. Refer to Table BCS-B for codes to identify exclusions.

**Table BCS-B: Codes to Identify Exclusions**

Description	CPT	ICD-9-CM Procedure
Bilateral mastectomy	19180, 19200, 19220, 19240, 19303-19307 <b>WITH</b> Modifier .50 or modifier code 09950*	85.42, 85.44, 85.46, 85.48
Unilateral mastectomy (members must have 2 separate occurrences on 2 different dates of service)	19180, 19200, 19220, 19240, 19303-19307	85.41, 85.43, 85.45, 85.47

\*.50 and 09950 modifier codes indicate the procedure was bilateral and performed during the same operative session.

## Note

---

*The purpose of this measure is to evaluate primary screening. Do not count biopsies, breast ultrasounds or MRIs for this measure because they are not appropriate methods for primary breast cancer screening.*

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table BCS-1/2/3: Data Elements for Breast Cancer Screening**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓

---

Current Procedural Terminology © 2009 American Medical Association. All rights reserved.

---

## Colorectal Cancer Screening (COL)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Lowered the upper age limit from 80 to 75 years of age.

Removed double contrast barium enema (DCBE) from the numerator criteria.

Clarified requirements for medical record documentation for the FOBT.

Deleted HCPCS code G0107 from Table COL-A.

Deleted LOINC code 50196-5 from Table COL-A "FOBT" description.

### Description

The percentage of members 50–75 years of age who had appropriate screening for colorectal cancer.

### Eligible Population

<b>Product lines</b>	Commercial, Medicare (report each product line separately).
<b>Ages</b>	51–75 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year and the year prior to the measurement year.
<b>Allowable gap</b>	No more than one gap in continuous enrollment of up to 45 days during each year of continuous enrollment.
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

### Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	One or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the following criteria. <ul style="list-style-type: none"><li>Fecal occult blood test (FOBT) during the measurement year. Regardless of FOBT type, guaiac (gFOBT) or immunochemical (iFOBT), assume that the required number of samples was returned.</li><li>Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year</li><li>Colonoscopy during the measurement year or the nine years prior to the measurement year</li></ul> A member had an appropriate screening if a submitted claim/encounter contains any code in Table COL-A.

**Table COL-A: Codes to Identify Colorectal Cancer Screening**

Description	CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure	LOINC
FOBT	82270, 82274	G0328, G0394	V76.51		2335-8, 12503-9, 12504-7, 14563-1, 14564-9, 14565-6, 27396-1, 27401-9, 27925-7, 27926-5, 29771-3
Flexible sigmoidoscopy	45330-45335, 45337-45342, 45345	G0104		45.24	
Colonoscopy	44388-44394, 44397, 45355, 45378-45387, 45391, 45392	G0105, G0121		45.22, 45.23, 45.25, 45.42, 45.43	

**Exclusion (optional)**

Members with a diagnosis of colorectal cancer or total colectomy. Look for evidence of colorectal cancer or total colectomy as far back as possible in the member's history. Refer to Table COL-B for codes to identify exclusions.

**Table COL-B: Codes to Identify Exclusions**

Description	CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure
Colorectal cancer		G0213-G0215, G0231	153, 154.0, 154.1, 197.5, V10.05	
Total colectomy	44150-44153, 44155-44158, 44210-44212			45.8

**Hybrid Specification**

**Denominator** A systematic sample drawn from the eligible population for each product line. The organization may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate. Refer to the *Guidelines for Calculations and Sampling* for information on reducing the sample size.

**Numerator** One or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the following criteria.

FOBT during the measurement year

Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year

Colonoscopy during the measurement year or the nine years prior to the measurement year

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from the administrative data.



---

**Medical record** Documentation in the medical record must include a note indicating the date the colorectal cancer screening was performed. A result is not required if the documentation is clearly part of the “medical history” section of the record. If it is unclear whether the documentation is part of the medical history, then the result or finding must also be present (this ensures that the screening was performed and not merely ordered).

There are two types of FOBT tests: guaiac (gFOBT) and immunochemical (iFOBT). Depending on the type of FOBT test, a certain number of samples are required for numerator compliance. Follow the instructions below to determine member compliance.

If the medical record does not indicate the type of test and there is no indication as to how many samples were returned, assume the required number was returned. The member meets the screening criteria for inclusion in the numerator.

If the medical record does not indicate the type of test and the number of returned samples is specified, the member would only meet the screening criteria if the number of samples specified is greater than or equal to three samples. If the number of samples is less than three, the member does not meet the screening criteria for inclusion in the numerator.

iFOBT tests may require fewer than three samples. If the medical record indicates that an iFOBT was done, the member meets the screening criteria for inclusion in the numerator regardless of the number of returned samples.

If the medical record indicates that a gFOBT was done, follow the scenarios below.

*If the medical record does not indicate the number of returned samples, assume the required number was returned. The member meets the screening criteria for inclusion in the numerator.*

*If the medical record indicates that three or more samples were returned, the member meets the screening criteria for inclusion in the numerator.*

*If the medical record indicates that fewer than three samples were returned, the member does not meet the screening criteria.*

Do not count *digital rectal exam* as evidence of a colorectal screening because it is not specific or comprehensive enough to screen for colorectal cancer.

### **Exclusion (optional)**

---

Refer to *Administrative Specification* for exclusion criteria. Exclusionary evidence in the medical record must include a note indicating a diagnosis of colorectal cancer or total colectomy. The diagnosis must have occurred by December 31 of the measurement year. Use the codes in Table COL-B as synonyms for a diagnosis of colorectal cancer or total colectomy.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table COL-2/3: Data Elements for Colorectal Cancer Screening**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		✓
Current year's administrative rate (before exclusions)		✓
Minimum required sample size (MRSS) or other sample size		✓
Oversampling rate		✓
Final sample size (FSS)		✓
Number of numerator events by administrative data in FSS		✓
Administrative rate on FSS		✓
Number of original sample records excluded because of valid data errors		✓
Number of administrative data records excluded		✓
Number of medical records excluded		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	✓	✓
Numerator events by medical records		✓
Reported rate	✓	✓
Lower 95% confidence interval	✓	✓
Upper 95% confidence interval	✓	✓

---

# Glaucoma Screening in Older Adults (GSO)

---

## SUMMARY OF CHANGES TO HEDIS 2010

---

No changes to this measure.

### Description

The percentage of Medicare members 65 years and older, without a prior diagnosis of glaucoma or glaucoma suspect, who received a glaucoma eye exam by an eye care professional for early identification of glaucomatous conditions.

### Eligible Population

<b>Product line</b>	Medicare.
<b>Age</b>	67 years and older as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year and the year prior to the measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment.
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

### Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	One or more eye exams for glaucoma by an eye care professional (i.e., ophthalmologist, optometrist) during the measurement year or the year prior to the measurement year. A member is considered to have had an eye exam for glaucoma if a submitted claim/encounter contains any code in Table GSO-A.

**Table GSO-A: Codes to Identify Glaucoma Screening Eye Exams**

CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure
92002, 92004, 92012, 92014, 92081-92083, 92135, 92140, 99202-99205, 99213-99215, 99242-99245	G0117, G0118, S0620, S0621	V80.1	95.02, 95.03, 95.26

---

## Exclusion (optional)

---

Members who had a prior diagnosis of glaucoma or glaucoma suspect. Look for evidence of glaucoma as far back as possible in the member's history through December 31 of the measurement year. Refer to Table GSO-B for codes to identify exclusions.

**Table GSO-B: Codes to Identify Exclusions**

Description	ICD-9-CM Diagnosis
Glaucoma suspect	365.0
Glaucoma	365.1-365.9

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table GSO-3: Data Elements for Glaucoma Screening in Older Adults**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓

---

## Care for Older Adults (COA)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Added HCPCS G8427, G8428 to Table COA-C.

Clarified that a complete physical functional status assessment is required.

Clarified that a comprehensive pain assessment is required.

#### Description

The percentage of adults 65 years and older who had each of the following during the measurement year.

Advance care planning

Medication review

Functional status assessment

Pain screening

#### Definitions

**Medication list** A list of the member's medications in the medical record, which may include prescriptions, over-the-counter (OTC) medications and herbal or supplemental therapies.

**Medication review** A review of all a member's medications, including prescription medications, OTC medications and herbal or supplemental therapies.

#### Eligible Population

**Product line** Medicare SNP.

**Ages** 66 years and older as of December 31 of the measurement year.

**Continuous enrollment** The measurement year.

**Allowable gap** No more than one gap in continuous enrollment of up to 45 days during the measurement year.

**Anchor date** December 31 of the measurement year.

**Benefit** Medical.

**Event/diagnosis** None.

#### Administrative Specification

**Denominator** The eligible population.

**Numerators**

**Advance care planning** Evidence of advance care planning during the measurement year (Table COA-A).

---

**Table COA-A: Codes to Identify Advance Care Planning**

Description	CPT Category II	HCPCS
Advance care planning	1157F, 1158F	S0257

**Medication review** At least one medication review (Table COA-B) conducted by a prescribing practitioner or clinical pharmacist during the measurement year and the presence of a medication list in the medical record (Table COA-C), as documented through administrative data.

The claim/encounter for a member's medication review and medication list must be on the same date of service.

**Table COA-B: Codes to Identify Medication Review**

Description	CPT	CPT Category II	HCPCS*
Medication review	90862, 99605, 99606	1160F	G8427, G8428

**Table COA-C: Code to Identify Medication List**

Description	CPT Category II	HCPCS*
Medication list	1159F	G8427, G8428

\*The HCPCS codes meet criteria for both medication review and medication list.

**Functional status assessment** At least one functional status assessment during the measurement year (Table COA-D).

**Table COA-D: Codes to Identify Functional Status Assessment**

Description	CPT Category II	ICD-9-CM Procedure
Functional status assessment	1170F	
Functional evaluation		93.01

**Pain screening** At least one pain screening or pain management plan during the measurement year. A member had a pain screening if a submitted claim/encounter contains any code in Table COA-E.

**Table COA-E: Codes to Identify Pain Screening**

Description	CPT Category II
Pain screening	0521F, 1125F, 1126F

---

## Hybrid Specification

**Denominator** A systematic sample drawn from the eligible population. The organization may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate. Refer to the *Guidelines for Calculations and Sampling* for information on reducing the sample size.

### Numerators

**Advance care Planning** Evidence of advance care planning as documented through either administrative data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** **Advanced care planning** is a discussion about preferences for resuscitation, life-sustaining treatment and end of life care. Evidence of advance care planning must include either:

The presence of an advanced care plan in the medical record, **or**

Documentation of an advance care planning discussion with the provider *and* the date on which it was discussed. The documentation of discussion must be notated in the measurement year. Notation that the member has previously executed an advance care plan meets criteria.

Examples of advance care plans include:

**Advance directives.** Directives pertaining to treatment preferences and the designation of a surrogate decision maker in the event that a person should become unable to make medical decisions on their own behalf. (e.g., living will, power of attorney, health care proxy).

**Actionable medical orders.** Written instructions regarding initiation, continuation, withholding or withdrawal of particular forms of life-sustaining treatment.

**Living wills.** Legal documents denoting preferences for life-sustaining treatment and end-of-life care.

**Surrogate decision maker.** A written document designating someone else to make future medical treatment choices.

Examples of an advance care planning discussion include either:

Notation in the medical record of a discussion with a provider or the initiation of a discussion by a provider during the measurement year, **or**

**Oral statements.** Conversations with relatives or friends about life-sustaining treatment and end-of-life care, documented in the medical record. Patient designation of an individual who can make decisions on their behalf. Evidence of oral statements must be noted in the medical record during the measurement year.

**Medication Review** At least one medication review conducted by a prescribing practitioner or clinical pharmacist during the measurement year and the presence of a medication list in the medical record, as documented through either administrative data or medical record review.

---

<b><u>Administrative</u></b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from administrative data.
<b><u>Medical record</u></b>	Documentation must come from the same medical record and must include the following. <p style="margin-left: 40px;">A medication list in the medical record, <b>and</b> evidence of a medication review by a prescribing practitioner or clinical pharmacist and the date on which it was performed</p> <p style="margin-left: 40px;">Notation that the member is not taking any medication and the date on which it was noted</p> <p>A review of side effects for a single medication at the time of prescription alone is not sufficient.</p> <p>An outpatient visit is not required to meet criteria.</p>
<b><i>Functional Status Assessment</i></b>	At least one functional status assessment during the measurement year, as documented through either administrative data or medical record review.
<b><u>Administrative</u></b>	Refer to <i>Administrative Specification</i> to identify positive numerator hits from administrative data.
<b><u>Medical record</u></b>	Documentation in the medical record must include evidence of a complete physical functional status assessment and the date on which it was performed. <p>Notations for a complete physical functional status assessment may include the following.</p> <ul style="list-style-type: none"> <li>Functional independence</li> <li>Loss of independent performance, Activities of Daily Living (ADL), social activities, or Instrumental Activities of Daily Living (IADL)</li> <li>The level of assistance needed to accomplish daily activities</li> <li>Result of assessment using a standardized functional status assessment tool, not limited to: <ul style="list-style-type: none"> <li>SF-36®</li> <li>ADL list</li> <li>Assessment of Living Skills and Resources (ALSAR)</li> <li>Barthel ADL Index Physical Self-Maintenance (ADLS) Scale</li> <li>Bayer Activities of Daily Living (B-ADL) Scale</li> <li>Barthel Index</li> <li>Extended Activities of Daily Living (EADL) Scale</li> <li>Independent Living Scale (ILS)</li> <li>Katz Index of Independence in Activities of Daily Living</li> <li>Kenny Self-Care Evaluation</li> <li>Klein-Bell Activities of Daily Living Scale</li> <li>Kohlman Evaluation of Living Skills (KELS)</li> <li>Lawton &amp; Brody's IADL scales</li> </ul> </li> </ul>
<b><i>Pain Screening</i></b>	At least one pain screening or a pain management plan during the measurement year, as documented through either administrative data or medical record review.

---



---

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** Documentation in the medical record must include evidence of a comprehensive pain screening or a pain management plan and the date on which it was performed. Evidence of a comprehensive pain screening may include the following.

Notation of a comprehensive pain assessment. Pain assessment associated with an acute event (e.g., toothache, earache, localized pain from trauma) does not meet criteria for a comprehensive pain assessment.

Results of a screening using a standardized pain screening tool, as in but not limited to:

Multidimensional Pain Inventory

Faces Pain Scale

0–10 Numeric Rating Scales, verbal or visual

Verbal Descriptor Scale

Brief Pain Inventory (Short Form)

Evidence of a pain management plan may include the following.

Notation of no pain intervention and the rationale

Notation of plan for treatment of pain, which may include use of pain medications, psychological support and patient/family education

Notation of plan for reassessment of pain, including reassessment time interval

**Note**

---

Refer to *Appendix 3* for the definition of clinical pharmacist.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table COA-3: Data Elements for Care for Older Adults**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		<i>Each of the 4 rates</i>
Current year's administrative rate (before exclusions)		<i>Each of the 4 rates</i>
Minimum required sample size (MRSS) or other sample size		✓
Oversampling rate		✓
Final sample size (FSS)		✓
Number of numerator events by administrative data in FSS		<i>Each of the 4 rates</i>
Administrative rate on FSS		<i>Each of the 4 rates</i>
Number of original sample records excluded because of valid data errors		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	<i>Each of the 4 rates</i>	<i>Each of the 4 rates</i>
Numerator events by medical records		<i>Each of the 4 rates</i>
Reported rate	<i>Each of the 4 rates</i>	<i>Each of the 4 rates</i>
Lower 95% confidence interval	<i>Each of the 4 rates</i>	<i>Each of the 4 rates</i>
Upper 95% confidence interval	<i>Each of the 4 rates</i>	<i>Each of the 4 rates</i>

---

## ***Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

The percentage of members 40 years of age and older with a new diagnosis or newly active COPD who received appropriate spirometry testing to confirm the diagnosis.

#### **Definitions**

<b>Intake Period</b>	A 12-month window that begins on July 1 of the year prior to the measurement year and ends on June 30 of the measurement year. The Intake Period captures the first COPD diagnosis.
<b>IESD</b>	Index Episode Start Date. The earliest date of service for any encounter during the Intake Period with any diagnosis of COPD (Table SPR-A).  <i>For an outpatient claim/encounter, the IESD is the date of service.</i>  <i>For an inpatient (acute or nonacute) claim/encounter, the IESD is the date of discharge.</i>  <i>For a transfer or readmission, the IESD is the discharge date of the original admission.</i>
<b>Negative Diagnosis History</b>	A period of 730 days (2 years) prior to the IESD (inclusive), during which the member had no claims/encounters containing any diagnosis of COPD (Table SPR-A). For an <i>inpatient (acute or nonacute) IESD</i> , use the date of admission to determine the Negative Diagnosis History.

#### **Eligible Population**

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	42 years or older as of December 31 of the measurement year.
<b>Continuous enrollment</b>	730 days (2 years) prior to the IESD through 180 days after the IESD.
<b>Allowable gap</b>	One gap in enrollment of up to 45 days is allowed in each of the 12-month periods prior to the IESD or in the 6-month period after the IESD, for a maximum of two gaps total. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	IESD.
<b>Benefit</b>	Medical.

**Event/ diagnosis** The first COPD diagnosis. Follow the steps below to identify the eligible population for the measure.

**Step 1** Identify all members who had any diagnosis of COPD (Table SPR-A) during the Intake Period. If the member had more than one diagnosis of COPD, include only the first one.

**Table SPR-A: Codes to Identify COPD**

Description	ICD-9-CM Diagnosis
Chronic bronchitis	491
Emphysema	492
COPD	496

**Step 2** Test for Negative Diagnosis History. Exclude members who had a claim/encounter with a COPD diagnosis during the 730 days (2 years) prior to the IESD. For an inpatient (acute or nonacute) IESD, use the date of admission to determine the Negative Diagnosis History.

**Step 3** Calculate continuous enrollment. Members must be continuously enrolled in the organization 730 days (2 years) prior to the IESD through 180 days after the IESD.

### Administrative Specification

**Denominator** The eligible population.

**Numerator** At least one claim/encounter with any code listed in Table SPR-B for spirometry in the 730 days (2 years) before the IESD to 180 days after the IESD.

**Table SPR-B: Codes to Identify Spirometry Testing**

Description	CPT
Spirometry	94010, 94014-94016, 94060, 94070, 94375, 94620

### Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table SPR-1/2/3: Data Elements for Use of Spirometry Testing in the Assessment and Diagnosis of COPD**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓

---

## Pharmacotherapy Management of COPD Exacerbation (PCE)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Clarified in Step 2 that for ED visits resulting in an inpatient stay only the inpatient stay should be included.

Clarified that an ED visit for any diagnosis on or seven days after the Episode Date should be excluded in step 4.

### Description

The percentage of COPD exacerbations for members 40 years of age and older who had an acute inpatient discharge or ED encounter between January 1–November 30 of the measurement year and who were dispensed appropriate medications. Two rates are reported.

1. Dispensed a systemic corticosteroid within 14 days of the event
2. Dispensed a bronchodilator within 30 days of the event

**Note:** *The eligible population for this measure is based on acute inpatient discharges and ED visits, not on members. It is possible for the denominator to include multiple events for the same individual.*

### Definitions

<b>Intake Period</b>	An 11-month period that begins on January 1 of the measurement year and ends on November 30 of the measurement year. The Intake Period captures eligible episodes of treatment.
<b>Episode Date</b>	The date of service for any acute inpatient discharge or ED claim/encounter during the Intake Period with a principal diagnosis of COPD.  <i>For an acute inpatient claim/encounter, the Episode Date is the date of discharge.</i>  <i>For an ED claim/encounter, the Episode Date is the date of service.</i>
<b>Active prescription</b>	A prescription is considered active if the “days supply” indicated on the date the member filled the prescription is the number of days or more between that date and the relevant Episode Date.

### Eligible Population

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	40 years or older as of January 1 of the measurement year.
<b>Continuous enrollment</b>	Episode Date through 30 days after the Episode Date.
<b>Allowable gap</b>	None.
<b>Anchor date</b>	Episode Date.
<b>Benefits</b>	Medical and pharmacy.

---

Current Procedural Terminology © 2009 American Medical Association. All rights reserved.

**Event/  
diagnosis** A COPD exacerbation as indicated by an acute inpatient discharge or ED encounter with a principal diagnosis of COPD.

Follow the steps below to identify the eligible population.

**Step 1** Identify all members who during the Intake Period had an acute inpatient discharge or an ED visit with a primary diagnosis of COPD (Table PCE-A). Use Table PCE-B to identify acute inpatient discharges and ED visits.

**Table PCE-A: Codes to Identify COPD**

Description	ICD-9-CM Diagnosis
Chronic bronchitis	491
Emphysema	492
COPD	496

**Table PCE-B: Codes to Identify Visit Type**

Description	CPT	UB Revenue
Acute inpatient		010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x-022x, 072x, 0987
ED*	99281-99285	045x, 0981

\*Do not include ED visits that result in an inpatient admission.

**Step 2** Determine all COPD Episode Dates. For each member identified in step 1, identify all acute inpatient discharges and ED visits. Do not include ED visits that result in an inpatient admission.

**Step 3** Test for transfers. Exclude Episode Dates on which the member was transferred directly to an acute or nonacute care facility for any diagnosis.

**Step 4** Test for readmission and additional ED visits. Exclude Episode Dates for which the member was readmitted to an acute or nonacute care facility for any diagnosis on or within seven days after the Episode Date. Exclude Episode Dates for which the member had an ED visit for any diagnosis on or seven days after the Episode Date.

**Step 5** Calculate continuous enrollment. The member must be continuously enrolled without any gaps in coverage from the Episode Date through 30 days after the Episode Date.

**Note:** All Episode Dates that were not excluded should remain in the denominator. The denominator for this measure is based on acute inpatient discharges and ED visits, not members.

## Administrative Specification

**Denominator** The eligible population.

### Numerators

**Systemic corticosteroid** Dispensed prescription for systemic corticosteroid (Table PCE-C) on or 14 days after the Episode Date. The organization may count systemic corticosteroids that are active on the Episode Date.

**Table PCE-C: Systemic Corticosteroids**

Description	Prescription			
Glucocorticoids	betamethasone	hydrocortisone	prednisolone	triamcinolone
	dexamethasone	methylprednisolone	prednisone	

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

**Bronchodilator** Dispensed prescription for a bronchodilator (Table PCE-D) on or 30 days after the Episode Date. The organization may count bronchodilators that are active on the Episode Date.

**Table PCE-D: Bronchodilators**

Description	Prescription		
Anticholinergic agents	albuterol-ipratropium	ipratropium	tiotropium
Beta 2-agonists	albuterol	fluticasone-salmeterol	metaproterenol
	arformoterol	formoterol	pirbuterol
	budesonide-formoterol	levalbuterol	salmeterol
Methylxanthines	dyphylline-guaifenesin	aminophylline	
	guaifenesin-theophylline	dyphylline	
	potassium iodide-theophylline	theophylline	

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table PCE-1/2/3: Data Elements for Pharmacotherapy Management of COPD Exacerbation**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Exclusions based on direct transfers to another facility*	✓
Exclusions based on readmissions*	✓
Numerator events by administrative data	Each of the 2 rates
Reported rate	Each of the 2 rates
Lower 95% confidence interval	Each of the 2 rates
Upper 95% confidence interval	Each of the 2 rates

\*Reporting this additional data element is optional in IDSS.

---

## ***Cholesterol Management for Patients With Cardiovascular Conditions (CMC)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Clarified that a calculated or direct LDL may be used for LDL-C screening and control.

Deleted CPT codes 99261–99263 from Table CMC-C.

Deleted LOINC code 24331-1 from Table CMC-D.

#### **Description**

The percentage of members 18–75 years of age who were discharged alive for AMI, coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to measurement year, who had each of the following during the measurement year.

LDL-C screening

LDL-C control (<100 mg/dL)

#### **Eligible Population**

**Product lines** Commercial, Medicaid, Medicare (report each product line separately).

**Ages** 18–75 years as of December 31 of the measurement year.

**Continuous enrollment** The measurement year and the year prior to the measurement year.

**Allowable gap** No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

**Anchor date** December 31 of the measurement year.

**Benefit** Medical.

**Event/diagnosis** Members are identified for the eligible population in two ways: by event or by diagnosis. The organization must use *both* to identify the eligible population, but a member only needs to be identified in one to be included in the measure.

*Event.* Discharged alive for AMI, CABG or PTCA on or between January 1 and November 1 of the year prior to the measurement year. Refer to Table CMC-A for codes to identify AMI, PTCA and CABG. The organization should include AMI and CABG from inpatient claims/encounters only. All cases of PTCA should be included, regardless of setting (e.g., inpatient, outpatient, ED).



**Table CMC-A: Codes to Identify AMI, PTCA and CABG**

Description	CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure
AMI (include only inpatient claims)			410.x1	
CABG (include only inpatient claims)	33510-33514, 33516-33519, 33521-33523, 33533-33536	S2205-S2209		36.1, 36.2
PTCA	33140, 92980, 92982, 92995			00.66, 36.06, 36.07, 36.09

*Diagnosis.* Identify members as having IVD who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across both years.

At least one outpatient visit (Table CMC-C) with any IVD diagnosis (Table CMC-B), **or**

At least one acute inpatient claim/encounter (Table CMC-C) with any IVD diagnosis (Table CMC-B)

**Table CMC-B: Codes to Identify IVD**

Description	ICD-9-CM Diagnosis
IVD	411, 413, 414.0, 414.2, 414.8, 414.9, 429.2, 433-434, 440.1, 440.2, 440.4, 444, 445

**Table CMC-C: Codes to Identify Visit Type**

Description	CPT	UB Revenue
Outpatient	99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456	051x, 0520-0523, 0526-0529, 057x-059x, 077x, 0982, 0983
Acute inpatient	99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291	010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x-022x, 072x, 0987

**Administrative Specification**

**Denominator** The eligible population.

**Numerators**

**LDL-C Screening** An LDL-C test performed any time during the measurement year, as identified by claim/encounter or automated laboratory data. Use any code listed in Table CMC-D.

The organization may use a calculated or direct LDL for LDL-C screening and control indicators.

**Table CMC-D: Codes to Identify LDL-C Screening**

CPT	CPT Category II	LOINC
80061, 83700, 83701, 83704, 83721	3048F, 3049F, 3050F	2089-1, 12773-8, 13457-7, 18261-8, 18262-6, 22748-8, 39469-2, 49132-4

---

**LDL-C Level <100 mg/dL** Using automated laboratory data, the member is numerator compliant if the most recent LDL-C level during the measurement year is <100 mg/dL. The member is noncompliant if the automated result for the most recent LDL-C test is ≥100 mg/dL or is missing, or if an LDL-C test was not done during the measurement year.

An organization that uses CPT Category II codes to identify numerator compliance for this indicator must search for all codes in Table CDC-I and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

## Hybrid Specification

**Denominator** A systematic sample drawn from the eligible population for each product line. The organization may reduce its sample size using the current year's lowest administrative rate or the prior year's audited, product line-specific results for the two rates. Refer to the *Guidelines for Calculations and Sampling* for information about sampling.

### Numerators

**LDL-C Screening** An LDL-C test performed during the measurement year as determined by administrative data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** Documentation in medical record must include, at a minimum, a note indicating the date on which the LDL-C test was performed and the result.

The organization may use a calculated LDL for LDL-C screening and control indicators.

**LDL-C Level <100 mg/dL** The *most recent* LDL-C level performed during the measurement year is <100 mg/dL, as documented through automatic laboratory data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from the administrative data.

**Medical record** Documentation in medical record must include, at a minimum, a note indicating the date on which the LDL-C test was performed and the result.

The organization may calculate LDL-C levels from total cholesterol, HDL-C and triglycerides using the Friedewald equation if the triglycerides are ≤400 mg/dL.

$$(\text{LDL-C}) = (\text{total cholesterol}) - (\text{HDL}) - (\text{triglycerides}/5)$$

If lipoprotein (a) is measured, this calculation is:

$$(\text{LDL-C}) = (\text{total cholesterol}) - (\text{HDL}) - (\text{triglycerides}/5) - 0.3[\text{lipoprotein (a)}]$$

These formulae are used when all levels are expressed in mg/dL and cannot be used if triglycerides are >400 mg/dL.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CMC-1/2/3: Data Elements for Cholesterol Management for Patients With Cardiovascular Conditions**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		<i>Each of the 2 rates</i>
Current year's administrative rate (before exclusions)		<i>Each of the 2 rates</i>
Minimum required sample size (MRSS) or other sample size		✓
Oversampling rate		✓
Final sample size (FSS)		✓
Number of numerator events by administrative data in FSS		<i>Each of the 2 rates</i>
Administrative rate on FSS		<i>Each of the 2 rates</i>
Number of original sample records excluded because of valid data errors		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	<i>Each of the 2 rates</i>	<i>Each of the 2 rates</i>
Numerator events by medical records		<i>Each of the 2 rates</i>
Reported rate	<i>Each of the 2 rates</i>	<i>Each of the 2 rates</i>
Lower 95% confidence interval	<i>Each of the 2 rates</i>	<i>Each of the 2 rates</i>
Upper 95% confidence interval	<i>Each of the 2 rates</i>	<i>Each of the 2 rates</i>

---

## Controlling High Blood Pressure (CBP)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Clarified that member-reported BP readings are not acceptable.

Added CPT codes 90957–90962, 90965, 90966, 90969, 90970 to Table CBP-C “Evidence of ESRD” description.

Added ICD-9-CM Diagnosis codes 678, 679 to Table CBP-C “Pregnancy” description.

Deleted CPT code 90939 from Table CBP-C.

### Description

The percentage of members 18–85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90) during the measurement year. Use the Hybrid Method for this measure.

### Definitions

<b>Adequate control</b>	Both a representative systolic BP <140 mm Hg and a representative diastolic BP <90 mm Hg (BP in the normal or high-normal range).
<b>Representative BP</b>	The most recent BP reading during the measurement year (as long as it occurred after the diagnosis of hypertension was made). If multiple BP measurements occur on the same date or are notated in the chart on the same date, the lowest systolic and lowest diastolic BP reading should be used. If no BP is recorded during the measurement year, assume that the member is “not controlled.”

### Eligible Population

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	18–85 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in continuous enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a one-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	<i>Hypertensive</i> . A member is considered hypertensive if there is at least one outpatient encounter (Table CBP-B) with a diagnosis of hypertension (Table CBP-A) during the first six months of the measurement year.

**Table CBP-A: Codes to Identify Hypertension**

Description	ICD-9-CM Diagnosis
Hypertension	401

**Table CBP-B: Codes to Identify Outpatient Visits**

Description	CPT
Outpatient visits	99201-99205, 99211-99215, 99241-99245, 99384-99387, 99394-99397

## Hybrid Specification

**Denominator** A systematic sample drawn from the eligible population for each product line whose diagnosis of hypertension is confirmed by chart review. The organization may reduce the sample size using the prior year's audited, product line-specific rate. Refer to the *Guidelines for Calculations and Sampling* for information on reducing the sample size.

To confirm the diagnosis of hypertension, the organization must find notation of one of the following in the medical record on or before June 30 of the measurement year.

HTN	History of HTN
High BP (HBP)	Hypertensive vascular disease (HVD)
Elevated BP (↑BP)	Hyperpiesia
Borderline HTN	Hyperpiesis
Intermittent HTN	

The notation of hypertension may appear anytime on or before June 30 of the measurement year, including prior to the measurement year. It does not matter if hypertension was treated or is currently being treated. The notation indicating a diagnosis of hypertension may be recorded in any of the following documents.

Problem list (this may include a diagnosis prior to June 30 of the measurement year or an undated diagnosis; see **Note** at the end of this section)

Office note

Subjective, Objective, Assessment, Plan (SOAP) note

Encounter form

Telephone call record

Diagnostic report

Hospital discharge summary

Statements such as “rule out HTN,” “possible HTN,” “white-coat HTN,” “questionable HTN” and “consistent with HTN” are not sufficient to confirm the diagnosis if such statements are the *only* notations of hypertension in the medical record.

---

**Identifying the medical record**

The organization should use only the medical records of one practitioner or provider team for both the confirmation of the diagnosis of hypertension and the representative BP. All eligible BP measurements recorded in the records from one practitioner or provider team (even if obtained by a different practitioner) should be considered (e.g., from a consultation note or other note relating to a BP reading from a health care practitioner or provider team). If the organization cannot find the medical record, the member remains in the measure denominator and is considered noncompliant for the numerator.

The organization should use the following algorithm to find the appropriate medical record to review.

**Step 1** Identify the member's primary care practitioner (PCP).

If the member had more than one PCP for the time period, identify the PCP who most recently provided care to the member

If the member did not visit a PCP for the time period or does not have a PCP, identify the practitioner who most recently provided care to the member

If a practitioner other than the member's PCP manages the hypertension, the organization may use the medical record of that practitioner, instead

**Step 2** Use one medical record to both confirm the diagnosis for the denominator and identify the representative BP level for the numerator. There are circumstances in which the organization may need to go to a second medical record to either confirm the diagnosis or obtain the BP reading, as in the following two examples.

*If a member sees one PCP during the denominator confirmation period (on or before June 30 of the measurement year) and another PCP after June 30, the diagnosis of hypertension and BP reading may be identified through two different medical records.*

*If a member has the same PCP for the entire measurement year, but it is clear from claims or medical record data that a specialist (e.g., cardiologist) manages the member's hypertension after June 30, the organization may use the PCP's chart to confirm the diagnosis and use the specialist's chart to obtain the BP reading. For example, if all recent claims coded with 401 came from the specialist, the organization may elect to use this chart for the most recent BP reading. If the member did not have any visits with the specialist prior to June 30 of the measurement year, the organization must go to another medical record to confirm the diagnosis.*

**Numerator**

The number of members in the denominator whose most recent BP is adequately controlled during the measurement year. For a member's BP to be controlled, *both* the systolic and diastolic BP *must be* <140/90 (adequate control). To determine if a member's BP is adequately controlled, the organization must identify the representative BP.

**Administrative**

None.

**Medical record**

Follow the steps below to determine representative BP.

**Step 1** Identify the most recent BP reading noted during the measurement year. The reading must occur after the date on which the diagnosis of hypertension was made or confirmed. Do not include BP readings that meet the following criteria.

BPs taken during an acute inpatient stay or an ED visit

BPs taken during an outpatient visit which was for the sole purpose of having a diagnostic test or surgical procedure performed (e.g., sigmoidoscopy, removal of a mole)

BPs obtained the same day as a major diagnostic or surgical procedure (e.g., stress test, administration of IV contrast for a radiology procedure, endoscopy)

BP readings reported by or taken by the member

**Step 2** Identify the lowest systolic and lowest diastolic BP reading from the most recent BP notation in the medical record. If multiple readings were recorded for a single date, use the lowest systolic and lowest diastolic BP on that date as the representative BP. The systolic and diastolic results do not need to be from the same reading.

### Exclusions (optional)

Exclude from the eligible population all members with evidence of end-stage renal disease (ESRD) (Table CBP-C) on or prior to December 31 of the measurement year. Documentation in the medical record must include a dated note indicating evidence of ESRD. Documentation of dialysis or renal transplant also meets the criteria for evidence of ESRD.

Exclude from the eligible population all members with a diagnosis of pregnancy (Table CBP-C) during the measurement year.

Exclude from the eligible population all members who had an admission to a nonacute inpatient setting any time during the measurement year. Refer to Table FUH-B for codes to identify nonacute care.

**Table CBP-C: Codes to Identify Exclusions**

Description	CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure	UB Revenue	UB Type of Bill	POS
Evidence of ESRD	36145, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90920, 90921, 90924, 90925, 90935, 90937, 90940, 90945, 90947, 90957-90962, 90965, 90966, 90969, 90970, 90989, 90993, 90997, 90999, 99512	G0257, G0308-G0319, G0322, G0323, G0326, G0327, G0392, G0393, S9339	585.5, 585.6, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6	0367, 080x, 082x-085x, 088x	72x	65
Pregnancy			630-679, V22, V23, V28				

### Note

*The organization may use an undated notation of hypertension on problem lists. Problem lists generally indicate established conditions; to discount undated entries might hinder confirmation of the denominator.*

*Organizations generally require an oversample of 10 percent–15 percent to meet the MRSS for confirmed cases of hypertension.*

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CBP-1/2/3: Data Elements for Controlling High Blood Pressure**

	Hybrid
Measurement year	✓
Data collection methodology (Hybrid)	✓
Eligible population	✓
Number of numerator events by administrative data in eligible population (before exclusions)	✓
Current year's administrative rate (before exclusions)	✓
Minimum required sample size (MRSS) or other sample size	✓
Oversampling rate	✓
Final sample size (FSS)	✓
Number of numerator events by administrative data in FSS	✓
Administrative rate on FSS	✓
Number of original sample records excluded because of valid data errors	✓
Number of records excluded because of false-positive diagnoses	✓
Number of administrative data records excluded	✓
Number of medical record data records excluded	✓
Number of employee/dependent medical records excluded	✓
Records added from the oversample list	✓
Denominator	✓
Numerator events by administrative data	✓
Numerator events by medical records	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓



---

## ***Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged alive from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

#### **Definition**

**Treatment days (covered days)** The actual number of calendar days covered with prescriptions within the specified 180-day measurement interval (i.e., a prescription of 90 days supply dispensed on the 100th day will have 80 days counted in the 180-day interval).

#### **Eligible Population**

**Product lines** Commercial, Medicaid, Medicare (report each product line separately).

**Ages** 18 years and older as of December 31 of the measurement year.

**Continuous enrollment** Discharge date through 180 days after discharge.

**Allowable gap** No more than one gap in enrollment of up to 45 days within the 180 days of the event. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not continuously enrolled).

**Anchor date** Discharge date.

**Benefit** Medical and pharmacy.

**Event/diagnosis** Discharged alive from an acute inpatient setting with an AMI (Table PBH-A) from July 1 of the year prior to the measurement year through June 30 of the measurement year.

If a member has more than one episode of AMI from July 1 of the year prior to the measurement year through June 30 of the measurement year, the organization should only include the first discharge.

**Table PBH-A: Codes to Identify AMI**

<b>Description</b>	<b>ICD-9-CM Diagnosis</b>
AMI	410.x1*

\*An organization that does not have fifth-digit specificity must develop a methodology to ensure that only the first eligible episode of an AMI is included in the measure.

*Transfers to acute facilities.* Include hospitalizations in which the member was transferred directly to another acute inpatient facility for any diagnosis. Count the discharge from the subsequent acute inpatient facility, not the initial discharge. The discharge date from the facility to which the member was transferred must occur on or before June 30 of the measurement year.

*Transfers to nonacute facilities.* Exclude from the denominator hospitalizations in which the member was transferred directly to a nonacute care facility for any diagnosis.

*Readmissions.* If the member was readmitted to an acute or nonacute care facility for any diagnosis, include the member in the denominator and use the discharge date from the original hospitalization.

### Administrative Specification

**Denominator** The eligible population.

**Numerator** A 180-day course of treatment with beta-blockers.

Identify all members in the denominator population whose dispensed days supply is  $\geq 135$  days in the 180 days following discharge. Persistence of treatment for this measure is defined as at least 75 percent of the days supply filled.

To determine continuity of treatment during the 180-day period, sum the number of allowed gap days to the number of treatment days for a maximum of 180 days (i.e., 135 treatment days + 45 gap days = 180 days); identify all prescriptions filled within 180 days of the Discharge Date.

To account for members who are on beta-blockers prior to admission, the organization should factor those prescriptions into adherence rates if the actual treatment days fall within the 180 days following discharge.

**Table PBH-B: Beta-Blocker Medications**

Description	Prescription		
Noncardioselective beta-blockers	carteolol carvedilol labetalol	nadolol penbutolol pindolol	propranolol timolol sotalol
Cardioselective beta-blockers	acebutolol atenolol	betaxolol bisoprolol	metoprolol nebivolol
Antihypertensive combinations	atenolol-chlorthalidone bendroflumethiazide-nadolol bisoprolol-hydrochlorothiazide		hydrochlorothiazide-metoprolol hydrochlorothiazide-propranolol hydrochlorothiazide-timolol

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

---

## Exclusion (optional)

---

Use administrative data to look as far back as possible in the member's history through the end of the continuous enrollment period for evidence of a contraindication to beta-blocker therapy. Refer to Table PBH-C and Table PBH-D for codes and medications representing contraindications to beta-blocker therapy.

**Table PBH-C: Codes to Identify Exclusions**

Description	ICD-9-CM Diagnosis
History of asthma	493
Hypotension	458
Heart block >1 degree	426.0, 426.12, 426.13, 426.2-426.4, 426.51-426.54, 426.7
Sinus bradycardia	427.81
COPD	491.2, 496, 506.4

**Table PBH-D: Medications to Identify Exclusions (History of Asthma)**

Description	Prescription		
Bronchodilator combinations	budesonide-formoterol	fluticasone-salmeterol	
Inhaled corticosteroids	beclomethasone budesonide flunisolide	fluticasone mometasone triamcinolone	fluticasone CFC free

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table PBH-1/2/3: Data Elements for Persistence of Beta-Blocker Treatment After a Heart Attack**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓

---

## Comprehensive Diabetes Care (CDC)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Clarified that HbA1c control (<7.0%) is only reported for the commercial and Medicaid product lines.

Deleted CPT codes 99261–99263, 99301–99303, 99311–99313, 99321–99323, 99331–99333 from Table CDC-C.

Deleted CPT Category II code 3047F from Tables CDC-D, CDC-E, CDC-F and CDC-Q.

Clarified that a calculated or direct LDL may be used for LDL-C screening and control.

Deleted LOINC code 24331-1 from Table CDC-H.

Deleted LOINC codes 34535-5, 50561-0, 53525-2 from Table CDC-J.

Added CPT codes 90957–90962, 90965, 90966, 90969, 90970 to Table CDC-K “Evidence of treatment for nephropathy” description.

Added LOINC code 53525-2 to Table CDC-K.

Deleted LOINC codes 24356-8, 24357-6, 50556-0, 50564-4 from Table CDC-K.

Deleted CPT code 90939 from Tables CDC-K, CDC-P.

Deleted CPT Category II code 3076F from Table CDC-N.

Clarified that member-reported BP readings are not acceptable.

Added ICD-9-CM Diagnosis code 249 to Table CDC-O “Steroid induced” description.

Added CPT codes 90957–90962, 90965, 90966, 90969, 90970 to Table CDC-P “ESRD” description.

### Description

The percentage of members 18–75 years of age with diabetes (type 1 and type 2) who had each of the following.

Hemoglobin A1c (HbA1c) testing	LDL-C screening
HbA1c poor control (>9.0%)	LDL-C control (<100 mg/dL)
HbA1c control (<8.0%)	Medical attention for nephropathy
HbA1c control (<7.0%) *	BP control (<130/80 mm Hg)
Eye exam (retinal) performed	BP control (<140/90 mm Hg)

*\*Additional exclusion criteria are required for this indicator. This indicator is only reported for the commercial and Medicaid product lines.*

## Eligible Population

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	18–75 years as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	There are two ways to identify members with diabetes: by pharmacy data and by claim/encounter data. The organization must use both to identify the eligible population, but a member only needs to be identified in one to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.

*Pharmacy data.* Members who were dispensed insulin or oral hypoglycemics/antihyperglycemics during the measurement year or year prior to the measurement year on an ambulatory basis (Table CDC-A).

**Table CDC-A: Prescriptions to Identify Members With Diabetes**

Description	Prescription			
Alpha-glucosidase inhibitors	acarbose	miglitol		
Amylin analogs	pramlintide			
Antidiabetic combinations	glimepiride-pioglitazone	glyburide-metformin	metformin-rosiglitazone	
	glimepiride-rosiglitazone	metformin-pioglitazone	metformin-sitagliptin	
	glipizide-metformin			
Insulin	insulin aspart		insulin lispro	
	insulin aspart-insulin aspart protamine		insulin lispro-insulin lispro protamine	
	insulin detemir		insulin regular beef-pork	
	insulin glargine		insulin regular human	
	insulin glulisine		insulin regular pork	
	insulin inhalation		insulin zinc beef-pork	
	insulin isophane beef-pork		insulin zinc extended human	
	insulin isophane human		insulin zinc human	
	insulin isophane pork		insulin zinc pork	
	insulin isophane-insulin regular			
Meglitinides	nateglinide	repaglinide		
Miscellaneous antidiabetic agents	exenatide	sitagliptin		
Sulfonylureas	acetohexamide	glimepiride	glyburide	tolbutamide
	chlorpropamide	glipizide	tolazamide	
Thiazolidinediones	pioglitazone	rosiglitazone		

**Note:** *Glucophage/metformin is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only. NCQA will post a complete list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.*

*Claim/encounter data.* Members who had two face-to-face encounters with a diagnosis of diabetes (Table CDC-B) on different dates of service in an outpatient setting or nonacute inpatient setting, or one face-to-face encounter in an acute inpatient or ED setting during the measurement year or the year prior to the measurement year. The organization may count services that occur over both years. Refer to Table CDC-C for codes to identify visit type.

**Table CDC-B: Codes to Identify Diabetes**

Description	ICD-9-CM Diagnosis
Diabetes	250, 357.2, 362.0, 366.41, 648.0

**Table CDC-C: Codes to Identify Visit Type**

Description	CPT	UB Revenue
Outpatient	92002, 92004, 92012, 92014, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456	051x, 0520-0523, 0526-0529, 057x-059x, 077x, 082x-085x, 088x, 0982, 0983
Nonacute inpatient	99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337	0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x
Acute inpatient	99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291	010x, 0110-0114, 0119, 0120-0124, 0129, 0130-0134, 0139, 0140-0144, 0149, 0150-0154, 0159, 016x, 020x-022x, 072x, 080x, 0987
ED	99281-99285	045x, 0981

## Administrative Specification

**Denominator** The eligible population.

**Required exclusions for the HbA1c Control <7% indicator** For the HbA1c control <7% indicator, exclude members who meet any of the following criteria.

65–75 years of age as of December 31 of the measurement year.

CABG or PTCA. Members discharged alive for CABG or PTCA in the measurement year or the year prior to the measurement year. Refer to Table CMC-A and use codes for PTCA and CABG only. CABG cases should be from inpatient claims/encounters only. Include all cases of PTCA, regardless of setting (e.g., inpatient, outpatient, ED).

IVD. Members who met at least one of the following criteria during both the measurement year and the year prior to the measurement year. Criteria need not be the same across both years.

At least one outpatient visit (Table CMC-C) with an IVD diagnosis (Table CMC-B), **or**

At least one acute inpatient claim/encounter (Table CMC-C) with an IVD diagnosis (Table CMC-B)

Chronic heart failure (CHF). Members who had at least one encounter, in any setting, with CHF. Refer to Table RCA-A and use codes for CHF only. Look as far back as possible in the member's history through December 31 of the measurement year.

Prior MI. Members who had at least one encounter, in any setting, with any code to identify MI (Table CDC-P). Look as far back as possible in the member's history through December 31 of the measurement year.

Chronic renal failure (CRF)/ESRD. Members who had at least one encounter, in any setting, with any code to identify CRF/ESRD (Table CDC-P). Look as far back as possible in the member's history through December 31 of the measurement year.

Dementia. Members who had at least one encounter, in any setting, with any code to identify dementia (Table DDE-E). Look as far back as possible in the member's history through December 31 of the measurement year.

Blindness. Members who had at least one encounter, in any setting, with any code to identify blindness (Table CDC-P). Look as far back as possible in the member's history through December 31 of the measurement year.

Amputation (lower extremity). Members who had at least one encounter, in any setting, with any code to identify lower extremity amputation (Table CDC-P). Look as far back as possible in the member's history through December 31 of the measurement year.

**Table CDC-P: Codes to Identify Required Exclusions**

Description	CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure	UB Revenue	UB Type of Bill	POS
MI			410, 412				
CRF/ESRD	36145, 36800-36821, 36831-36833, 90919-90921, 90923-90925, 90935, 90937, 90940, 90945, 90947, 90957-90962, 90965, 90966, 90969, 90970, 90989, 90993, 90997, 90999, 99512	G0257, G0311-G0319, G0321-G0323, G0325-G0327, G0392, G0393, S9339	585.4, 585.5, 585.6, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.43, 39.53, 39.93, 39.94, 39.95, 54.98	080x, 082x-085x, 088x	72x	65
Blindness			369.0, 369.1, 369.2, 369.4, 369.6, 369.7				
Amputation (lower extremity)	27290, 27295, 27590-27592, 27594, 27596, 27598, 27880, 27881, 27882, 27884, 27886, 27888, 27889, 28800, 28805, 28810, 28820, 28825			84.1			

---

## Numerators

**HbA1c Testing** An HbA1c test performed during the measurement year, as identified by claim/ encounter or automated laboratory data. Use any code listed in Table CDC-D.

**Table CDC-D: Codes to Identify HbA1c Tests**

CPT	CPT Category II	LOINC
83036, 83037	3044F, 3045F, 3046F	4548-4, 4549-2, 17856-6

**HbA1c Poor Control >9%** Use automated laboratory data to identify the *most recent* HbA1c test during the measurement year. The member is numerator compliant if the most recent automated HbA1c level is >9.0% or is missing a result or if an HbA1c test was not done during the measurement year. The member is not numerator compliant if the automated result for the most recent HbA1c test during the measurement year is ≤9.0%.

An organization that uses CPT Category II codes to identify numerator compliance for this indicator must search for all codes in Table CDC-E and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

**Note:** For this indicator, a lower rate indicates better performance (i.e., low rates of poor control indicate better care).

**Table CDC-E: Codes to Identify HbA1c Levels >9%**

Description	CPT Category II
Numerator compliant (HbA1c >9.0%)	3046F
Not numerator compliant (HbA1c ≤9.0%)	3044F, 3045F

**HbA1c Control <8%** Use automated laboratory data to identify the *most recent* HbA1c test during the measurement year. The member is numerator compliant if the most recent automated HbA1c level is <8.0%. The member is not numerator compliant if the automated result for the most recent HbA1c test is ≥8.0% or is missing a result, or if an HbA1c test was not done during the measurement year.

An organization that uses CPT Category II codes to identify numerator compliance for this indicator must search for all codes in Table CDC-Q and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

**Table CDC-Q: Codes to Identify HbA1c Levels <8%**

Description	CPT Category II
Numerator compliant (HbA1c <8.0%)	3044F
Not numerator compliant (HbA1c ≥8.0%)	3045F*, 3046F

\*CPT Category II code 3045F indicates most recent HbA1c (HbA1c) level 7.0%–9.0% and is not specific enough to denote numerator compliance for this indicator. For members with this code, the organization may use other sources (laboratory data, hybrid reporting method) to determine if the HbA1c result was <8%.



**HbA1c Control <7%** Use automated laboratory data to identify the *most recent* HbA1c test during the measurement year. The member is numerator compliant if the most recent automated HbA1c level is <7.0%. The member is not numerator compliant if the automated result for the most recent HbA1c test is ≥7.0% or is missing a result, or if an HbA1c test was not done during the measurement year.

An organization that uses CPT Category II codes to identify numerator compliance for this indicator must search for all codes in Table CDC-F and use the most recent code during the measurement year to evaluate whether the member is numerator compliant.

**Note:** This indicator uses the eligible population with additional eligible population criteria (e.g., removing members with required exclusions).

**Table CDC-F: Codes to Identify HbA1c Levels <7%**

Description	CPT Category II
Numerator compliant (HbA1c <7.0%)	3044F
Not numerator compliant (HbA1c ≥7.0%)	3045F, 3046F

**Eye Exam** An eye screening for diabetic retinal disease as identified by administrative data. This includes diabetics who had one of the following.

A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year, **or**

A *negative* retinal exam (no evidence of retinopathy) by an eye care professional in the year prior to the measurement year

Refer to Table CDC-G for codes to identify eye exams. For exams performed in the year prior to the measurement year, a result must be available.

**Table CDC-G: Codes to Identify Eye Exams\***

CPT	CPT Category II**	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure
67028, 67030, 67031, 67036, 67038-67043, 67101, 67105, 67107, 67108, 67110, 67112, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92225, 92226, 92230, 92235, 92240, 92250, 92260, 99203-99205, 99213-99215, 99242-99245	2022F, 2024F, 2026F, 3072F***	S0620, S0621, S0625**, S3000	V72.0	14.1-14.5, 14.9, 95.02-95.04, 95.11, 95.12, 95.16

\* Eye exams provided by eye care professionals are a proxy for dilated eye examinations because there is no administrative way to determine that a dilated exam was performed.

\*\* The organization does not need to limit CPT Category II codes or HCPCS S0625 to an optometrist or an ophthalmologist. These codes indicate an eye exam was performed by an eye care professional.

\*\*\* CPT Category II code 3072F can only be used if the claim/encounter was during the measurement year because it indicates the member had "no evidence of retinopathy in the prior year." Additionally, because the code definition itself indicates results were negative, an automated result is not required.

**LDL-C Screening** An LDL-C test performed during the measurement year, as identified by claim/ encounter or automated laboratory data. Use any code listed in table CDC-H.

The organization may use a calculated or direct LDL for LDL-C screening and control indicators.

**Table CDC-H: Codes to Identify LDL-C Screening**

CPT	CPT Category II	LOINC
80061, 83700, 83701, 83704, 83721	3048F, 3049F, 3050F	2089-1, 12773-8, 13457-7, 18261-8, 18262-6, 22748-8, 39469-2, 49132-4

**LDL-C Control <100 mg/dL** Use automated laboratory data to identify the *most recent* LDL-C test during the measurement year. The member is numerator compliant if the most recent automated LDL-C level is <100 mg/dL. If the automated result for the most recent LDL-C test during the measurement year is ≥100 mg/dL or is missing, or if an LDL-C test was not done during the measurement year, the member is not numerator compliant.

An organization that uses CPT Category II codes to identify numerator compliance for this indicator must search for all codes in Table CDC-I and use the most recent code during the measurement year to evaluate whether the member is numerator compliant. Use Table CDC-I to determine compliance.

**Table CDC-I: Codes to Identify LDL-C Levels**

Description	CPT Category II
Numerator compliant (LDL-C <100 mg/dL)	3048F
Not numerator compliant (LDL-C ≥100 mg/dL)	3049F, 3050F

**Medical Attention for Nephropathy** A nephropathy screening test **or** evidence of nephropathy, as documented through administrative data.

**Note:** A process flow diagram is included at the end of this specification to help implement this specification.

**Nephropathy screening test** A nephropathy screening test during the measurement year (Table CDC-J).

**Table CDC-J: Codes to Identify Nephropathy Screening Tests**

Description	CPT	CPT Category II	LOINC
Nephropathy screening test	82042, 82043, 82044, 84156	3060F, 3061F	1753-3, 1754-1, 1755-8, 1757-4, 2887-8, 2888-6, 2889-4, 2890-2, 9318-7, 11218-5, 12842-1, 13801-6, 14956-7, 14957-5, 14958-3, 14959-1, 13705-9, 14585-4, 18373-1, 20621-9, 21059-1, 21482-5, 26801-1, 27298-9, 30000-4, 30001-2, 30003-8, 32209-9, 32294-1, 32551-4, 34366-5, 35663-4, 40486-3, 40662-9, 40663-7, 43605-5, 43606-3, 43607-1, 44292-1, 47558-2, 49023-5, 50949-7, 53121-0, 53530-2, 53531-0, 53532-8

---

**Evidence of nephropathy**

Any of the following meet criteria for evidence of nephropathy.

A claim/encounter with a code to indicate evidence of treatment for nephropathy (Table CDC-K) during the measurement year.

A nephrologist visit during the measurement year, as identified by the organization's specialty provider codes (no restriction on the diagnosis or procedure code submitted).

A *positive* urine macroalbumin test in the measurement year, as documented by claim/encounter or automated laboratory data. Refer to Table CDC-K for codes to identify urine macroalbumin tests. "Trace" urine macroalbumin test results are not considered numerator-compliant.

Evidence of ACE inhibitor/ARB therapy during the measurement year. Members who had a claim indicating therapy (Table CDC-K) or received an ambulatory prescription or were dispensed an ambulatory prescription for ACE inhibitors or ARBs during the measurement year are compliant. Table CDC-L lists the ACE inhibitors/ARBs included in this measure.

**Table CDC-K: Codes to Identify Evidence of Nephropathy**

Description	CPT	CPT Category II*	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure	UB Revenue	UB Type of Bill	POS	LOINC
Urine macroalbumin test*	81000-81003, 81005	3062F							5804-0, 20454-5, 50561-0, 53525-2
Evidence of treatment for nephropathy	36145, 36800, 36810, 36815, 36818, 36819-36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90920, 90921, 90924, 90925, 90935, 90937, 90940, 90945, 90947, 90957-90962, 90965, 90966, 90969, 90970, 90989, 90993, 90997, 90999, 99512	3066F	G0257, G0314-G0319, G0322, G0323, G0326, G0327, G0392, G0393, S9339	250.4, 403, 404, 405.01, 405.11, 405.91, 580-588, 753.0, 753.1, 791.0, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.4-55.6	0367, 080x, 082x-085x, 088x	72x	65	
ACE inhibitor/ARB therapy		4009F							

\* A CPT Category II code indicates a positive result for urine macroalbumin; the organization must use automated laboratory data to confirm a positive result for tests identified by CPT or LOINC codes.

**Table CDC-L: ACE Inhibitors/ARBs**

Description	Prescription				
Angiotensin converting enzyme inhibitors	benazepril captopril	enalapril fosinopril	lisinopril moexipril	perindopril quinapril	ramipril trandolapril
Angiotensin II inhibitors	candesartan eprosartan	irbesartan losartan	olmesartan telmisartan	valsartan	
Antihypertensive combinations	amlodipine-benazepril amlodipine-olmesartan amlodipine-valsartan benazepril-hydrochlorothiazide candesartan-hydrochlorothiazide captopril-hydrochlorothiazide	enalapril-hydrochlorothiazide eprosartan-hydrochlorothiazide fosinopril-hydrochlorothiazide hydrochlorothiazide-irbesartan hydrochlorothiazide-lisinopril hydrochlorothiazide-losartan	hydrochlorothiazide-moexipril hydrochlorothiazide-olmesartan hydrochlorothiazide-quinapril hydrochlorothiazide-telmisartan hydrochlorothiazide-valsartan trandolapril-verapamil		

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

---

**BP Control <130/80 mm Hg** Use automated data to identify the most recent BP reading during the measurement year.

The member is numerator compliant if the BP is <130/80 mm Hg. The member is not compliant if the BP is  $\geq$ 130/80 mm Hg or if there is no automated BP reading during the measurement year. If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.

An organization that uses CPT Category II codes to identify numerator compliance for this indicator must search for all codes in Table CDC-M and use the most recent codes during the measurement year to evaluate whether the member is numerator compliant for both systolic and diastolic levels.

**Table CDC-M: Codes to Identify Systolic and Diastolic BP Levels <130/80**

Description	CPT Category II	
	Systolic	Diastolic
Numerator compliant (BP <130/80 mm Hg)	3074F	3078F
Not numerator compliant (BP $\geq$ 130/80 mm Hg)	3075F, 3077F	3079F, 3080F

**BP Control <140/90 mm Hg** Use automated data to identify the most recent BP reading during the measurement year. Refer to Table CDC-N and use the most recent code to evaluate whether the member is numerator compliant.

The member is numerator compliant if the BP is <140/90 mm Hg. The member is not compliant if the BP is  $\geq$ 140/90 mm Hg or if there is no automated BP reading during the measurement year. If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.

An organization that uses CPT Category II codes to identify numerator compliance for this indicator must search for all codes in Table CDC-N and use the most recent codes during the measurement year to evaluate whether the member is numerator compliant for both systolic and diastolic levels.

**Table CDC-N: Codes to Identify Systolic and Diastolic BP Levels <140/90**

Description	CPT Category II	
	Systolic	Diastolic
Numerator compliant (BP <140/90 mm Hg)	3074F, 3075F	3078F, 3079F
Not numerator compliant (BP $\geq$ 140/90 mm Hg)	3077F	3080F

---

## Hybrid Specification

**Denominator** A systematic sample of 548 drawn from the eligible population for each product line. A sample size of 548 is based on the goal of achieving a sample of at least 411 for the HbA1c <7% denominator after required exclusions.

Members who meet the required exclusion criteria for the HbA1c <7% indicator should not be substituted with members from the oversample. These members will only be excluded when reporting the denominator for the HbA1c <7% indicator. In other words, organizations should report the FSS for the HbA1c <7% indicator as 548 minus the required exclusions.

**Required  
exclusions for  
HbA1c Good  
Control <7%**

**Administrative** Refer to *Administrative Specification* to identify required exclusions from administrative data.

**Medical record** Exclude members who meet any of the following criteria.

- 65–75 years of age as of December 31 of the measurement year.
- CABG or PTCA. Dated documentation of CABG or PTCA in the measurement year or the year prior to the measurement year.
- IVD. Documentation of an IVD diagnosis. Look as far back as possible in the member's history through December 31 of the measurement year. Appropriate diagnoses include:
  - IVD
  - Ischemic heart disease
  - Angina
  - Coronary atherosclerosis
  - Coronary artery occlusion
  - Cardiovascular disease
  - Occlusion or stenosis of precerebral arteries (including basilar, carotid and vertebral arteries)
  - Atherosclerosis of renal artery
  - Atherosclerosis of native arteries of the extremities
  - Chronic total occlusion of artery of the extremities
  - Arterial embolism and thrombosis
  - Atheroembolism
- CHF. Documentation of CHF diagnosis. Look as far back as possible in the member's history through December 31 of the measurement year.
- Prior MI. Documentation of prior MI. Look as far back as possible in the member's history through December 31 of the measurement year.
- CRF/ESRD. Documentation of Stage 4 or 5 CRF or ESRD. Look as far back as possible in the member's history through December 31 of the measurement year.

---

Dementia. Documentation of dementia. Look as far back as possible in the member's history through December 31 of the measurement year.

Blindness. Documentation of blindness in one or both eyes. Look as far back as possible in the member's history through December 31 of the measurement year.

Amputation (lower extremity). Documentation of lower extremity amputation. Look as far back as possible in the member's history through December 31 of the measurement year.

**Note:** *The organization must search the medical record for required exclusions before it searches for a numerator hit.*

## Numerators

**HbA1c Testing** An HbA1c test performed during the measurement year as identified by administrative data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** At a minimum, documentation in the medical record must include a note indicating the date on which the HbA1c test was performed and the result. The organization may count notation of the following in the medical record.

A1c	Hemoglobin A1c	HgbA1c
HbA1c	Glycohemoglobin A1c	

**HbA1c Poor Control >9%** The *most recent* HbA1c level (performed during the measurement year) is >9.0% or is missing or was not done during the measurement year, as documented through automated laboratory data or medical record review.

**Note:** *For this indicator, a lower rate indicates better performance (i.e., low rates of poor control indicate better care).*

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** At a minimum, documentation in the medical record must include a note indicating the date on which the HbA1c test was performed and the result.

**HbA1c Control <8%** The *most recent* HbA1c level (performed during the measurement year) is <8.0% as identified by automated laboratory data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** At a minimum, documentation in medical record must include a note indicating the date on which the HbA1c test was performed and the result.

**HbA1c Good Control <7%** The *most recent* HbA1c level (performed during the measurement year) is <7.0% as identified by automated laboratory data or medical record review.

**Note:** *This indicator uses the eligible population with additional eligible population criteria (i.e., removing members with comorbid conditions.)*

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

---

**Medical record** At a minimum, documentation in medical record must include a note indicating the date on which the HbA1c test was performed and the result.

**Eye Exam** An eye screening for diabetic retinal disease as identified by administrative data or medical record review. This includes diabetics who had one of the following.

A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year, **or**

A *negative* retinal exam (no evidence of retinopathy) by an eye care professional in the year prior to the measurement year

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** At a minimum, documentation in the medical record must include one of the following.

A note or letter prepared by an ophthalmologist, optometrist, PCP or other health care professional indicating that an ophthalmoscopic exam was completed by an eye care professional, the date on which the procedure was performed and the results, **or**

A chart or photograph of retinal abnormalities indicating the date on which the fundus photography was performed and evidence that an eye care professional reviewed the results. Alternatively, results may be read by a qualified reading center that operates under the direction of a medical director who is a retinal specialist.

**LDL-C Screening** An LDL-C test performed during the measurement year as identified by claim/encounter or automated laboratory data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** At a minimum, documentation in the medical record must include a note indicating the date on which the LDL-C test was performed and the result. The organization may use a calculated LDL for LDL-C screening and control indicators.

**LDL-C Control <100 mg/dL** The *most recent* LDL-C level performed during the measurement year is <100 mg/dL, as documented through automated laboratory data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** Documentation in medical record must include, at a minimum, a note indicating the date on which the LDL-C test was performed and the result.

The organization may calculate LDL-C levels from total cholesterol, HDL-C and triglycerides using the Friedewald equation if the triglycerides are ≤400 mg/dL.

$$(\text{LDL-C}) = (\text{total cholesterol}) - (\text{HDL}) - (\text{triglycerides}/5)$$

If lipoprotein (a) is measured, use the following calculation.

$$(\text{LDL-C}) = (\text{total cholesterol}) - (\text{HDL}) - (\text{triglycerides}/5) - 0.3 [\text{lipoprotein (a)}]$$

These formulae are used when all levels are expressed in mg/dL and cannot be used if triglycerides >400 mg/dL.



---

**Medical  
Attention for  
Nephropathy**

A nephropathy screening test during the measurement year **or** evidence of nephropathy during the measurement year as documented through either administrative data or medical record review.

**Note:** A process flow diagram is included at the end of this specification to help implement this specification.

**Administrative**

Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record**

*Nephropathy screening test.* At a minimum, documentation must include a note indicating the date on which a urine microalbumin test was performed, and the result. Any of the following meet the criteria for a urine microalbumin test.

24-hour urine for microalbumin

Timed urine for microalbumin

Spot urine for microalbumin

Urine for microalbumin/creatinine ratio

24-hour urine for total protein

Random urine for protein/creatinine ratio

*Evidence of nephropathy.* Any of the following meet the criteria for evidence of nephropathy.

Documentation of a visit to a nephrologist.

Documentation of medical attention for any of the following (no restriction on provider type).

Diabetic nephropathy

ESRD

CRF

Chronic kidney disease (CKD)

Renal insufficiency

Proteinuria

Albuminuria

Renal dysfunction

Acute renal failure (ARF)

Dialysis, hemodialysis or peritoneal dialysis

A positive urine macroalbumin test. At a minimum, documentation in the medical record must include a note indicating the date on which the test was performed, and a positive result. Any of the following meet the criteria for a positive urine macroalbumin test.

Positive urinalysis (random, spot or timed) for protein

Positive urine (random, spot or timed) for protein

Positive urine dipstick for protein

Positive tablet reagent for urine protein

Positive result for albuminuria

Positive result for macroalbuminuria

Positive result for proteinuria

Positive result for gross proteinuria

---

**Note:** "Trace" urine macroalbumin test results are not considered numerator compliant.

Evidence of ACE inhibitor/ARB therapy. Documentation in medical record must include, at minimum, a note indicating that the member received an ambulatory prescription for ACE inhibitors/ARBs within the measurement year.

**BP Control <130/80 mm Hg** The *most recent* BP level (taken during the measurement year) is <130/80 mm Hg, as documented through administrative data or medical record review.

**BP Control <140/90 mm Hg** The *most recent* BP level (taken during the measurement year) is <140/90 mm Hg, as documented through administrative data or medical record review.

**Administrative** Refer to *Administrative Specification* to identify positive numerator hits from administrative data.

**Medical record** To determine if BP is adequately controlled, the organization must identify the representative BP following the steps below.

**Identifying the medical record** The organization should use the medical record from which it abstracts data for the other CDC indicators. If the organization does not abstract for other indicators, it should use the medical record of the provider that manages the member's diabetes. If that medical record does not contain a BP, the organization may use the medical record of another PCP or specialist from which the member receives care.

**Step 1** Identify the most recent BP reading notated during the measurement year. Do not include BP readings that meet the following criteria.

BPs taken during an acute inpatient stay or an ED visit

BPs taken during an outpatient visit which was for the sole purpose of having a diagnostic test or surgical procedure performed (e.g., sigmoidoscopy, removal of a mole)

BPs obtained the same day as a major diagnostic or surgical procedure (e.g., stress test, administration of IV contrast for a radiology procedure, endoscopy)

BP readings reported by or taken by the member

**Step 2** Identify the lowest systolic and lowest diastolic BP reading from the most recent BP notation in the medical record. If there are multiple BPs recorded for a single date, use the lowest systolic and lowest diastolic BP on that date as the representative BP. The systolic and diastolic results do not need to be from the same reading.

### Exclusions (optional)

---

Members with a diagnosis of polycystic ovaries (Table CDC-O) who did not have any face-to-face encounters with a diagnosis of diabetes (CDC-B), in any setting, during the measurement year or the year prior to the measurement year. Diagnosis can occur at any time in the member's history, but must have occurred by December 31 of the measurement year.

Members with gestational or steroid-induced diabetes (CDC-O) who did not have any face-to-face encounters with a diagnosis of diabetes (CDC-B), in any setting, during the measurement year or the year prior to the measurement year. Diagnosis can occur during the measurement year or the year prior to the measurement year, but must have occurred by December 31 of the measurement year.

### Table CDC-O: Codes to Identify Exclusions

Description	ICD-9-CM Diagnosis
-------------	--------------------

---

---

Polycystic ovaries	256.4
Steroid induced	249, 251.8, 962.0
Gestational diabetes	648.8


**Note**

---

*The organization may select data collection method (Administrative vs. Hybrid) at the indicator level, but the method for screening and control rates must be consistent, as must the methodology for BP control indicators.*

*Blindness is not an exclusion for a diabetic eye exam because it is difficult to distinguish between individuals who are legally blind but require a retinal exam and those who are completely blind and therefore do not require an exam.*

## Monitoring for Diabetic Nephropathy



## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CDC-1/2/3: Data Elements for Comprehensive Diabetes Care**

	Administrative	Hybrid
Measurement year	<i>Each of the 10 rates</i>	<i>Each of the 10 rates</i>
Data collection methodology (Administrative or Hybrid)	<i>Each of the 10 rates</i>	<i>Each of the 10 rates</i>
Eligible population	<i>Each of the 10 rates</i>	<i>Each of the 10 rates</i>
Number of numerator events by administrative data in eligible population (before exclusions)		<i>Each of the 10 rates</i>
Current year's administrative rate (before exclusions)		<i>Each of the 10 rates</i>
Minimum required sample size (MRSS) or other sample size		<i>Each of the 10 rates</i>
Oversampling rate		<i>Each of the 10 rates</i>
Final sample size (FSS)		<i>Each of the 10 rates</i>
Number of numerator events by administrative data in FSS		<i>Each of the 10 rates</i>
Administrative rate on FSS		<i>Each of the 10 rates</i>
Number of original sample records excluded because of valid data errors		<i>Each of the 10 rates</i>
Number of administrative data records excluded		<i>Each of the 10 rates</i>
Number of medical records excluded		<i>Each of the 10 rates</i>
Number of employee/dependent medical records excluded		<i>Each of the 10 rates</i>
Number of HbA1c <7 required exclusions		<i>Each of the 10 rates</i>
Records added from the oversample list		<i>Each of the 10 rates</i>
Denominator		<i>Each of the 10 rates</i>
Numerator events by administrative data	<i>Each of the 10 rates</i>	<i>Each of the 10 rates</i>
Numerator events by medical records		<i>Each of the 10 rates</i>
Reported rate	<i>Each of the 10 rates</i>	<i>Each of the 10 rates</i>
Lower 95% confidence interval	<i>Each of the 10 rates</i>	<i>Each of the 10 rates</i>
Upper 95% confidence interval	<i>Each of the 10 rates</i>	<i>Each of the 10 rates</i>

## ***Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)***

### **SUMMARY OF CHANGES TO HEDIS 2010**

Deleted CPT codes 99301–99303, 99311–99313, 99321–99323, 99331–99333 from Table ART-B.

Added J codes J2910 “Anti-rheumatics” description and J9310 “Immunomodulators” description.

Added ICD-9-CM Diagnosis codes 678, 679 to Table ART-D “Pregnancy” description.

### **Description**

The percentage of members who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease modifying anti-rheumatic drug (DMARD).

### **Eligible Population**

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	18 years and older as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefits</b>	Medical and pharmacy.
<b>Event/diagnosis</b>	Two face-to-face physician encounters with different dates of service in an outpatient or nonacute inpatient setting on or between January 1 and November 30 of the measurement year with any diagnosis of rheumatoid arthritis. A diagnosis code from Table ART-A must be in conjunction with a visit type code in Table ART-B.

**Table ART-A: Codes to Identify Rheumatoid Arthritis**

Description	ICD-9-CM Diagnosis
Rheumatoid arthritis	714.0, 714.1, 714.2, 714.81

**Table ART-B: Codes to Identify Visit Type**

Description	CPT	UB Revenue
Outpatient	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456	051x, 0520-0523, 0526-0529, 057x-059x, 077x, 0982, 0983
Nonacute inpatient	99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337	0118, 0128, 0138, 0148, 0158, 019x, 0524, 0525, 055x, 066x

## Administrative Specification

**Denominator** The eligible population.

**Numerator** Members who had at least one ambulatory prescription dispensed for a DMARD during the measurement year. Table ART-C lists the DMARDs included in this measure.

**Table ART-C: DMARDs**

Description	Prescription			J Codes
5-Aminosalicylates	sulfasalazine			
Alkylating agents	cyclophosphamide			
Aminoquinolines	hydroxychloroquine			
Anti-rheumatics	auranofin aurothioglucose	gold sodium thiomalate leflunomide	methotrexate penicillamine	J1600, J2910, J9250, J9260
Immunomodulators	abatacept adalimumab anakinra	etanercept golimumab infliximab	rituximab	J0129, J0135, J1438, J1745, J9310
Immunosuppressive agents	azathioprine	cyclosporine		J7502, J7515, J7516
Tetracyclines	minocycline			

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

### Exclusions (optional)

Members diagnosed with HIV. Look for evidence of HIV diagnosis as far back as possible in the member's history through December 31 of the measurement year.

Members who have a diagnosis of pregnancy during the measurement year.

**Table ART-D: Codes to Identify Exclusions**

Description	ICD-9-CM Diagnosis
HIV	042, V08
Pregnancy	630-679, V22, V23, V28

---

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table ART-1/2/3: Data Elements for DMARD Therapy for Rheumatoid Arthritis**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Number of numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓



---

## Osteoporosis Management in Women Who Had a Fracture (OMW)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Added ICD-9-CM Diagnosis codes 733.93–733.98 to Table OMW-A.

Deleted HCPCS S2362 from Table OMW-A.

#### Description

The percentage of women 67 years of age and older who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis in the six months after the fracture.

#### Definitions

<b>Intake Period</b>	A 12-month window that begins on July 1 of the year prior to the measurement year and ends on June 30 of the measurement year. The Intake Period is used to capture the first fracture.
<b>IESD</b>	Index Episode Start Date. The earliest date of service for any encounter during the Intake Period with a diagnosis of fracture (Table OMW-A). <i>For an outpatient or ED claim/encounter, the IESD is date of service.</i> <i>For an inpatient claim/encounter, the IESD is the date of discharge.</i> <i>For direct transfers, the IESD is the discharge date from the second admission.</i>
<b>Negative Diagnosis History</b>	A period of 60 days prior to the IESD, during which time the member had no diagnosis of fracture using Table OMW-A. For fractures requiring an inpatient stay, use the date of admission to determine Negative Diagnosis History. For direct transfers, use the first admission to determine the Negative Diagnosis History.

#### Eligible Population

<b>Product line</b>	Medicare.
<b>Age</b>	Women 67 years and older as of December 31 of the measurement year.
<b>Continuous enrollment</b>	12 months prior to the IESD through 6 months (180 days) after the IESD.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the continuous enrollment period.
<b>Anchor date</b>	IESD.
<b>Benefits</b>	Medical and pharmacy.
<b>Event/diagnosis</b>	The earliest fracture during the Intake Period. Follow the steps below to identify the eligible population.

**Step 1** Identify all members who had a fracture (Table OMW-A) during the 12-month Intake Period. If the member had more than one fracture, include only the first fracture.

**Table OMW-A: Codes to Identify Fractures\***

CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure
21800-21825, 22305-22328, 22520, 22521, 22523, 22524, 23500-23515, 23570-23630, 23665-23680, 24500-24587, 24620, 24635, 24650-24685, 25500-25652, 25680, 25685, 26600, 26605, 26607, 26608, 26615, 27193-27248, 27254, 27267-27269, 27500-27514, 27520-27540, 27750-27828, 28400, 28405, 28406, 28415, 28420, 28430, 28435, 28436, 28445, 28450, 28455, 28456, 28465, 28470, 28475, 28476, 28485, 29850, 29851, 29855, 29856	S2360	733.1, 733.93-733.98, 805-806, 807.0-807.4, 808-815, 818-825, 827, 828	79.01-79.03, 79.05-79.07, 79.11-79.13, 79.15-79.17, 79.21-79.23, 79.25-79.27, 79.31-79.33, 79.35-79.37, 79.61-79.63, 79.65-79.67, 81.65, 81.66

\*Fractures of finger, toe, face and skull are not included in this measure.

**Step 2** Test for Negative Diagnosis History. Exclude members with a fracture (Table OMW-A) during the 60 days prior to the IESD. For fractures requiring an inpatient stay, use the admission date to determine Negative Diagnosis History. For direct transfers, use the first admission to determine the Negative Diagnosis History.

**Step 3** Calculate continuous enrollment. Members must be continuously enrolled during the 12 months prior to the fracture through 6 months (180 days) post-fracture.

**Step 4** Exclude members who had a BMD test (Table OMW-B) or who received any osteoporosis treatment (Table OMW-C) during the 365 days prior to the IESD.

For an inpatient claim/encounter, use the admission date to determine the 365 days prior to the IESD.

### Administrative Specification

**Denominator** The eligible population.

**Numerator** Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria.

A BMD test (Table OMW-B) on the IESD or in the 180-day period after the IESD, **or**

A BMD test (Table OMW-B) during the inpatient stay for the fracture (applies only to fractures requiring hospitalization), **or**

A dispensed prescription (Table OMW-C) to treat osteoporosis on the IESD or in the 180-day period after the IESD

**Table OMW-B: Codes to Identify Bone Mineral Density Test**

CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure
76070, 76071, 76075-76078, 76977, 77078-77083, 78350, 78351	G0130	V82.81	88.98

**Table OMW-C: FDA-Approved Osteoporosis Therapies**

Description	Prescription		J Codes
Biphosphonates	alendronate alendronate-cholecalciferol calcium carbonate-risedronate	ibandronate risedronate zoledronic acid	J3488
Estrogens	conjugated estrogens conjugated estrogens synthetic esterified estrogens	estradiol estradiol acetate estradiol cypionate	estradiol valerate estropipate ethinyl estradiol
Miscellaneous hormones	calcitonin	raloxifene	teriparatide
Sex hormone combinations	conjugated estrogens— medroxy-progesterone estradiol-levonorgestrel	estradiol-norethindrone estradiol-norgestimate ethinyl estradiol-norethindrone	

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

### Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table OMW-3: Data Elements for Osteoporosis Management in Women Who Had a Fracture**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓

## Antidepressant Medication Management (AMM)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Clarified Negative Diagnosis History for inpatient claims/encounters and transfers.

Deleted CPT codes 90871, 99261–99263 from Table AMM-B.

#### Description

The percentage of members 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication treatment. Two rates are reported.

*Effective Acute Phase Treatment.* The percentage of newly diagnosed and treated members who remained on an antidepressant medication for at least 84 days (12 weeks).

*Effective Continuation Phase Treatment.* The percentage of newly diagnosed and treated members who remained on an antidepressant medication for at least 180 days (6 months).

#### Definitions

<b>Intake Period</b>	The 12-month window starting on May 1 of the year prior to the measurement year and ending on April 30 of the measurement year.
<b>IESD</b>	Index Episode Start Date. The earliest encounter during the Intake Period with any diagnosis of major depression (Table AMM-A) that meets the following criteria. A 120-day Negative Diagnosis History A 90-day Negative Medication History  <i>For an inpatient (acute or nonacute) claim/encounter,</i> the IESD is the date of discharge.  <i>For a direct transfer,</i> the IESD is the discharge date from the facility to which the member was transferred.
<b>Negative Diagnosis History</b>	A period of 120 days (4 months) prior to the IESD, during which time the member had no claims/encounters with any diagnosis of major depression (Table AMM-A) or prior episodes of depression (Table AMM-C).  <i>For an inpatient (acute or nonacute) claim/encounter,</i> use the date of admission to determine Negative Diagnosis History.  <i>For direct transfers,</i> use the first admission to determine Negative Diagnosis History.
<b>IPSD</b>	Index Prescription Start Date. The earliest prescription dispensing date for an antidepressant medication during the period of 30 days prior to the IESD (inclusive) through 14 days after the IESD (inclusive).
<b>Negative Medication History</b>	A period of 90 days (3 months) prior to the IPSD, during which time the member had no pharmacy claims for either new or refill prescriptions for an antidepressant medication (Table AMM-D).

**Treatment days** The actual number of calendar days covered with prescriptions within the specified 180-day measurement interval. For Effective Continuation Phase Treatment, a prescription of 90 days supply dispensed on the 151st day will have 80 days counted in the 231-day interval.

## Eligible Population

**Product lines** Commercial, Medicaid, Medicare (report each product line separately).

**Ages** 18 years and older as of April 30 of the measurement year.

**Continuous enrollment** 120 days prior to the IESD through 245 days after the IESD.

**Allowable gap** One gap in enrollment of up to 45 days. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).

**Anchor date** IESD.

**Benefits** Medical, pharmacy and mental health (inpatient and outpatient).

**Event/diagnosis** The organization should follow the steps below to identify the eligible population, which should be used for both rates.

**Step 1** Identify all members who met at least one of the following criteria during the Intake Period.

- At least one principal diagnosis of major depression (Table AMM-A) in an outpatient, ED, intensive outpatient or partial hospitalization setting (Table AMM-B), **or**
- At least two visits in an outpatient, ED, intensive outpatient or partial hospitalization setting (Table AMM-B) on different dates of service with any diagnosis of major depression (Table AMM-A), **or**
- At least one inpatient (acute or nonacute) claim/encounter with any diagnosis of major depression (Table AMM-A)

**Table AMM-A: Codes to Identify Major Depression**

Description	ICD-9-CM Diagnosis
Major depression	296.20-296.25, 296.30-296.35, 298.0, 300.4, 309.1, 311

\*Brief depressive reaction (309.0) is not used for diagnosis, since it includes grief reaction (believed to be the most common use of that code). Additionally, other possible codes that could indicate a depression diagnosis (296.4–296.9, 309.0, 309.28) are not included in this list because these codes are less specific in identifying members with major depression.

**Table AMM-B: Codes to Identify Visit Type**

Description	CPT	HCPCS	UB Revenue
ED	99281-99285		045x, 0981
Outpatient, intensive outpatient and partial hospitalization	90804-90815, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99411, 99412, 99510	G0155, G0176, G0177, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485	0510, 0513, 0515-0517, 0519-0523, 0526-0529, 077x, 0900, 0901, 0902-0905, 0907, 0911-0917, 0919, 0982, 0983
	CPT		POS
	90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255	<i>WITH</i>	03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 33, 49, 50, 52, 53, 71, 72

**Step 2** Determine the IESD. For each member identified in step 1, identify the date of the earliest encounter during the Intake Period with any diagnosis of major depression. If the member had more than one encounter during the Intake Period, include only the first encounter.

**Step 3** Test for Negative Diagnosis History. Exclude members who had a claim/encounter for any diagnosis of major depression (Table AMM-A) or prior episodes of depression (Table AMM-C) during the 120 days prior to the IESD.

**Table AMM-C: Additional Codes to Identify Depression**

Description	ICD-9-CM Diagnosis
Depression	296.26, 296.36, 296.4-296.9, 309.0, 309.28

**Step 4** Identify the IPSD. The IPSD is the date of the earliest dispensing event for an antidepressant medication (Table AMM-D) during the period of 30 days prior to the IESD (inclusive) through 14 days after the IESD (inclusive). Exclude members who did not fill a prescription for an antidepressant medication during this period.

**Step 5** Test for Negative Medication History. Exclude members who filled a prescription for an antidepressant medication 90 days (3 months) prior to the IPSD.

**Step 6** Calculate continuous enrollment. Members must be continuously enrolled for 120 days prior to the IESD to 245 days after the IESD.

## Administrative Specification

**Denominator** The eligible population.

### Numerators

**Effective Acute Phase Treatment** At least 84 days (12-weeks) of continuous treatment with antidepressant medication (Table AMM-D) during the 114-day period following the IPSD (inclusive). The continuous treatment allows gaps in medication treatment up to a total of 30 days during the 114-day period.

Allowable medication changes or gaps include:

Washout period gaps to change medication

Treatment gaps to refill the same medication

Regardless of the number of gaps, there may be no more than 30 gap days. The organization may count any combination of gaps (e.g., two washout gaps of 15 days each, or two washout gaps of 10 days each and one treatment gap of 10 days).

**Table AMM-D: Antidepressant Medications**

Description	Prescription		
Miscellaneous antidepressants	bupropion		
Monoamine oxidase inhibitors	isocarboxazid phenelzine	selegiline tranylcypromine	
Phenylpiperazine antidepressants	nefazodone	trazodone	
Psychotherapeutic combinations	amitriptyline-chlordiazepoxide amitriptyline-perphenazine		fluoxetine-olanzapine
SSNRI antidepressants	desvenlafaxine	duloxetine	venlafaxine
SSRI antidepressants	citalopram escitalopram	fluoxetine fluvoxamine	paroxetine sertraline
Tetracyclic antidepressants	maprotiline	mirtazapine	
Tricyclic antidepressants	amitriptyline amoxapine clomipramine	desipramine doxepin imipramine	nortriptyline protriptyline trimipramine

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

**Effective Continuation Phase Treatment** At least 180 days (6 months) of continuous treatment with antidepressant medication (Table AMM-D) during the 231-day period following the IPSD (inclusive). The continuous treatment allows gaps in medication treatment up to a total of 51 days during the 231-day period.

Allowable medication changes or gaps include the following.

Washout period gaps to change medication

Treatment gaps to refill the same medication

Regardless of the number of gaps, gap days may total no more than 51. The organization may count any combination of gaps (e.g., two washout gaps, each 25 days or two washout gaps of 10 days each and one treatment gap of 10 days).

---

**Note**

---

Organizations may have different methods for billing intensive outpatient encounters and partial hospitalizations. Some methods may be comparable to outpatient billing, with separate claims for each date of service; others may be comparable to inpatient billing, with an admission date, a discharge date and units of service. Organizations whose billing methods are comparable to inpatient billing may count each unit of service as an individual visit. The unit of service must have occurred during the time frame specified (e.g., during the Intake Period).

**Data Elements for Reporting**

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table AMM-1/2/3: Data Elements for Antidepressant Medication Management**

	<b>Administrative</b>
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	<i>Each of the 2 rates</i>
Reported rate	<i>Each of the 2 rates</i>
Lower 95% confidence interval	<i>Each of the 2 rates</i>
Upper 95% confidence interval	<i>Each of the 2 rates</i>



---

## ***Follow-Up After Hospitalization for Mental Illness (FUH)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Deleted CPT codes 90871, 99261–99263 from Table FUH-C.

#### **Description**

The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental health disorders and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported.

1. The percentage of members who received follow-up within 30 days of discharge
2. The percentage of members who received follow-up within 7 days of discharge

#### **Eligible Population**

**Product lines** Commercial, Medicaid, Medicare (report each product line separately).

**Ages** 6 years and older as of the date of discharge.

**Continuous enrollment** Date of discharge through 30 days after discharge.

**Allowable gap** No gaps in enrollment.

**Anchor date** None.

**Benefits** Medical and mental health (inpatient and outpatient).

**Event/diagnosis** Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a principal mental health diagnosis (Table FUH-A) on or between January 1 and December 1 of the measurement year.

The denominator for this measure is based on discharges, not members. Include all discharges for members who have more than one discharge on or between January 1 and December 1 of the measurement year.

#### **Table FUH-A: Codes to Identify Mental Health Diagnosis**

<b>ICD-9-CM Diagnosis</b>
295–299, 300.3, 300.4, 301, 308, 309, 311–314

**Mental health  
readmission or  
direct transfer**

If the discharge is followed by readmission or direct transfer to an *acute facility* for any mental health principal diagnosis (Tables MPT-A, MPT-B) within the 30-day follow-up period, count only the readmission discharge or the discharge from the facility to which the member was transferred. Although rehospitalization might not be for a selected mental health disorder, it is probably for a related condition.

Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year.

Exclude discharges followed by readmission or direct transfer to a *nonacute facility* for any mental health principal diagnosis (Tables MPT-A, MPT-B) within the 30-day follow-up period. These discharges are excluded from the measure because readmission or transfer may prevent an outpatient follow-up visit from taking place. Refer to Table FUH-B for codes to identify nonacute care.

**Non-mental  
health  
readmission or  
direct transfer**

Exclude discharges in which the patient was transferred directly or readmitted within 30 days after discharge to an acute or nonacute facility for a non-mental health principal diagnosis. This includes any ICD-9-CM Diagnosis code or DRG code other than those in Tables MPT-A and MPT-B. These discharges are excluded from the measure because rehospitalization or transfer may prevent an outpatient follow-up visit from taking place.

**Table FUH-B: Codes to Identify Nonacute Care**

Description	HCPCS	UB Revenue	UB Type of Bill	POS
Hospice		0115, 0125, 0135, 0145, 0155, 0650, 0656, 0658, 0659	81x, 82x	34
SNF		019x	21x, 22x, 28x	31, 32
Hospital transitional care, swing bed or rehabilitation			18x	
Rehabilitation		0118, 0128, 0138, 0148, 0158		
Respite		0655		
Intermediate care facility				54
Residential substance abuse treatment facility		1002		55
Psychiatric residential treatment center	T2048, H0017-H0019	1001		56
Comprehensive inpatient rehabilitation facility				61
Other nonacute care facilities that do not use the UB revenue or type of bill codes for billing (e.g., ICF, SNF)				

## Administrative Specification

**Denominator** The eligible population.

### Numerators

**30-Day Follow-Up** An outpatient visit, intensive outpatient encounter or partial hospitalization (Table FUH-C) with a mental health practitioner within 30 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.

**7-Day Follow-Up** An outpatient visit, intensive outpatient encounter or partial hospitalization (Table FUH-C) with a mental health practitioner within 7 days after discharge. Include outpatient visits, intensive outpatient encounters or partial hospitalizations that occur on the date of discharge.

**Table FUH-C: Codes to Identify Visits**

CPT		HCPCS	
<b>Follow-up visits identified by the following CPT or HCPCS codes must be with a mental health practitioner.</b>			
90804-90815, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99383-99387, 99393-99397, 99401-99404, 99411, 99412, 99510		G0155, G0176, G0177, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485	
CPT		POS	
<b>Follow-up visits identified by the following CPT/POS codes must be with a mental health practitioner.</b>			
90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876		<i>WITH</i>	03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 33, 49, 50, 52, 53, 71, 72
99221-99223, 99231-99233, 99238, 99239, 99251-99255		<i>WITH</i>	52, 53
UB Revenue			
<b>The organization does not need to determine practitioner type for follow-up visits identified by the following UB revenue codes.</b>			
0513, 0900-0905, 0907, 0911-0917, 0919			
<b>Visits identified by the following revenue codes must be with a mental health practitioner or in conjunction with any diagnosis code from Table FUH-A.</b>			
0510, 0515-0517, 0519-0523, 0526-0529, 077x, 0982, 0983			

### Note

*Organizations may have different methods for billing intensive outpatient encounters and partial hospitalizations. Some methods may be comparable to outpatient billing, with separate claims for each date of service; others may be comparable to inpatient billing, with an admission date, a discharge date and units of service. Organizations whose billing methods are comparable to inpatient billing may count each unit of service as an individual visit. The unit of service must have occurred during the time frame required for the rate (e.g., within 30 days after discharge or within 7 days after discharge).*

Refer to Appendix 3 for the definition of mental health practitioner.

---

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table FUH-1/2/3: Data Elements for Follow-Up After Hospitalization for Mental Illness**

	<b>Administrative</b>
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	<i>Each of the 2 rates</i>
Reported rate	<i>Each of the 2 rates</i>
Lower 95% confidence interval	<i>Each of the 2 rates</i>
Upper 95% confidence interval	<i>Each of the 2 rates</i>

---

## ***Annual Monitoring for Patients on Persistent Medications (MPM)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Clarified numerator criteria for Rates 1–3.

Clarified codes that identified a lab panel in Table MPM-A.

Deleted LOINC codes 24320-4, 24321-2, 24326-1, 24322-0, 24323-8, 24362-6, 34554-6, 34555-3, 45064-3, 45065-0, 45066-8, 50261-7 from Table MPM-A.

Deleted LOINC codes 34540-5, 34545-4 from Table MPM-E.

### **Description**

The percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year. For each product line, report each of the four rates separately and as a total rate.

Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB)

Annual monitoring for members on digoxin

Annual monitoring for members on diuretics

Annual monitoring for members on anticonvulsants

Total rate (the sum of the four numerators divided by the sum of the four denominators)

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

### **Eligible Population**

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	18 years and older as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.

---

<b>Benefits</b>	Medical and pharmacy.
<b>Event/ diagnosis</b>	Members on persistent medications—defined as members who received at least 180 treatment days of ambulatory medication in the measurement year. Refer to <i>Additional Eligible Population Criteria</i> for each rate.  <b>Treatment days</b> are the actual number of calendar days covered with prescriptions within the measurement year (i.e., a prescription of 90 days supply dispensed on December 1 of the measurement year counts as 31 treatment days).

### Administrative Specification

For each product line, report each of the four rates separately and as a combined rate. The total rate is the sum of the four numerators divided by the sum of the four denominators.

#### Rate 1: Annual Monitoring for Members on ACE Inhibitors or ARBs

---

<b>Additional eligible population criteria</b>	Members who received at least 180 treatment days of ACE inhibitors or ARBs, during the measurement year. Refer to Table CDC-L to identify ACE inhibitors and ARBs.  <b>Note:</b> <i>Members may switch therapy with any medication listed in Table CDC-L during the measurement year and have the days supply for those medications count toward the total 180 treatment days (i.e., a member who received 90 days of ACE inhibitors and 90 days of ARBs meets the denominator definition for rate 1).</i>
<b>Numerator</b>	At least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year (Table MPM-A). The member must meet one of the following criteria to be compliant. <ul style="list-style-type: none"> <li>A code for a <i>lab panel</i> test during the measurement year</li> <li>A code for a serum potassium <b>and</b> a code for serum creatinine during the measurement year</li> <li>A code for serum potassium <b>and</b> a code for blood urea nitrogen during the measurement year</li> </ul> <b>Note:</b> <i>The tests do not need to occur on the same service date, only within the measurement year.</i>

**Table MPM-A: Codes to Identify Physiologic Monitoring Tests**

Description	CPT	LOINC
Lab panel	80047, 80048, 80050, 80053, 80069	
Serum potassium (K+)	80051, 84132	2824-1, 2823-3, 6298-4, 12812-4, 12813-2, 22760-3, 29349-8, 32713-0, 34548-8, 39789-3, 39790-1, 41656-0, 51618-7
Serum creatinine (SCr)	82565, 82575	2160-0, 2163-4, 2164-2, 11041-1, 11042-9, 12195-4, 13441-1, 13442-9, 13443-7, 13446-0, 13447-8, 13449-4, 13450-2, 14682-9, 16188-5, 16189-3, 21232-4, 26752-6, 31045-8, 33558-8, 35203-9, 35591-7, 35592-5, 35593-3, 35594-1, 38483-4, 39955-0, 39956-8, 39957-6, 39958-4, 39959-2, 39960-0, 39961-8, 39962-6, 39963-4, 39964-2, 39965-9, 39966-7, 39967-5, 39968-3, 39969-1, 39970-9, 39971-7, 39972-5, 39973-3, 39974-1, 39975-8, 39976-6, 40112-5, 40113-3, 40114-1, 40115-8, 40116-6, 40117-4, 40118-2, 40119-0, 40120-8, 40121-6, 40122-4, 40123-2, 40124-0, 40125-7, 40126-5, 40127-3, 40128-1, 40248-7, 40249-5, 40250-3, 40251-1, 40252-9, 40253-7, 40254-5, 40255-2, 40256-0, 40257-8, 40258-6, 40264-4, 40265-1, 40266-9, 40267-7, 40268-5, 40269-3, 40270-1, 40271-9, 40272-7, 40273-5, 44784-7, 50380-5, 50381-3, 51619-5, 51620-3
Blood urea nitrogen (BUN)	84520, 84525	3094-0, 6299-2, 11064-3, 11065-0, 12964-3, 12965-0, 12966-8, 14937-7, 44734-2, 49071-4

**Rate 2: Annual Monitoring for Members on Digoxin**

**Additional eligible population criteria** Members who received at least 180 treatment days of digoxin (Table MPM-B) during the measurement year.

**Table MPM-B: Drugs to Identify Members on Digoxin**

Description	Prescription
Inotropic agents	• digoxin

**Numerator** At least one serum potassium *and* either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year (Table MPM-A). The member must meet one of the following criteria to be compliant.

A code for a *lab panel* test during the measurement year

A code for a serum potassium *and* a code for serum creatinine during the measurement year

A code for serum potassium *and* a code for blood urea nitrogen during the measurement year

**Note:** The two tests do not need to occur on the same service date, only within the measurement year.

**Rate 3: Annual Monitoring for Members on Diuretics**

**Additional eligible population criteria** Members who received at least 180 treatment days of a diuretic (Table MPM-C), during the measurement year.

**Note:** Members may switch therapy with any medication listed in Table MPM-C during the measurement year and have the days supply for those medications count toward the total 180 treatment days.

**Table MPM-C: Drugs to Identify Members on Diuretics**

Description	Prescription		
Antihypertensive combinations	aliskiren-hydrochlorothiazide amiloride-hydrochlorothiazide amlodipine-hydrochlorothiazide-valsartan atenolol-chlorthalidone benazepril-hydrochlorothiazide bendroflumethiazide-nadolol bisoprolol-hydrochlorothiazide candesartan-hydrochlorothiazide captopril-hydrochlorothiazide chlorthalidone-clonidine enalapril-hydrochlorothiazide eprosartan-hydrochlorothiazide fosinopril-hydrochlorothiazide hydrochlorothiazide-irbesartan	hydrochlorothiazide-lisinopril hydrochlorothiazide-losartan hydrochlorothiazide-methyldopa hydrochlorothiazide-metoprolol hydrochlorothiazide-moexipril hydrochlorothiazide-olmesartan hydrochlorothiazide-propranolol hydrochlorothiazide-quinapril hydrochlorothiazide-spirolactone hydrochlorothiazide-telmisartan hydrochlorothiazide-timolol hydrochlorothiazide-triamterene hydrochlorothiazide-valsartan polythiazide-prazosin	
Loop diuretics	bumetanide ethacrynic acid	furosemide torsemide	
Potassium-sparing diuretics	amiloride eplerenone	spironolactone triamterene	
Thiazide diuretics	bendroflumethiazide chlorothiazide chlorthalidone hydrochlorothiazide	hydroflumethiazide indapamide methyclothiazide metolazone	polythiazide trichlormethiazide

**Numerator**

At least one serum potassium *and* either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year (Table MPM-A). The member must meet one of the following criteria to be compliant.

A code for a *lab panel* test during the measurement year

A code for a serum potassium *and* a code for serum creatinine during the measurement year

A code for serum potassium *and* a code for blood urea nitrogen during the measurement year

**Note:** *The two tests do not need to occur on the same service date, only within the measurement year.*



## Rate 4: Annual Monitoring for Members on Anticonvulsants

**Additional eligible population criteria** Members who received at least 180 treatment days for an anticonvulsant (Table MPM-D) during the measurement year.

**Note:** Members who are on multiple anticonvulsant drugs count toward the denominator multiple times if they meet the persistent medications criteria for each drug taken during the measurement year (i.e., a member who received at least 180 days of phenytoin and 180 days of valproic acid is counted twice in the denominator for Rate 4, once for each drug).

**Table MPM-D: Drugs to Identify Members on Anticonvulsants**

Description	Drugs
Barbiturate anticonvulsants	phenobarbital
Dibenzazepine anticonvulsants	carbamazepine
Hydantoin anticonvulsants	phenytoin
Miscellaneous anticonvulsants	divalproex sodium      valproic acid

**Numerator** At least one drug serum concentration level monitoring test for the prescribed drug in the measurement year (Table MPM-E).

If a member received only one type of anticonvulsant, the drug serum concentration level test must be for the specific drug taken as a persistent medication (i.e., a member on phenytoin received a drug serum test for phenytoin).

If a member persistently received multiple types of anticonvulsants, each anticonvulsant medication and drug monitoring test combination is counted as a unique event (i.e., a member on both phenytoin and valproic acid with at least 180 treatment days for each drug in the measurement year must separately show evidence of receiving drug serum concentration tests for each drug [Table MPM-E] to be considered numerator-compliant for each drug).

**Table MPM-E: Codes to Identify Drug Serum Concentration Monitoring Tests**

Description	CPT	LOINC
Drug serum concentration for phenobarbital	80184	3948-7, 3951-1, 10547-8, 14874-2, 34365-7
Drug serum concentration for phenytoin	80185, 80186	3968-5, 3969-3, 14877-5, 32109-1, 40460-8
Drug serum concentration for valproic acid or divalproex sodium	80164	4086-5, 4087-3, 4088-1, 14946-8, 18489-5, 21590-5, 32119-0, 32283-4
Drug serum concentration for carbamazepine	80156, 80157	3432-2, 3433-0, 9415-1, 14056-6, 14639-9, 18270-9, 29147-6, 29148-4, 32058-0, 32852-6, 47097-1

---

**Exclusion (optional)**

---

Members from each eligible population rate who had an inpatient (acute or nonacute) claim/encounter during the measurement year.

**Data Elements for Reporting**

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table MPM-1/2/3: Data Elements for Annual Monitoring for Patients on Persistent Medications**

	<b>Administrative</b>
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	<i>For each of the 4 rates and total</i>
Numerator events by administrative data	<i>For each of the 4 rates and total</i>
Reported rate	<i>For each of the 4 rates and total</i>
Lower 95% confidence interval	<i>For each of the 4 rates and total</i>
Upper 95% confidence interval	<i>For each of the 4 rates and total</i>

---

## Potentially Harmful Drug-Disease Interactions in the Elderly (DDE)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Added CPT codes 90960–90962, 90966, 90970 to Table DDE-H “Chronic renal failure” description.

Deleted CPT code 90939 from Table DDE-H.

### Description

The percentage of Medicare members 65 years of age and older who have evidence of an underlying disease, condition or health concern and who were dispensed an ambulatory prescription for a contraindicated medication, concurrent with or after the diagnosis.

Report each of the three rates separately and as a total rate.

A history of falls and a prescription for tricyclic antidepressants, antipsychotics or sleep agents

Dementia and a prescription for tricyclic antidepressants or anticholinergic agents

CRF and prescription for nonaspirin NSAIDs or Cox-2 Selective NSAIDs

Total rate (the sum of the three numerators divided by the sum of the three denominators)

Members with more than one disease or condition can appear in the measure multiple times (i.e., in each indicator for which they qualify). For all three rates, a lower rate represents better performance.

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

### Definitions

#### IESD

Index Episode Start Date. The earliest diagnosis, procedure or prescription between January 1 of the year prior to the measurement year and December 1 of the measurement year.

*For an outpatient claim/encounter, the IESD is the date of service.*

*For an inpatient claim/encounter, the IESD is the discharge date.*

*For dispensed prescriptions, the IESD is the dispense date.*

## Eligible Population

<b>Product line</b>	Medicare.
<b>Age</b>	67 years and older as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year and the year prior to the measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment.
<b>Anchor date</b>	Enrolled as of December 31 of the measurement year.
<b>Benefit</b>	Medical and pharmacy.
<b>Event/diagnosis</b>	Members with at least one disease or condition or procedure in the measurement year or the year prior to the measurement year. Refer to <i>Additional Eligible Population Criteria</i> for each rate.

## Administrative Specification

Report each rate separately and as a combined rate. The total rate is the sum of the three numerators divided by the sum of the three denominators.

## Rate 1: Drug-Disease Interactions—History of Falls and Tricyclic Antidepressants, Antipsychotics or Sleep Agents

**Additional eligible population criteria** An accidental fall or hip fracture on or between January 1 of the year prior to the measurement year and December 1 of the measurement year.

Follow the steps below to identify the eligible population.

**Step 1** Identify members who had an accidental fall or hip fracture (Table DDE-A) on or between January 1 of the year prior to the measurement year and December 1 of the measurement year. Identify the IESD for each member.

**Table DDE-A: Codes to Identify Falls or Hip Fractures**

Description	CPT	ICD-9-CM Diagnosis
Falls		E880, E884, E885.9, E887, E888
Hip fracture*	27230, 27232, 27235, 27236, 27238, 27240, 27244-27246, 27248, 27254, 27267-27269, 27767-27769	820, V54.13

\*Hip fracture may be used as a proxy for identifying falls.

**Step 2** Exclude members with a diagnosis of psychosis (Table DDE-B) on or between January 1 of the year prior to the measurement year and December 1 of the measurement year.

**Table DDE-B: Codes to Identify Psychosis**

Description	ICD-9-CM Diagnosis
Dementias (with delirium or delusions)	290.11, 290.12, 290.20, 290.3, 290.41, 290.42, 290.8, 290.9
Transient mental disorders due to conditions classified elsewhere	293
Dementia in conditions classified elsewhere with behavioral disturbance	294.11
Schizophrenic disorders	295
Episodic mood disorders with psychotic behavior	296.x4
Delusional disorders	297
Other nonorganic psychoses	298

**Numerator** Dispensed an ambulatory prescription for a tricyclic antidepressant (Table DDE-C) or an antipsychotic or sleep agent (Table DDE-D) on or between the IESD and December 31 of the measurement year.

**Table DDE-C: Tricyclic Antidepressants**

Description	Prescription		
Psychotherapeutic combinations	amitriptyline-chlordiazepoxide	amitriptyline-perphenazine	
Tricyclic antidepressants	amitriptyline amoxapine clomipramine	desipramine doxepin imipramine	nortriptyline protriptyline trimipramine

**Table DDE-D: Antipsychotics and Sleep Agents**

Description	Prescription			
Miscellaneous antipsychotic agents	aripiprazole clozapine haloperidol	loxapine molindone olanzapine	paliperidone pimozide quetiapine	risperidone ziprasidone
Miscellaneous anxiolytics, sedatives and hypnotics	eszopiclone ramelteon	zaleplon zolpidem		
Phenothiazine antipsychotics	prochlorperazine chlorpromazine	fluphenazine mesoridazine	perphenazine thioridazine	trifluoperazine
Psychotherapeutic combinations	fluoxetine-olanzapine			
Thioxanthenes	thiothixene			

## Rate 2: Drug-Disease Interactions—Dementia and Tricyclic Antidepressants or Anticholinergic Agents

**Additional eligible population criteria** A diagnosis of dementia (Table DDE-E) or a dispensed dementia medication (Table DDE-F) on or between January 1 of the year prior to the measurement year and December 1 of the measurement year. Identify the IESD for each member.

### Table DDE-E: Codes to Identify Dementia

ICD-9-CM Diagnosis
290, 291.2, 292.82, 294.0, 294.1, 294.8, 331.0, 331.1, 331.82

### Table DDE-F: Medications for Dementia

Description	Prescription
Cholinesterase inhibitors	donepezil      rivastigmine galantamine      tacrine
Miscellaneous central nervous system agents	memantine

**Numerator** Dispensed an ambulatory prescription for a tricyclic antidepressant (Table DDE-C), or anticholinergic agent (Table DDE-G) on or between the IESD and December 31 of the measurement year.

Table DDE-G: Anticholinergic Agents

Description	Prescription		
Anticholinergic antiemetics	cyclizine dimenhydrinate	meclizine scopolamine	trimethobenzamide
Anticholinergic anti-Parkinson agents	benztropine	trihexyphenidyl	
Anticholinergics/ antispasmodics	belladonna	dicyclomine	hyoscyamine propantheline
Antihistamines	azatadine brompheniramine chlorpheniramine	clemastine cyproheptadine dexchlorpheniramine	diphenhydramine hydroxyzine hydrochloride hydroxyzine pamoate triprolidine
Phenothiazine antiemetics	prochlorperazine	promethazine	
Skeletal muscle relaxants	carisoprodol chlorzoxazone	cyclobenzaprine metaxalone	methocarbamo orphenadrine
Upper respiratory combinations	APAP/diphenhydramine/pseudoephedrine atropine/CPM/hyoscyamine/PSE/scopolamine brompheniramine/carbetapentane/ phenylephrine brompheniramine/dextromethorphan/phenylephrine brompheniramine/dextromethorphan/PSE brompheniramine/DM/guaifenesin/ phenylephrine brompheniramine/DM/guaifenesin/PSE brompheniramine/DM/phenylephrine brompheniramine/hydrocodone/phenylephrine brompheniramine/hydrocodone/pseudo-ephedrine brompheniramine-phenylephrine brompheniramine-pseudoephedrine carbetapentane/chlorpheniramine/ phenylephrine carbetapentane/CPM/ephedrine/phenylephrine carbetapentane/diphenhydramine/ phenylephrine carbetapentane-chlorpheniramine	carbetapentane-diphenhydramine chlorpheniramine/codeine/PE/K iodide chlorpheniramine/codeine/pseudoephedrine chlorpheniramine/dextromethorphan/phenylephrine chlorpheniramine/dextromethorphan/PSE chlorpheniramine/dihydrocodeine/phenylephrine chlorpheniramine/dihydrocodeine/PSE chlorpheniramine/DM/guaifenesin/ phenylephrine chlorpheniramine/DM/methscopolamine chlorpheniramine/DM/phenylephrine chlorpheniramine/guaifenesin/phenylephrine chlorpheniramine/hydrocodone/phenylephrine chlorpheniramine/hydrocodone/PSE chlorpheniramine/methscopolamine/PE chlorpheniramine/methscopolamine/PSE chlorpheniramine/PE/phenyltoloxamine chlorpheniramine/phenylephrine/pyrilamine chlorpheniramine-hydrocodone chlorpheniramine-methscopolamine	chlorpheniramine-phenylephrine chlorpheniramine-pseudoephedrine codeine/phenylephrine/promethazine codeine/pseudoephedrine/triprolidine codeine-promethazine dexchlorpheniramine/dextromethorphan/PE/pyrilamine dexchlorpheniramine/dextromethorphan/PE dexchlorpheniramine/dextromethorphan/PSE dexchlorpheniramine/hydrocodone/phenylephrine dexchlorpheniramine/methscopolamine/PE dexchlorpheniramine/methscopolamine/PSE dexchlorpheniramine-pseudoephedrine dextromethorphan/diphenhydramine/PE dextromethorphan-promethazine diphenhydramine/hydrocodone/phenylephrine diphenhydramine-phenylephrine hydrocodone/pseudoephedrine/triprolidine phenylephrine-promethazine pseudoephedrine-triprolidine
Urinary antispasmodics	butabarbital/hyoscyamine/phenazopyridine flavoxate	hyoscyamine/methenam/m-blue/phenyl oxybutynin	tolterodine

### Rate 3: Drug-Disease Interactions—CRF and Nonaspirin NSAIDs or Cox-2 Selective NSAIDs

**Additional eligible population criteria**

A diagnosis of CRF (Table DDE-H) on or between January 1 of the year prior to the measurement year and December 1 of the measurement year. Identify the IESD for each member.

**Table DDE-H: Codes to Identify CRF**

Description	CPT	HCPCS	ICD-9-CM Diagnosis	ICD-9-CM Procedure	UB Revenue	UB Type of Bill	POS
Chronic renal failure	36145, 36800, 36810, 36815, 36818, 36819-36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90921, 90925, 90935, 90937, 90940, 90945, 90947, 90960-90962, 90966, 90970, 90989, 90993, 90997, 90999, 99512	G0257, G0317-G0319, G0323, G0327, G0392, G0393, S9339	585.5, 585.6, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6	0367, 080x, 082x-085x, 088x	72x	65

**Numerator**

Dispensed an ambulatory prescription for an NSAID or Cox-2 selective NSAID (Table DDE-I) on or between the IESD and December 31 of the measurement year.

**Table DDE-I: NSAIDs and Cox-2 Selective NSAIDs**

Description	Prescription			
Cox-2 inhibitors	celecoxib			
Nonsteroidal anti-inflammatory agents	diclofenac potassium	ibuprofen	mefenamic acid	oxaprozin
	diclofenac sodium	indomethacin	meloxicam	piroxicam
	etodolac	ketoprofen	nabumetone	sulindac
	fenoprofen	ketorolac	naproxen	tolmetin
	flurbiprofen	meclofenamate	naproxen sodium	

### Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table DDE-3: Data Elements for Potentially Harmful Drug-Disease Interactions in the Elderly**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	<i>For each of the 3 rates and total</i>
Numerator events by administrative data	<i>For each of the 3 rates and total</i>
Reported rate	<i>For each of the 3 rates and total</i>
Lower 95% confidence interval	<i>For each of the 3 rates and total</i>
Upper 95% confidence interval	<i>For each of the 3 rates and total</i>



---

## ***Use of High-Risk Medications in the Elderly (DAE)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

The percentage of Medicare members 65 years of age and older who received at least one high risk medication

The percentage of Medicare members 65 years of age and older who received at least two different high risk medications

For both rates, a lower rate represents better performance.

**Note:** NCQA will post a comprehensive list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org) by November 16, 2009.

#### **Eligible Population**

<b>Product line</b>	Medicare.
<b>Age</b>	65 years and older as of December 31 of the measurement year.
<b>Continuous enrollment</b>	The measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during the measurement year.
<b>Anchor date</b>	Enrolled as of December 31 of the measurement year.
<b>Benefits</b>	Medical and pharmacy.
<b>Event/diagnosis</b>	None.

#### **Administrative Specification**

<b>Denominator</b>	The eligible population.
<b>Numerator 1</b>	At least one prescription dispensed for any high-risk medication (Table DAE-A) during the measurement year.
<b>Numerator 2</b>	At least two prescriptions dispensed for different high risk medications (Table DAE-A) during the measurement year. <b>Note:</b> Identify different drugs using the Drug ID field located in the NDC list on NCQA's Web site ( <a href="http://www.ncqa.org">www.ncqa.org</a> ).

Table DAE-A: High-Risk Medications

Description	Prescription		
Antianxiety (includes combination drugs)	aspirin-meprobamate	meprobamate	
Antiemetics	scopolamine	trimethobenzamide	
Analgesics (includes combination drugs)	<ul style="list-style-type: none"> <li>• acetaminophen-diphenhydramine</li> <li>• diphenhydramine-magnesium salicylate</li> </ul>		ketorolac
Antihistamines (includes combination drugs)	<ul style="list-style-type: none"> <li>• APAP/dextromethorphan/diphenhydramine</li> <li>• APAP/diphenhydramine/phenylephrine</li> <li>• APAP/diphenhydramine/pseudoephedrine</li> <li>• acetaminophen-diphenhydramine</li> <li>atropine/CPM/hyoscyamine/PE/PPA/scopolamine</li> <li>carbetapentane/diphenhydramine/phenylephrine</li> <li>codeine/phenylephrine/promethazine</li> <li>codeine-promethazine</li> <li>cyproheptadine</li> <li>dexchlorpheniramine</li> <li>dexchlorpheniramine/dextromethorphan/PSE</li> <li>• dexchlorpheniramine/guaifenesin/PSE</li> <li>dexchlorpheniramine/hydrocodone/phenylephrine</li> </ul>		dexchlorpheniramine/methscopolamine/PSE <ul style="list-style-type: none"> <li>• dexchlorpheniramine-pseudoephedrine</li> </ul> dextromethorphan-promethazine diphenhydramine diphenhydramine/hydrocodone/phenylephrine <ul style="list-style-type: none"> <li>• diphenhydramine-magnesium salicylate</li> </ul> diphenhydramine-phenylephrine diphenhydramine-pseudoephedrine hydroxyzine hydrochloride hydroxyzine pamoate phenylephrine-promethazine promethazine tripeleminamine
Antipsychotic, typical	mesoridazine	thioridazine	
Amphetamines	amphetamine-dextroamphetamine benzphetamine dexmethylphenidate	dextroamphetamine diethylpropion methamphetamine methylphenidate	pemoline phendimetrazine phentermine
Barbiturates	amobarbital butabarbital mephobarbital	pentobarbital phenobarbital secobarbital	
Long-acting benzodiazepines (includes combination drugs)	amitriptyline-chlordiazepoxide chlordiazepoxide	chlordiazepoxide-clidinium diazepam	flurazepam
Calcium channel blockers	nifedipine—short-acting only		
Gastrointestinal anti-spasmodics	dicyclomine	propantheline	
Belladonna alkaloids (includes combination drugs)	atropine atropine/CPM/hyoscyamine/PE/scopolamine atropine/hyoscyamine/PB/scopolamine atropine-difenoxin atropine-diphenoxylate atropine-edrophonium belladonna belladonna/caffeine/ergotamine/pentobarbital		belladonna/ergotamine/phenobarbital butabarbital/hyoscyamine/phenazopyridine digestive enzymes/hyoscyamine/ phenyltoloxamine hyoscyamine hyoscyamine/methenam/m-blue/phenyl salicyl hyoscyamine-phenobarbital
Skeletal muscle relaxants (includes combination drugs)	ASA/caffeine/orphenadrine ASA/carisoprodol/codeine aspirin-carisoprodol aspirin-meprobamate	aspirin-methocarbamol carisoprodol chlorzoxazone cyclobenzaprine	metaxalone methocarbamol orphenadrine
Oral estrogens (includes combination drugs)	conjugated estrogen conjugated estrogen-medroxyprogesterone	esterified estrogen esterified estrogen-methyltestosterone	estropipate

**Table DAE-A: High-Risk Medications (continued)**

Description	Prescription	
Oral hypoglycemics	chlorpropamide	
Narcotics (includes combination drugs)	ASA/caffeine/propoxyphene acetaminophen-pentazocine acetaminophen-propoxyphene belladonna-opium meperidine	meperidine-promethazine naloxone-pentazocine pentazocine propoxyphene hydrochloride propoxyphene napsylate
Vasodilators	cyclandelate dipyridamole—short-acting only	ergot mesyloid isoxsuprine
Others (including androgens and anabolic steroids, thyroid drugs, urinary anti-infectives)	methyltestosterone nitrofurantoin nitrofurantoin macrocrystals	nitrofurantoin macrocrystals-monohydrate thyroid desiccated

**Data Elements for Reporting**

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table DAE-3: Data Elements for Use of High-Risk Medications in the Elderly**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	<i>For each of the 2 rates</i>
Reported rate	<i>For each of the 2 rates</i>
Lower 95% confidence interval	<i>For each of the 2 rates</i>
Upper 95% confidence interval	<i>For each of the 2 rates</i>

## **Medication Reconciliation Post-Discharge (MRP)**

### **SUMMARY OF CHANGES TO HEDIS 2010**

Added definition of “medication reconciliation.”

Clarified medical record documentation for evidence of medication reconciliation.

#### **Description**

The percentage of discharges from January 1–December 1 of the measurement year for members 65 years of age and older for whom medications were reconciled on or within 30 days of discharge.

#### **Definition**

**Medication reconciliation** A type of review in which the discharge medications are reconciled with the current medication list in the outpatient medical record.

#### **Eligible Population**

**Product line** Medicare SNP.

**Ages** 66 years and older as of December 31 of the measurement year.

**Continuous enrollment** Date of discharge through 30 days after discharge.

**Allowable gap** None.

**Anchor date** Date of discharge.

**Benefit** Medical.

**Event/diagnosis** An acute or nonacute inpatient discharge on or between January 1 and December 1 of the measurement year.

The denominator for this measure is based on discharges, not members. Include all discharges for members who have one or more discharges on or between January 1 and December 1 of the measurement year.

**Readmission or direct transfer** If the discharge is followed by a readmission or direct transfer to an acute or nonacute facility within the 30-day follow-up period, count only the readmission discharge or the discharge from the facility to which the member was transferred.

Exclude both the initial discharge and the readmission/direct transfer discharge if the readmission/direct transfer discharge occurs after December 1 of the measurement year.

## Administrative Specification

<b>Denominator</b>	The eligible population.
<b>Numerator</b>	Medication reconciliation (Table MRP-A) conducted by a prescribing practitioner or clinical pharmacists on or within 30 days of discharge. A member had a medication reconciliation if a claim/encounter contains a code in Table MRP-A.

**Table MRP-A: Codes to Identify Medication Reconciliation**

Description	CPT Category II
Medication reconciliation	1111F

## Hybrid Specification

<b>Denominator</b>	<p>A systematic sample drawn from the eligible population. The organization may reduce the sample size using the current year's administrative rate or the prior year's audited, product line-specific rate. Refer to the <i>Guidelines for Calculations and Sampling</i> for information on reducing the sample size.</p> <p>The denominator is based on episodes, not members. Members may appear more than once in the sample.</p>
<b>Numerator</b>	<p>Medication reconciliation conducted by a prescribing practitioner or clinical pharmacist, as documented through either administrative data or medical record review on or within 30 days of discharge.</p> <p><b>Administrative</b> Refer to <i>Administrative Specification</i> to identify positive numerator hits from administrative data.</p> <p><b>Medical record</b> Documentation in the medical record must include evidence of medication reconciliation, and the date on which it was performed. The following evidence meets criteria.</p> <p style="padding-left: 40px;">Notation that the medications prescribed or ordered upon discharge were reviewed, <b>or</b></p> <p style="padding-left: 40px;">Notation that no medications were prescribed or ordered upon discharge</p> <p>Only documentation in the outpatient chart meets the intent of the measure, but an outpatient visit is not required. A medication list in a discharge summary obtained from the hospital or inpatient chart should not be used as evidence of medication reconciliation, but the intent of the measure is met if the discharge summary is in the outpatient chart.</p>

### Note

*The denominator is based on the discharge date found in administrative/claims data. This date must be used, regardless of subsequent data errors or corrections found during medical record review.*

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table MRP-3: Data Elements for Medication Reconciliation Post-Discharge**

	Administrative	Hybrid
Measurement year	✓	✓
Data collection methodology (Administrative or Hybrid)	✓	✓
Eligible population	✓	✓
Number of numerator events by administrative data in eligible population (before exclusions)		✓
Current year's administrative rate (before exclusions)		✓
Minimum required sample size (MRSS) or other sample size		✓
Oversampling rate		✓
Final sample size (FSS)		✓
Number of numerator events by administrative data in FSS		✓
Administrative rate on FSS		✓
Number of original sample records excluded because of valid data errors		✓
Number of employee/dependent medical records excluded		✓
Records added from the oversample list		✓
Denominator		✓
Numerator events by administrative data	✓	✓
Numerator events by medical records		✓
Reported rate	✓	✓
Lower 95% confidence interval	✓	✓
Upper 95% confidence interval	✓	✓

---

## ***Medicare Health Outcomes Survey (HOS)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 6: Specifications for the Medicare Health Outcomes Survey*.

#### **Description**

This measure provides a general indication of how well a Medicare organization manages the physical and mental health of its members. The survey measures each member's physical and mental health status at the beginning and the end of a two-year period.

A two-year change score is calculated and each member's physical and mental health status is categorized as better, the same or worse than expected, taking into account risk adjustment factors. Organization-specific results are assigned as percentages of members whose health status was better, the same or worse than expected.

---

## ***Fall Risk Management (FRM)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 6: Specifications for the Medicare Health Outcomes Survey*.

#### **Description**

The following components of this measure assess different facets of fall risk management.

**Discussing  
Fall Risk**

The percentage of Medicare members 75 years of age and older or 65–74 years of age with balance or walking problems or a fall in the past 12 months, who were seen by a practitioner in the past 12 months and who discussed falls or problems with balance or walking with their current practitioner.

**Managing  
Fall Risk**

The percentage of Medicare members 65 years of age and older who had a fall or had problems with balance or walking in the past 12 months, who were seen by a practitioner in the past 12 months and who received fall risk intervention from their current practitioner.



---

## ***Management of Urinary Incontinence in Older Adults (MUI)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 6: Specifications for the Medicare Health Outcomes Survey*.

#### **Description**

The following components of this measure assess the management of urinary incontinence in older adults.

<b>Discussing Urinary Incontinence</b>	The percentage of Medicare members 65 years of age and older who reported having a problem with urine leakage in the past six months and who discussed their urine leakage problem with their current practitioner.
<b>Receiving Urinary Incontinence Treatment</b>	The percentage of Medicare members 65 years of age and older who reported having a urine leakage problem in the past six months and who received treatment for their current urine leakage problem.

---

## ***Osteoporosis Testing in Older Women (OTO)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 6: Specifications for the Medicare Health Outcomes Survey*.

#### **Description**

The percentage of Medicare women 65 years of age and older who report ever having received a bone density test to check for osteoporosis.

---

## ***Physical Activity in Older Adults (PAO)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 6: Specifications for the Medicare Health Outcomes Survey*.

#### **Description**

The following components of this measure assess different facets of promoting physical activity in older adults.

**Discussing Physical Activity** The percentage of Medicare members 65 years of age and older who had a doctor's visit in the past 12 months and who spoke with a doctor or other health provider about their level of exercise or physical activity.

**Advising Physical Activity** The percentage of Medicare members 65 years of age and older who had a doctor's visit in the past 12 months and who received advice to start, increase or maintain their level exercise or physical activity.

---

## ***Flu Shots for Older Adults (FSO)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 3: Specifications for Survey Measures*.

#### **Description**

The percentage of Medicare members 65 years of age and older as of January 1 of the measurement year who received an influenza vaccination between September 1 of the measurement year and the date on which the Medicare CAHPS survey was completed.

---

## ***Medical Assistance With Smoking and Tobacco Use Cessation (MSC)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 3: Specifications for Survey Measures*.

#### **Description**

The following components of this measure assess different facets of providing medical assistance with smoking and tobacco use cessation.

<b>Advising Smokers and Tobacco Users to Quit</b>	A rolling average represents the percentage of members 18 years of age and older who are current smokers or tobacco users and who received advice to quit during the measurement year.
<b>Discussing Cessation Medications</b>	A rolling average represents the percentage of members 18 years of age and older who are current smokers or tobacco users and who discussed or were recommended medications to quit during the measurement year.
<b>Discussing Cessation Strategies</b>	A rolling average represents the percentage of members 18 years of age and older who are current smokers or tobacco users who discussed or were provided cessation methods or strategies during the measurement year.

---

## ***Pneumonia Vaccination Status for Older Adults (PNU)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

This measure is collected using survey methodology. Detailed specifications and summary of changes are contained in *HEDIS 2010, Volume 3: Specifications for Survey Measures*.

#### **Description**

The percentage of Medicare members 65 years of age and older as of January 1 of the measurement year who have ever received a pneumococcal vaccine

---

## Adults' Access to Preventive/Ambulatory Health Services (AAP)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

No changes to this measure.

#### Description

The percentage of members 20 years and older who had an ambulatory or preventive care visit. The organization reports three separate percentages for each product line.

*Medicaid and Medicare members* who had an ambulatory or preventive care visit during the measurement year

*Commercial members* who had an ambulatory or preventive care visit during the measurement year or the two years prior to the measurement year

#### Eligible Population

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).
<b>Ages</b>	20–65 years and older as of December 31 of the measurement year. Report three age stratifications and a total rate. 20–44 years      45–64 years      65 years and older      Total  Total. The total rate is the sum of the three numerators divided by the sum of the three denominators.
<b>Continuous enrollment</b>	<i>Medicaid and Medicare:</i> The measurement year. <i>Commercial:</i> The measurement year and the two years prior to the measurement year.
<b>Allowable gap</b>	No more than one gap in enrollment of up to 45 days during each year of continuous enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (i.e., a member whose coverage lapses for 2 months [60 days] is not considered continuously enrolled).
<b>Anchor date</b>	December 31 of the measurement year.
<b>Benefit</b>	Medical.
<b>Event/diagnosis</b>	None.

## Administrative Specification

**Denominator** The eligible population (report each age stratification separately).

**Numerator** *Medicaid and Medicare:* One or more ambulatory or preventive care visits (Table AAP-A) during the measurement year.

*Commercial:* One or more ambulatory or preventive care visits (Table AAP-A) during the measurement year or the two years prior to the measurement year.

**Table AAP-A: Codes to Identify Preventive/Ambulatory Health Services**

Description	CPT	HCPCS	ICD-9-CM Diagnosis	UB Revenue
Office or other outpatient services	99201-99205, 99211-99215, 99241-99245			051x, 052x, 0982, 0983
Home services	99341-99345, 99347-99350			
Nursing facility care	99304-99310, 99315, 99316, 99318			
Domiciliary, rest home or custodial care services	99324-99328, 99334-99337			
Preventive medicine	99385-99387, 99395-99397, 99401-99404, 99411, 99412, 99420, 99429	G0344		077x
Ophthalmology and optometry	92002, 92004, 92012, 92014			
General medical examination			V70.0, V70.3, V70.5, V70.6, V70.8, V70.9	

## Data Elements for Reporting

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table AAP-1/2/3: Data Elements for Adults' Access to Preventive/Ambulatory Health Services**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	<i>For each age stratification and total</i>
Numerator events by administrative data	<i>For each age stratification and total</i>
Reported rate	<i>For each age stratification and total</i>
Lower 95% confidence interval	<i>For each age stratification and total</i>
Upper 95% confidence interval	<i>For each age stratification and total</i>



---

## ***Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Deleted CPT codes 99261–99263 from Table IET-B.

#### **Description**

The percentage of adolescent and adult members with a new episode of alcohol or other drug (AOD) dependence who received the following.

*Initiation of AOD Treatment.* The percentage of members who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis.

*Engagement of AOD Treatment.* The percentage of members who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.

#### **Definitions**

<b>Intake Period</b>	January 1–November 15 of the measurement year. The Intake Period is used to capture new episodes of AOD.
<b>Index Episode</b>	The earliest inpatient, intensive outpatient, partial hospitalization, outpatient, detoxification or ED encounter during the Intake Period with a diagnosis of AOD.  <i>For ED visits that result in an inpatient stay, the inpatient stay is the Index Episode.</i>
<b>IESD</b>	Index Episode Start Date. The earliest date of service for any inpatient, intensive outpatient, partial hospitalization, outpatient, detoxification or ED encounter during the Intake Period with any diagnosis of AOD.  <i>For an outpatient, intensive outpatient, partial hospitalization, detoxification or ED (not resulting in an inpatient stay) claim/encounter, the IESD is the date of service.</i>  <i>For an inpatient (acute or nonacute) claim/encounter, the IESD is the date of discharge.</i>  <i>For an ED visit that results in an inpatient stay, the IESD is the date of the inpatient discharge.</i>  <i>For direct transfers, the IESD is the discharge date from the second admission.</i>

---

**Negative  
Diagnosis  
History**

A period of 60 days prior to the IESD, during which the member had no claims/encounters with any diagnosis of AOD dependence.

*For an inpatient claim/encounter, use the admission date to determine the Negative Diagnosis History.*

*For ED visits that result in an inpatient stay, use the ED date of service to determine the Negative Diagnosis History.*

*For direct transfers, use the first admission to determine the Negative Diagnosis History.*

**Eligible Population**

**Product lines**

Commercial, Medicaid, Medicare (report each product line separately).

**Age**

13 years and older as of the December 31 of the measurement year. Report two age stratifications and a total rate.

13-17 years

18+ years

Total

The total rate is the sum of the two numerators divided by the sum of the two denominators.

**Continuous enrollment**

60 days prior to the IESD through 44 days after the IESD (inclusive).

**Allowable gap**

None.

**Anchor date**

None.

**Benefits**

Medical and chemical dependency (inpatient and outpatient).

**Note:** *Members with detoxification-only chemical dependency benefits do not meet these criteria.*

**Event/  
diagnosis**

New episode of AOD during the Intake Period.

Follow the steps below to identify the eligible population, which is the denominator for both rates.

**Step 1** Identify the Index Episode. Identify all members in the specified age range who during the Intake Period had one of the following.

An outpatient visit, intensive outpatient encounter or partial hospitalization (Table IET-B) with a diagnosis of AOD (Table IET-A)

A detoxification visit (Table IET-C)

An ED visit (Table IET-D) with a diagnosis of AOD (Table IET-A)

An inpatient discharge with a diagnosis of AOD as identified by either of the following.

An inpatient facility code in conjunction with a diagnosis of AOD (IET-A)

An inpatient facility code in conjunction with an AOD procedure code (IET-E)

*For members with more than one episode of AOD, use the first episode.*

*For members whose first episode was an ED visit that resulted in an inpatient stay, use the inpatient discharge.*

Select the IESD.

**Table IET-A: Codes to Identify AOD Dependence**

ICD-9-CM Diagnosis
291.292, 303.00-303.02, 303.90-303.92, 304.00-304.02, 304.10-304.12, 304.20-304.22, 304.30-304.32, 304.40-304.42, 304.50-304.52, 304.60-304.62, 304.70-304.72, 304.80-304.82, 304.90-304.92, 305.00-305.02, 305.20-305.22, 305.30-305.32, 305.40-305.42, 305.50-305.52, 305.60-305.62, 305.70-305.72, 305.80-305.82, 305.90-305.92, 535.3, 571.1

**Table IET-B: Codes to Identify Outpatient, Intensive Outpatient and Partial Hospitalization Visits**

CPT	HCPCS	UB Revenue
90804-90815, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99394-99397, 99401-99404, 99408, 99409, 99411, 99412, 99510	G0155, G0176, G0177, G0396, G0397, H0001, H0002, H0004, H0005, H0007, H0015, H0016, H0020, H0022, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, H2035, H2036, M0064, S0201, S9480, S9484, S9485, T1006, T1012	0510, 0513, 0515-0517, 0519-0523, 0526-0529, 077x, 0900, 0902-0907, 0911-0917, 0919, 0944, 0945, 0982, 0983
CPT		POS
90801, 90802, 90845, 90847, 90849, 90853, 90857, 90862, 90875, 90876	<i>WITH</i>	03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 33, 49, 50, 52, 53, 57, 71, 72
90816-90819, 90821-90824, 90826-90829, 99221-99223, 99231-99233, 99238, 99239, 99251-99255	<i>WITH</i>	52, 53

**Table IET-C: Codes to Identify Detoxification Visits**

HCPCS	ICD-9-CM Procedure	UB Revenue
H0008-H0014	94.62, 94.65, 94.68	0116, 0126, 0136, 0146, 0156

**Table IET-D: Codes to Identify Emergency Department Visits**

CPT	UB Revenue
99281-99285	045x, 0981

**Table IET-E: Codes to Identify AOD Procedures**

ICD-9-CM Procedure
94.61, 94.63, 94.64, 94.66, 94.67, 94.69

---

**Step 2** Test for Negative Diagnosis History. Exclude members who had a claim/encounter with any diagnosis of AOD (Table IET-A) during the 60 days prior to the IESD.

*For an inpatient IESD, use the admission date to determine the Negative Diagnosis History.*

*For an ED visit that results in an inpatient stay, use the ED date of service to determine the Negative Diagnosis History.*

**Step 3** Calculate continuous enrollment. Members must be continuously enrolled without any gaps 60 days prior to the IESD through 44 days after the IESD.

## Administrative Specification

**Denominator** The eligible population.

### Numerator

**Initiation of AOD Treatment** Initiation of AOD treatment through an inpatient admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of diagnosis.

If the Index Episode was an inpatient discharge, the inpatient stay is considered initiation of treatment and the member is compliant

If the Index Episode was an outpatient, intensive outpatient, partial hospitalization, detoxification or ED visit, the member must have an inpatient admission, outpatient visit, intensive outpatient encounter or partial hospitalization (Table IET-B) with any AOD diagnosis (Table IET-A) within 14 days of the IESD (inclusive)

If the initiation encounter is an inpatient admission, the admission date (not the discharge date) must be within 14 days of the IESD (inclusive)

Do not count Index Episodes that include detoxification codes (including inpatient detoxification) as being initiation of treatment

Exclude from the denominator members whose initiation encounter is an inpatient stay with a discharge date after December 1 of the measurement year.

**Engagement of AOD Treatment** Initiation of AOD treatment and two or more inpatient admissions, outpatient visits, intensive outpatient encounters or partial hospitalizations (Table IET-B) with any AOD diagnosis (Table IET-A) within 30 days after the date of the Initiation encounter (inclusive). Multiple engagement visits may occur on the same day, but they must be with different providers in order to be counted.

*For members who initiated treatment via an inpatient stay, use the discharge date as the start of the 30-day engagement time period.*

If the engagement encounter is an inpatient admission, the admission date (not the discharge date) must be within 30 days of the Initiation encounter (inclusive).

Do not count engagement encounters that include detoxification codes (including inpatient detoxification)

---

**Note**

---

Organizations may have different methods for billing intensive outpatient encounters and partial hospitalizations. Some organizations may bill comparable to outpatient billing, with separate claims for each date of service; others may bill comparable to inpatient billing, with an admission date, a discharge date and units of service. Organizations that bill comparable to inpatient billing may count each unit of service as an individual visit. The unit of service must have occurred during the time frame required for the rate (e.g., within 14 days of the IESD or within 30 days after the date of the initiation encounter).

**Data Elements for Reporting**

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table IET-1/2/3: Data Elements for Initiation and Engagement of Alcohol and Other Drug Dependence Treatment**

	<b>Administrative</b>
Measurement year	✓
Data collection methodology (administrative)	✓
Eligible population	<i>For each age stratification and total</i>
Numerator events by administrative data	<i>For each age stratification and total</i>
Reported rate	<i>For each age stratification and total</i>
Lower 95% confidence interval	<i>For each age stratification and total</i>
Upper 95% confidence interval	<i>For each age stratification and total</i>

---

## Call Abandonment (CAB)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

No changes to this measure.

#### Description

The percentage of calls received by the organization's Member Services call centers (during operating hours) during the measurement year that were abandoned by the caller before being answered by a live voice. Lower rates represent better performance.

#### Definitions

<b>Abandonment</b>	The caller dials directly into the organization's Member Services call center or selects the Member Services option, is placed in the call queue and hangs up the phone, disconnecting from the call center before being answered by a Member Services representative.
<b>Call</b>	Telephone contact initiated by an external caller that connects to the organization Member Services call center. For calls transferred from other parts of the organization telephone system, measure time from after the call is transferred into the call center and the member chooses the option to speak to a Member Services representative and is placed in the call queue.
<b>Member Services operating hours</b>	Hours of live call-center operation indicated by membership materials (e.g., ID card, summary organization descriptions, enrollment materials).
<b>Member Services representative</b>	An employee at the organization's Member Services call center responsible for answering calls regarding enrollment, benefits and claims processing.
<b>Member Services call center</b>	An entity within the organization or under contract with the organization that is responsible for handling the organization's network Member Services inquiries regarding enrollment, benefits and claims processing.
<b>Queue</b>	A sequence of calls waiting to be handled by a Member Services representative. The wait time on a queued call is calculated by Automatic Call Distribution (ACD), which tracks incoming calls.

#### Calculation

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately). <b>Note:</b> An organization that uses the same systems, policies and procedures and staff to answer calls for all product lines may report the same rate for all product lines if it is not possible for it to report data by individual product line.
<b>Denominator</b>	The number of calls received by the organization's Member Services call center (during hours of operation) during the measurement year where the member called directly into Member Services or selected a Member Services option and was put in the call queue.  Exclude calls to the organization's benefit contractor (e.g., mental health, dental, vision, pharmacy) when the contractor has its own call center.

---

**Numerator**

The number of calls abandoned by the caller or the system before being answered by a live voice.

**Note:** Calls abandoned within 30 seconds remain in the measure and are compliant for the numerator. Calls sent directly to voicemail should also remain in the measure and are considered compliant.

**Formulas**

For an organization with one call center that answers all the organization's calls and has the organization as its only client, report the measure as specified.

For an organization with one call center that answers all the organization's calls and also has multiple clients, if the call center is unable to report abandonment data for the organization, report abandonment for the entire volume of calls the center handles.

For an organization with multiple call centers, each of which answers a portion of the total amount of calls for the organization and has the organization as its only client, report the measure as a weighted average (see the formula below).

**Definitions**

Let  $N_1$  = The total number of Member Services calls received by call center 1.

Let  $N_2$  = The total number of Member Services calls received by call center 2.

Let  $P_{CAB1}$  = The rate for the *Call Abandonment* HEDIS measure for call center 1.

Let  $P_{CAB2}$  = The rate for the *Call Abandonment* HEDIS measure for call center 2.

**Set-up calculations**

Let  $W_1$  = The weight assigned to call center 1. This result is calculated by the formula  $W_1 = N_1/(N_1+N_2)$ .

Let  $W_2$  = The weight assigned to call center 2. This result is calculated by the formula  $W_2 = N_2/(N_1+N_2)$ .

**Pooled analysis**

The pooled result from the two rates is calculated as:

$$P_{CA \text{ pooled}} = W_1 * P_{CAB1} + W_2 * P_{CAB2}$$

**Note**

---

If during peak call periods (or any regular business hours), the organization blocks calls by immediately giving members a busy signal and keeping the calls from reaching the call queue, the auditor assesses the percentage of blocked calls and its impact on the measure.

**Data Elements for Reporting**

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CAB-1/2/3: Data Elements for Call Abandonment**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓

---

## Call Answer Timeliness (CAT)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

No changes to this measure.

#### Description

The percentage of calls received by the organization's Member Services call centers (during operating hours) during the measurement year that were answered by a live voice within 30 seconds.

#### Definitions

<b>Call</b>	Telephone contact initiated by an external caller connects with the organization's Member Services call center. For calls transferred from other parts of the organization's telephone system, measure time from after the call is transferred into the Member Services call center, the member chooses the option to speak to a Member Services representative and is placed in the call queue.
<b>Member Services operating hours</b>	Hours of live call-center operation indicated by membership materials (e.g., ID card, summary organization descriptions, enrollment materials).
<b>Member Services representative</b>	An employee at the organization's Member Services call center responsible for answering calls regarding enrollment, benefits and claims processing.
<b>Member Services call center</b>	An entity within the organization or under contract with the organization that is responsible for handling the organization's network Member Services inquiries regarding enrollment, benefits and claims processing.
<b>Queue</b>	A sequence of calls waiting to be handled by the Member Services representative. The wait time on a queued call is calculated by ACD, which tracks incoming calls.

#### Calculation

<b>Product lines</b>	Commercial, Medicaid, Medicare (report each product line separately).  <i>Note: An organization that uses the same systems, policies and procedures and staff to answer calls for all product lines may report the same rate for all product lines if it is not possible for it to report data by individual product line.</i>
<b>Denominator</b>	The number of calls received by the Member Services call centers (during hours of operation) during the measurement year, where the member called directly into Member Services or selected a Member Services option and was put in the call queue. Exclude calls to a benefits contractor (e.g., mental health, dental, vision, pharmacy) that uses its own call center.
<b>Numerator</b>	The number of calls answered by a live voice within 30 seconds.  Time measured begins when the member is placed in the call queue and is waiting to speak to a Member Services representative.  <i>Note: Calls abandoned within 30 seconds remain in the measure and are noncompliant for the numerator. Calls sent directly to voicemail should also remain in the measure and are considered noncompliant.</i>



---

**Formulas**

*For an organization with one call center that answers all the organization's calls and has the organization as its only client, report the measure as specified.*

*For an organization with one call center that answers all the organization's calls and also has multiple clients, if the call center is unable to report timeliness data for the specific organization, report timeliness for the entire volume of calls the center handles.*

*For an organization with multiple call centers, each of which answers a portion of the total calls for the organization and has the organization as its only client, report the measure as a weighted average (see the formula below).*

- Definitions** Let  $N_1$  = The total number of Member Services calls received by call center 1.  
Let  $N_2$  = The total number of Member Services calls received by call center 2.  
Let  $P_{CAT1}$  = The rate for the *Call Answer Timeliness* HEDIS measure for call center 1.  
Let  $P_{CAT2}$  = The rate for the *Call Answer Timeliness* HEDIS measure for call center 2.

- Set-up calculations** Let  $W_1$  = The weight assigned to call center 1. This result is calculated by the formula  $W_1 = N_1/(N_1+N_2)$ .  
Let  $W_2$  = The weight assigned to call center 2. This result is calculated by the formula  $W_2 = N_2/(N_1+N_2)$ .

**Pooled analysis** The pooled result from the two rates is calculated as:

$$P_{CAT \text{ pooled}} = W_1 * P_{CAT1} + W_2 * P_{CAT2}$$

**Note**

*If during peak call periods (or any regular business hours), the organization blocks calls by immediately giving members a busy signal and keeping the calls from reaching the call queue, the auditor assesses the percentage of blocked calls and its impact on the measure.*

---

**Data Elements for Reporting**

Organizations that submit HEDIS data to NCQA must provide the following data elements.

**Table CAT-1/2/3: Data Elements for Call Answer Timeliness**

	Administrative
Measurement year	✓
Data collection methodology (Administrative)	✓
Eligible population	✓
Numerator events by administrative data	✓
Reported rate	✓
Lower 95% confidence interval	✓
Upper 95% confidence interval	✓

## **Total Membership (TLM)**

### **SUMMARY OF CHANGES TO HEDIS 2010**

Retired the *Years in Business* portion of the measure.

Renamed the measure.

Clarified Total Membership count.

### **Description**

The number of members enrolled as of December 31 of the measurement year.

### **Calculation**

For each product line the licensed organization offers (i.e., HMO, POS, PPO or FFS), report the number of members enrolled as of December 31 of the measurement year by product line (i.e., commercial, Medicaid, Medicare or other\*\*). The total category should equal the licensed organization's total membership as of December 31 of the measurement year. The organization should complete this measure once and report the information for each HEDIS submission.

Include all products and product lines (i.e., across all books of business), even if they were not included in a HEDIS submission. Include:

Special Needs Plans (SNP) in the Medicare count

ASO members in either the commercial HMO, POS or PPO count, as appropriate

EPO members in either the HMO, POS or PPO count, as appropriate

CHIP members in the Medicaid product line.

### **Table TLM-1/2/3: Total Membership\***

Organization Name: \_\_\_\_\_

Product/Product Line	Total Number of Members	Product/Product Line	Total Number of Members
<b>HMO</b>		<b>POS</b>	
Medicaid	_____	Medicaid	_____
Commercial	_____	Commercial	_____
Medicare	_____	Medicare	_____
Other	_____	Other	_____
<b>Total HMO:</b>	_____	<b>Total POS:</b>	_____
<b>PPO</b>		<b>FFS</b>	
Medicaid	_____	Medicaid	_____
Commercial	_____	Commercial	_____
Medicare	_____	Medicare	_____
Other	_____	Other	_____
<b>Total PPO:</b>	_____	<b>Total FFS:</b>	_____
<b>Total:</b>	_____		

\*Total number of members in each category as of December 31 of the measurement year.

---

## Frequency of Selected Procedures (FSP)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

Added CPT codes 22856, 22861, 22864, 27267–27269 to Table FSP-A.

Added ICD-9-CM Procedure codes 80.53, 80.54 to table FSP-A (“back surgery” description).

Deleted CPT codes 63035, 63043, 63044, 63048, 63057, 63066, 63076, 63078, 63082, 63086, 63088, 63091, 63103 from Table FSP-A.

Removed CMS-DRGs from Table FSP-A.

### Description

This measure summarizes the utilization of frequently performed procedures that often show wide regional variation and have generated concern regarding potentially inappropriate utilization.

### Calculations

#### Product lines

Report the following tables for each applicable product line.

Table FSP-1a Total Medicaid\*

Table FSP-2 Commercial—by Product or Combined HMO/POS

Table FSP-3 Medicare

\* Report this measure for Total Medicaid only; reporting by eligibility category will result in small numbers.

#### Member months

For each product line and table, report all member months for the measurement year. IDSS automatically produces member years data for the commercial and Medicare product lines. Refer to *Specific Instructions for Use of Services Tables* for more information.

#### Procedures

Use Table FSP-A to identify procedures for reporting. Report counts for the procedures as specified regardless of the site of care (e.g., inpatient or ambulatory setting). Report the number of procedures rather than the number of members who received the procedures. Do not double-count the same procedure. The two examples below illustrate scenarios counted as one procedure.

#### Count as one procedure...

If the date of service for two procedures is the same and both codes indicate CABG

If the date of service for a procedure falls between the admission and discharge dates for an inpatient stay where the procedure was performed  
For example, if a CABG was billed by a surgeon on March 4 of the measurement year and the facility bill shows a CABG for an admission that started on March 2 and lasted until March 7 of the measurement year, combine these to count one CABG

---

<b>Myringotomy</b>	Report myringotomy or myringotomy and adenoidectomy. Report toward both measures, myringotomy and tonsillectomy occurring on the same date of service. Report as two separate procedures, two myringotomies performed on the same date of service by the same provider.  Do not report adenoidectomy performed alone.
<b>Tonsillectomy</b>	Report tonsillectomy or tonsillectomy and adenoidectomy. Report toward both measures myringotomy and tonsillectomy occurring on the same date of service.  Do not report adenoidectomy performed alone.
<b>Nonobstetric D&amp;C</b>	Report nonobstetric D&C.  Do not report obstetric D&C or termination of pregnancy D&C.  Do not report a nonobstetric D&C performed in conjunction with (i.e., on the same date of service as) a hysterectomy. These services are reported under hysterectomy.
<b>Hysterectomy</b>	Report abdominal and vaginal hysterectomy separately.
<b>Cholecystectomy</b>	Report open and closed (laparoscopic) cholecystectomy separately.
<b>Back surgery</b>	Report all spinal fusion and disc surgery, including codes relating to laminectomy with and without disc removal.
<b>Coronary angioplasty (PTCA)</b>	Report all PTCAs performed separately. Do not report angioplasty or cardiac catheterization performed in conjunction with (i.e., on the same date of service as) a CABG in the angioplasty or the cardiac catheterization rate; report only the CABG.
<b>Cardiac catheterization</b>	Report all cardiac catheterizations performed separately. Do not report a cardiac catheterization performed in conjunction with (i.e., on the same date of service as) an angioplasty in the cardiac catheterization rate; report only the angioplasty.  Do not report angioplasty or cardiac catheterization performed in conjunction with (i.e., on the same date of service as) a CABG in the angioplasty or the cardiac catheterization rate; report only the CABG.
<b>CABG</b>	Coronary artery bypass graft. Report each CABG only once for each date of service per patient, regardless of the number of arteries involved or the number or types of grafts involved.  Do not report angioplasty or cardiac catheterization performed in conjunction with (i.e., on the same date of service as) a CABG in the angioplasty or the cardiac catheterization rate; report only the CABG.
<b>Prostatectomy</b>	Report the number of prostatectomies.
<b>Reduction of fracture of femur</b>	Report the number of reductions of fracture of the femur.

---

**Total hip replacement** Report the number of total hip replacements.

**Total knee replacement** Report the number of total knee replacements.

**Partial excision of large intestine** Report the number of partial excisions of the large intestine.

**Carotid endarterectomy** Report the number of carotid endarterectomies.

**Mastectomy** Report the number of mastectomies. Report bilateral mastectomy procedures as two procedures, even if performed on the same date.

**Lumpectomy** Report the number of lumpectomies. Report multiple lumpectomies on the same date of service as one lumpectomy procedure per patient.

**Table FSP-A: Codes to Identify Selected Procedures**

Description	CPT	HCPCS	ICD-9-CM Procedure	MS—DRG
Myringotomy or myringotomy with adenoidectomy	69433, 69436		20.01	
Tonsillectomy or tonsillectomy with adenoidectomy	42820, 42821, 42825, 42826, 42860		28.2-28.4	
Nonobstetric dilation and curettage	58120		69.09	
Hysterectomy (abdominal)	51925, 58150, 58152, 58180, 58200, 58210, 58240, 58541-58544, 58548, 58570-58573, 58951, 58953, 58954, 58956, 59135, 59525		68.3, 68.4, 68.6, 68.8, 68.9	
Hysterectomy (vaginal)	58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294, 58550, 58552-58554		68.5, 68.7	
Cholecystectomy (open)	47600, 47605, 47610, 47612, 47620		51.21, 51.22	
Cholecystectomy (closed/laparoscopic)	47562-47564		51.23, 51.24	
Back surgery	22220, 22222, 22224, 22532, 22533, 22548, 22554, 22556, 22558, 22590, 22595, 22600, 22610, 22612, 22630, 22830, 22856, 22857, 22861, 22862, 22864, 22865, 63001, 63003, 63005, 63011, 63012, 63015-63017, 63020, 63030, 63040, 63042, 63045-63047, 63050, 63051, 63055, 63056, 63064, 63075, 63077, 63081, 63085, 63087, 63090, 63101-63102	S2348, S2350	03.02, 03.09, 80.5, 81.0, 81.3, 81.6, 84.6, 84.8	453-460
Coronary angioplasty (PTCA)	92980, 92982, 92995		00.66, 36.06, 36.07, 36.09	246-251
Cardiac catheterization	93501, 93510, 93511, 93514, 93524, 93526-93529, 93539-93545		37.21-37.23, 88.55-88.57	216-218, 222-225, 286, 287
CABG	33510-33514, 33516-33519, 33521-33523, 33533-33536	S2205-S2209	36.1, 36.2	231-236

**Table FSP-A: Codes to Identify Selected Procedures (continued)**

Description	CPT	HCPCS	ICD-9-CM Procedure	MS—DRG
Prostatectomy	52601, 52612, 52614, 52620, 52630, 52647, 52648, 55801, 55810, 55812, 55815, 55821, 55831, 55840, 55842, 55845, 55866		60.2-60.6	665-667
Reduction of fracture of femur	27230, 27232, 27235, 27236, 27238, 27240, 27244-27246, 27248, 27267-27269		79.05, 79.15, 79.25, 79.35	
Total hip replacement	27130, 27132, 27134		00.70, 81.51, 81.53	
Total knee replacement	27446, 27447, 27486, 27487		00.80, 81.54, 81.55	
Partial excision of large intestine	44140, 44141, 44143-44147, 44160, 44204-44208		45.7	
Carotid endarterectomy	34001, 35001, 35301, 35501, 35601		38.12	
Mastectomy	<b>Bilateral:</b> 19303-19307 with a modifier .50 code <b>Unilateral:</b> 19303-19307		<b>Bilateral:</b> 85.42, 85.44, 85.46, 85.48 <b>Unilateral:</b> 85.41, 85.43, 85.45, 85.47	<b>NA</b> (no MS-DRGs are specific to total mastectomy)
Lumpectomy	19120, 19125, 19301, 19302		85.2	584, 585

**Table FSP-1: Frequency of Selected Procedures**

Member Months			
Age	Male	Female	Total
0-4			_____
0-9			_____
5-19			_____
10-19			_____
15-44		_____	
20-44	_____	_____	
30-64	_____		
45-64	_____	_____	

Procedure	Age	Sex	Number of Procedures	Procedures/ 1,000 Member Months
Myringotomy	0-4	Male and Female	_____	_____
	5-19		_____	_____
Tonsillectomy	0-9	Male and Female	_____	_____
	10-19		_____	_____
D&C	15-44	Female	_____	_____
	45-64		_____	_____
Hysterectomy, abdominal	15-44	Female	_____	_____
	45-64		_____	_____
Hysterectomy, vaginal	15-44	Female	_____	_____
	45-64		_____	_____
Cholecystectomy, open	30-64	Male	_____	_____
	15-44 45-64	Female	_____	_____
				_____
Cholecystectomy, closed (laparoscopic)	30-64	Male	_____	_____
	15-44 45-64	Female	_____	_____
				_____
Back surgery	20-44	Male	_____	_____
		Female	_____	_____
	45-64	Male	_____	_____
		Female	_____	_____
Mastectomy	15-44	Female	_____	_____
	45-64		_____	_____
Lumpectomy	15-44	Female	_____	_____
	45-64		_____	_____

**Table FSP-2: Frequency of Selected Procedures**

Member Months			
Age	Male	Female	Total
0-4			
0-9			
5-19			
10-19			
15-44			
20-44			
30-64			
45-64			
65+			

Procedure	Age	Sex	Number of Procedures	Procedures/ 1,000 Member Years
Myringotomy	0-4	Male and Female		
	5-19			
Tonsillectomy	0-9	Male and Female		
	10-19			
D&C	15-44	Female		
	45-64			
Hysterectomy, abdominal	15-44	Female		
	45-64			
	65+			
Hysterectomy, vaginal	15-44	Female		
	45-64			
	65+			
Cholecystectomy, open	30-64	Male		
	15-44	Female		
	45-64	Male		
65+			Female	
Cholecystectomy, closed (laparoscopic)	30-64	Male		
	15-44	Female		
	45-64	Male		
65+			Female	



**Table FSP-2: Frequency of Selected Procedures (continued)**

Procedure	Age	Sex	Number of Procedures	Procedures/ 1,000 Member Years
Back surgery	20-44	Male	_____	_____
		Female	_____	_____
	45-64	Male	_____	_____
		Female	_____	_____
	65+	Male	_____	_____
		Female	_____	_____
PTCA	45-64	Male	_____	_____
		Female	_____	_____
	65+	Male	_____	_____
		Female	_____	_____
Cardiac catheterization	45-64	Male	_____	_____
		Female	_____	_____
	65+	Male	_____	_____
		Female	_____	_____
CABG	45-64	Male	_____	_____
		Female	_____	_____
	65+	Male	_____	_____
		Female	_____	_____
Prostatectomy	45-64	Male	_____	_____
	65+		_____	_____
Mastectomy	15-44	Female	_____	_____
	45-64		_____	_____
	65+		_____	_____
Lumpectomy	15-44	Female	_____	_____
	45-64		_____	_____
	65+		_____	_____

**Table FSP-3: Frequency of Selected Procedures**

Member Months		
Age	Male	Female
<65	_____	_____
65-74	_____	_____
75-84	_____	_____
85+	_____	_____

Procedure	Age	Sex	Number of Procedures	Procedures/ 1,000 Member Years
CABG	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
PTCA	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
Cardiac catheterization	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____

**Table FSP-3: Frequency of Selected Procedures (continued)**

Procedure	Age	Sex	Number of Procedures	Procedures/ 1,000 Member Years
Carotid endarterectomy	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
Cholecystectomy, open	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
Cholecystectomy, closed (laparoscopic)	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
Back surgery	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____

**Table FSP-3: Frequency of Selected Procedures (continued)**

Procedure	Age	Sex	Number of Procedures	Procedures/ 1,000 Member Years
Hysterectomy (abdominal)	<65	Female	_____	_____
	65-74		_____	_____
	75-84		_____	_____
	85+		_____	_____
Hysterectomy (vaginal)	<65	Female	_____	_____
	65-74		_____	_____
	75-84		_____	_____
	85+		_____	_____
Prostatectomy	<65	Male	_____	_____
	65-74		_____	_____
	75-84		_____	_____
	85+		_____	_____
Reduction of fracture of femur	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
Total hip replacement	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
Total knee replacement	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____

**Table FSP-3: Frequency of Selected Procedures (continued)**

Procedure	Age	Sex	Number of Procedures	Procedures/ 1,000 Member Years
Partial excision of large intestine	<65	Male	_____	_____
		Female	_____	_____
	65-74	Male	_____	_____
		Female	_____	_____
	75-84	Male	_____	_____
		Female	_____	_____
	85+	Male	_____	_____
		Female	_____	_____
Mastectomy	<65	Female	_____	_____
	65-74		_____	_____
	75-84		_____	_____
	85+		_____	_____
Lumpectomy	<65	Female	_____	_____
	65-74		_____	_____
	75-84		_____	_____
	85+		_____	_____

---

## ***Inpatient Utilization—General Hospital/Acute Care (IPU)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Removed CMS-DRGs from Tables IPU-A and IPU-B.

Added ICD-9-CM Diagnosis codes 678–679 to Table IPU-B “Maternity” description.

### **Description**

This measure summarizes utilization of acute inpatient care and services in the following categories.

Total inpatient

Medicine

Surgery

Maternity

### **Calculations**

#### **Product lines**

Report the following tables for each applicable product line.

Table IPU-1a Total Medicaid

Table IPU-1b Medicaid/Medicare Dual-Eligibles

Table IPU-1c Medicaid—Disabled

Table IPU-1d Medicaid—Other Low Income

Table IPU-2 Commercial—by Product or Combined HMO/POS

Table IPU-3 Medicare

#### **Member months**

For each product line and table, report all member months for the measurement year. IDSS automatically produces member years data for the commercial and Medicare product lines. Refer to *Specific Instructions for Use of Services Tables* for more information.

Maternity rates are reported per 1,000 male and per 1,000 female total member months in order to capture deliveries as a percentage of the total inpatient discharges.

#### **Discharges**

Refer to the codes in Table IPU-A to identify total inpatient discharges, then use Table IPU-B to separate discharges into *Maternity*, *Surgery* and *Medicine*.

**Table IPU-A: Codes to Identify Total Inpatient Discharges**

Principal ICD-9-CM Diagnosis		MS—DRG
001-289, 317-999, V01-V29, V40-V86	<b>OR</b>	001-013, 020-042, 052-103, 113-117, 121-125, 129-139, 146-159, 163-168, 175-208, 215-264, 280-316, 326-358, 368-395, 405-425, 432-446, 453-517, 533-566, 573-585, 592-607, 614-630, 637-645, 652-675, 682-700, 707-718, 722-730, 734-750, 754-761, 765-770, 774-782, 789-795, 799-804, 808-816, 820-830, 834-849, 853-858, 862-872, 901-909, 913-923, 927-929, 933-935, 939-941, 947-951, 955-959, 963-965, 969-970, 974-977, 981-989, 998, 999

**WITH**

UB Type of Bill		
11x, 12x, 41x, 84x	<b>OR</b>	Any acute inpatient facility code

- Days** Count all days associated with the identified discharges. Report days for total inpatient, maternity, surgery and medicine.
- ALOS** Refer to the *Specific Instructions for Use of Services Tables* for the formula. Calculate average length of stay for total inpatient, medicine, surgery and maternity.
- Total inpatient** Use Table IPU-A to identify acute inpatient discharges.  
The Total Inpatient should be the sum of the three categories (*Medicine, Surgery, Maternity*) and any MS-DRGs defined as “principal diagnosis invalid as discharge diagnosis or ungroupable.”  
Use Table IPU-B to identify maternity, surgery and medicine inpatient discharges.
- Medicine** DRGs are the preferred method to identify medical discharges. An organization that uses ICD-9-CM Diagnosis codes must identify total acute inpatient discharges, remove maternity related discharges and remove all discharges accompanied by UB revenue code 036X.  
Report MS-DRGs 789–795 under *Medicine* if newborn care is rendered after the baby has been discharged home from delivery and is subsequently rehospitalized.
- Surgery** DRGs are the preferred method to identify surgical discharges. An organization that uses ICD-9-CM Diagnosis codes must identify total inpatient, remove maternity-related discharges and include the remaining discharges accompanied by UB revenue code 036X.
- Maternity** Include birthing center deliveries in this measure and count them as one day of stay. Refer to Table IPU-B for ICD-9-CM Principal Diagnosis codes, UB Revenue, UB Type of Bill and DRG codes.

**Table IPU-B: Codes to Identify Medicine, Surgery and Maternity Inpatient Discharges**

Description	Principal ICD-9-CM Diagnosis	UB Revenue	UB Type of Bill	MS—DRG
Medicine	Total—Maternity—Surgery			052-103, 121-125, 146-159, 175-208, 280-316, 368-395, 432-446, 533-566, 592-607, 637-645, 682-700, 722-730, 754-761, 789-795, 808-816, 834-849, 862-872, 913-923, 933-935, 947-951, 963-965, 974-977
Surgery	Total—Maternity*	036x		001-013, 020-042, 113-117, 129-139, 163-168, 215-264, 326-358, 405-425, 453-517, 573-585, 614-630, 652-675, 707-718, 734-750, 799-804, 820-830, 853-858, 901-909, 927-929, 939-941, 955-959, 969-970, 981-989
Maternity	630-676, 678-679, V24.0	0112, 0122, 0132, 0142, 0152, 0720-0722, 0724	84x	765-770, 774-782

\* If the organization uses ICD-9-CM Diagnosis codes to report this measure, all discharges reported in the *Surgery* group must be in conjunction with UB revenue code 036x.

**Exclusions (required)**

The measure does not include mental health or chemical dependency services. Exclude claims and encounters that contain any of the following codes.

**Table IPU-C: Codes to Identify Exclusions**

Principal ICD-9-CM Diagnosis	WITH	Secondary ICD-9-CM Diagnosis
960-979		291-292, 303-305

**Table IPU-1: Inpatient Utilization—General Hospital/Acute Care**

Age	Member Months
<1	_____
1-9	_____
10-19	_____
20-44	_____
45-64	_____
65-74	_____
75-84	_____
85+	_____
Unknown	_____
<b>Total:</b>	_____



**Table IPU-1: Inpatient Utilization—General Hospital/Acute Care (continued)**

Age	Discharges	Discharges/1,000 Member Months	Days	Days/1,000 Member Months	Average Length of Stay
<b>Total Inpatient</b>					
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____
<b>Medicine</b>					
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____
<b>Surgery</b>					
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____

**Table IPU-1: Inpatient Utilization—General Hospital/Acute Care (continued)**

Age	Discharges	Discharges/1,000 Member Months	Days	Days/1,000 Member Months	Average Length of Stay
<b>Maternity*</b>					
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____

\*The maternity category is calculated using member months for members 10–64 years.

**Table IPU-2/3: Inpatient Utilization—General Hospital/Acute Care**

Age	Member Months
<1	_____
1-9	_____
10-19	_____
20-44	_____
45-64	_____
65-74	_____
75-84	_____
85+	_____
Unknown	_____
<b>Total:</b>	_____

Age	Discharges	Discharges/1,000 Member Years	Days	Days/1,000 Member Years	Average Length of Stay
<b>Total Inpatient</b>					
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____

**Table IPU-2/3: Inpatient Utilization—General Hospital/Acute Care (continued)**

Age	Discharges	Discharges/1,000 Member Years	Days	Days/1,000 Member Years	Average Length of Stay
<b>Medicine</b>					
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____
<b>Surgery</b>					
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____
<b>Maternity</b>					
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____

---

## ***Ambulatory Care (AMB)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Added CPT code 99461 to Table AMB-A.

#### **Description**

This measure summarizes utilization of ambulatory care in the following categories.

Outpatient Visits

ED Visits

Ambulatory Surgery/Procedures

Observation Room Stays

#### **Calculations**

##### **Product lines**

Report the following tables for each applicable product line.

Table AMB-1a	Total Medicaid
Table AMB-1b	Medicaid/Medicare Dual-Eligibles
Table AMB-1c	Medicaid—Disabled
Table AMB-1d	Medicaid—Other Low Income
Table AMB-2	Commercial—by Product or Combined HMO/POS
Table AMB-3	Medicare

##### **Member months**

For each product line and table, report all member months for the measurement year. IDSS automatically produces member years data for the commercial and Medicare product lines. Refer to *Specific Instructions for Use of Services Tables* for more information.

##### **Counting multiple services**

*For ambulatory surgery/procedures* that occur on the same date of service as an ED visit, report as a single ED visit.

*For Observation Room visits* that occur on the same date of service as an ambulatory surgery/procedure, report as a single ambulatory surgery/procedure.

*For Observation Room visits* that occur on the same date of service as an ED visit, report as a single ED visit.

*For all other combinations of multiple ambulatory services* falling in different categories on the same day, report each service that meets the criteria in the appropriate category.

**Outpatient visits** Use Table AMB-A to identify outpatient visits. Count each occurrence of the CPT codes listed in Table AMB-A if rendered by different practitioners (a CPT code may count more than once on the same date of service if rendered by different practitioners).

Report services without regard to practitioner type, training or licensing. Include office-based surgical procedures (use the Ambulatory Surgery/Procedures codes in Table AMB-C and include surgeries conducted at the practitioner’s office).

**Table AMB-A: Codes to Identify Outpatient Visits**

Description	CPT	UB Revenue
Office or other outpatient visits	99201-99205, 99211-99215, 99241-99245	051x, 052x, 0982, 0983
Home visits	99341-99345, 99347-99350	
Nursing facility care	99304-99310, 99315, 99316, 99318	
Domiciliary or rest home care	99324-99328, 99334-99337	
Preventive medicine	99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99420, 99429	
Newborn care	99432, 99461	
Ophthalmology and optometry	92002, 92004, 92012, 92014	

**ED visits** Use Table AMB-B to identify ED visits. Count once each visit to an ED that does not result in an inpatient stay, regardless of the intensity or duration of the visit. Count multiple ED visits on the same date of service as one visit.

**Table AMB-B: Codes to Identify ED Visits**

CPT	UB Revenue
99281-99285	045x, 0981

OR

CPT	WITH	POS
10040-69979		23

**Ambulatory surgery/procedures** Use Table AMB-C to identify ambulatory surgeries/procedures. Identify encounters using Option A or Option B. Option A is the preferred method for this measure, though when necessary, the organization should use Option A and Option B.

Report only ambulatory surgeries/procedures performed at a hospital outpatient facility or at a free-standing surgery center. Do not report office-based surgeries/procedures in this category; report them under *Outpatient Visits*. Count multiple ambulatory surgeries/procedures on the same date of service as one ambulatory surgery/procedure.

## Table AMB-C: Codes to Identify Ambulatory Surgery/Procedures

### Option A

CPT		POS
All codes included in the CMS 2009 ASC Approved HCPCS Codes and Payment Rates file* and 92953, 92970, 92971, 92975, 92980, 92982, 92986, 92990, 92992, 92993, 92995, 92996, 93501-93533, 93600-93652	<i>WITH</i>	22, 24

### Option B

ICD-9-CM Procedure		UB Revenue		UB Type of Bill
01-86, 88.4, 88.5, 98.5	<i>WITH</i>	0320, 0321, 0323, 036x, 0480, 0481, 049x, 075x, 079x	<i>WITH</i>	13x, 83x

\*The CMS 2009 ASC Approved HCPCS Codes and Payment Rates files are available on the CMS Web site (<http://www.cms.hhs.gov/ASCPayment/>) under the *Addenda Updates* section. Use the file that was valid at the end of the measurement year.

**Observation Room stays** Use Table AMB-D to identify Observation Room stays.

Count once, each observation visit that does not result in an inpatient stay, regardless of the intensity or duration of the visit. Count multiple observation visits on the same date of service as one visit.

## Table AMB-D: Codes to Identify Observation Room Stays

CPT	UB Revenue
99217-99220	0762

## Exclusions (required)

The measure does not include mental health or chemical dependency services. Exclude from all categories claims and encounters that contain any code in Table AMB-E.

## Table AMB-E: Codes to Identify Exclusions

CPT	Principal ICD-9-CM Diagnosis	ICD-9-CM Procedure
90801-90899	290-316	94.26, 94.27, 94.6
Principal ICD-9-CM Diagnosis	<i>WITH</i>	Secondary ICD-9-CM Diagnosis
960-979		291-292, 303-305

## Note

*This measure provides a reasonable proxy for professional ambulatory encounters. It is neither a strict accounting of all ambulatory resources nor an effort to be all-inclusive.*

**Table AMB-1: Ambulatory Care**

Age	Member Months
<1	_____
1-9	_____
10-19	_____
20-44	_____
45-64	_____
65-74	_____
75-84	_____
85+	_____
Unknown	_____
<b>Total:</b>	_____

Age	Outpatient Visits		ED Visits		Ambulatory Surgery/ Procedures		Observation Room Stays	
	Visits	Visits/1,000 Member Months	Visits	Visits/1,000 Member Months	Procedures	Procedures/ 1,000 Member Months	Stays	Stays/ 1,000 Member Months
<1	_____	_____	_____	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____

**Table AMB-2/3: Ambulatory Care**

Age	Member Months
<1	_____
1-9	_____
10-19	_____
20-44	_____
45-64	_____
65-74	_____
75-84	_____
85+	_____
Unknown	_____
<b>Total:</b>	_____

Age	Outpatient Visits		ED Visits		Ambulatory Surgery/ Procedures		Observation Room Stays	
	Visits	Visits/ 1,000 Member Years	Visits	Visits/ 1,000 Member Years	Procedures	Procedures/ 1,000 Member Years	Stays	Stays/ 1,000 Member Years
<1	_____	_____	_____	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____



## ***Inpatient Utilization—Nonacute Care (NON)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

This measure summarizes utilization of nonacute inpatient care in hospice, nursing home, rehabilitation, SNF, transitional care and respite.

#### **Calculations**

- Product lines** Report the following tables for each applicable product line.
- Table NON-1a Total Medicaid
  - Table NON-1b Medicaid/Medicare Dual-Eligibles
  - Table NON-1c Medicaid—Disabled
  - Table NON-1d Medicaid—Other Low Income
  - Table NON-2 Commercial—by Product or Combined HMO/POS
  - Table NON-3 Medicare
- Member months** For each product line and table, report all member months for the measurement year. IDSS automatically produces member years data for the commercial and Medicare product lines. Refer to *Specific Instructions for Use of Services Tables* for more information.
- Discharges** Refer to the codes listed in Table NON-A to report discharges for nonacute inpatient care.

#### **Table NON-A: Codes to Identify Nonacute Care**

Description	UB Revenue	UB Type of Bill
Hospice	0115, 0125, 0135, 0145, 0155, 0650, 0656, 0658, 0659	81x, 82x
SNF	019x	21x, 22x, 28x
Hospital transitional care, swing bed or rehabilitation		18x
Rehabilitation	0118, 0128, 0138, 0148, 0158	
Respite	0655	
Other nonacute care facilities that do not use the UB revenue or type of bill codes for billing (e.g., ICF, SNF)		

- Days** Count all days associated with the identified discharges.
- ALOS** Refer to *Specific Instructions for Use of Services Tables* for the formula.
- Total nonacute inpatient care** Use the codes in Table NON-A to identify nonacute care. Include care from any institution that provides long-term/specialty nonacute care.

**Exclusions (required)**

The measure does not include mental health or chemical dependency services. Exclude claims and encounters that contain any of the following codes.

**Table NON-B: Codes to Identify Exclusions**

CPT	Principal ICD-9-CM Diagnosis	ICD-9-CM Procedure
90801-90899	290-316	94.26, 94.27, 94.6

Principal ICD-9-CM Diagnosis	WITH	Secondary ICD-9-CM Diagnosis
960-979		291-292, 303-305

**Table NON-1: Inpatient Utilization—Nonacute Care**

Age	Member Months
<1	_____
1-9	_____
10-19	_____
20-44	_____
45-64	_____
65-74	_____
75-84	_____
85+	_____
Unknown	_____
<b>Total:</b>	_____

Age	Discharges	Discharges/1,000 Member Months	Days	Days/1,000 Member Months	Average Length of Stay
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____

Current Procedural Terminology © 2009 American Medical Association. All rights reserved.

**Table NON-2/3: Inpatient Utilization—Nonacute Care**

Age	Member Months
<1	_____
1-9	_____
10-19	_____
20-44	_____
45-64	_____
65-74	_____
75-84	_____
85+	_____
Unknown	_____
<b>Total:</b>	_____

Age	Discharges	Discharges/1,000 Member Years	Days	Days/1,000 Member Years	Average Length of Stay
<1	_____	_____	_____	_____	_____
1-9	_____	_____	_____	_____	_____
10-19	_____	_____	_____	_____	_____
20-44	_____	_____	_____	_____	_____
45-64	_____	_____	_____	_____	_____
65-74	_____	_____	_____	_____	_____
75-84	_____	_____	_____	_____	_____
85+	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____

---

## ***Mental Health Utilization (MPT)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Removed CMS-DRGs from Table MPT-B.

Deleted CPT codes 90871, 99261-99263 from Table MPT-C.

Added CPT codes 96102, 96103, 96105, 96119, 96120, 96125 to Table MPT-D.

Deleted CPT code 90871 from Table MPT-D.

### **Description**

The number and percentage of members receiving the following mental health services during the measurement year.

Any services

Inpatient

Intensive outpatient or partial hospitalization

Outpatient or ED

### **Calculations**

#### **Product lines**

Report the following tables for each applicable product line.

Table MPT-1a	Total Medicaid
Table MPT-1b	Medicaid/Medicare Dual-Eligibles
Table MPT-1c	Medicaid—Disabled
Table MPT-1d	Medicaid—Other Low Income
Table MPT-2	Commercial—by Product or Combined HMO/POS
Table MPT-3	Medicare

Count members who received inpatient, intensive outpatient, partial hospitalization, outpatient and ED mental health services in each column. Count members only once in each column, regardless of number of visits.

Count members in the *Any Services* column only if they had at least one inpatient, intensive outpatient, partial hospitalization, outpatient or ED claim/encounter during the measurement year.

*For members who have had more than one encounter, count only the first visit in the measurement year and report the member in the respective age category as of the date of service or discharge.*

#### **Benefit**

Mental health.

---

**Member months**

For each product line and table, report all member months during the measurement year for members with the benefit. IDSS automatically produces member years data for the commercial and Medicare product lines. Refer to *Specific Instructions for Use of Services Tables* for more information.

Because some organizations may offer different benefits for inpatient and outpatient mental health services, denominators in the columns of the member months table may vary. The denominator in the *Any* column should include all members with any mental health benefit.

**Inpatient**

Include inpatient care at either a hospital or treatment facility with mental health as the principal diagnosis.

Use one of the following criteria to identify inpatient services.

An inpatient facility code in conjunction with a principal mental health diagnosis (Table MPT-A), **or**

DRGs (Table MPT-B)

Include discharges associated with residential care and rehabilitation.

**Table MPT-A: Codes to Identify Mental Health Diagnosis**

ICD-9-CM Diagnosis
290, 293-302, 306-316

**Note:** DSM-IV codes mirror ICD-9-CM codes. A health plan that has access only to DSM-IV codes should use and document them. Follow the specifications outlined above for ICD-9-CM codes.

**Table MPT-B: Codes to Identify Inpatient Services**

MS—DRG
876, 880-887; exclude discharges with ICD-9-CM Principal Diagnosis code 317-319

**Intensive outpatient and partial hospitalization**

Report intensive outpatient and partial hospitalization claims/encounters (Table MPT-C) in conjunction with a principal mental health diagnosis (Table MPT-A).

Count services provided by physicians and nonphysician practitioners.

Exclude any services the health plan knows to be inpatient based on type of bill, place of service or location of service codes.

**Table MPT-C: Codes to Identify Intensive Outpatient and Partial Hospitalization Services**

HCPCS		UB Revenue	
<b>Visits identified by the following HCPCS, UB revenue and CPT/POS codes may be with a mental health or non-mental health practitioner (the organization does not need to determine practitioner type).</b>			
H0035, H2001, H2012, S0201, S9480		0905, 0907, 0912, 0913,	
		<i>WITH</i>	<b>POS</b>
90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876			52, 53*
<b>Visits identified by the following CPT/POS codes must be with a mental health practitioner.</b>			
99221-99223, 99231-99233, 99238, 99239, 99251-99255		<i>WITH</i>	52, 53*

\* POS 53 identifies visits that occur in an outpatient, intensive outpatient or partial hospitalization setting. If the organization uses POS 53 for reporting, it must have a system to confirm the visit was in an intensive outpatient or partial hospitalization setting.

**Outpatient and ED**

Report outpatient and ED claims/encounters (Table MPT-D) in conjunction with a principal mental health diagnosis (Table MPT-A). Count services provided by physicians and nonphysicians.

Only include observation stays and ED visits that do not result in an inpatient stay.

**Table MPT-D: Codes to Identify Outpatient and ED Services**

CPT	HCPCS	UB Revenue
<b>Visits identified by the following CPT, HCPCS, UB Revenue and CPT/POS codes may be with a mental health or non-mental health practitioner (the organization does not need to determine practitioner type).</b>		
90804-90815, 96101-96103, 96105, 96110, 96111, 96116, 96118-96120, 96125CPT	G0155, G0176, G0177, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, M0064, S9484, S9485	0513, 0900-0904, 0911, 0914-0919
		<b>POS</b>
90801, 90802, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876	<i>WITH</i>	03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 23, 33, 49, 50, 53*, 71, 72
CPT	UB Revenue	
<b>Visits identified by the following CPT and UB Revenue codes must be with a mental health practitioner.</b>		
98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99281-99285, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99420, 99510	045x, 0510, 0515-0517, 0519-0523, 0526-0529, 0762, 077x, 0981-0983	

\* POS 53 identifies visits that occur in an outpatient, intensive outpatient or partial hospitalization setting. If the organization uses POS 53 for reporting, it must have a system to confirm the visit was in an outpatient setting.

**Table MPT-1/2/3: Mental Health Utilization**

Member Months (Any Services)				Member Months (Inpatient)		
Age	Male	Female	Total	Male	Female	Total
0-12	_____	_____	_____	_____	_____	_____
13-17	_____	_____	_____	_____	_____	_____
18-64	_____	_____	_____	_____	_____	_____
65+	_____	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____	_____
Member Months (Intensive Outpatient/Partial Hospitalization)				Member Months (Outpatient/ED)		
Age	Male	Female	Total	Male	Female	Total
0-12	_____	_____	_____	_____	_____	_____
13-17	_____	_____	_____	_____	_____	_____
18-64	_____	_____	_____	_____	_____	_____
65+	_____	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____	_____

Age	Sex	Any Services		Inpatient		Intensive Outpatient/Partial Hospitalization		Outpatient/ED	
		Number	Percent	Number	Percent	Number	Percent	Number	Percent
0-12	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
13-17	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
18-64	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
65+	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Unknown	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Total	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____

---

## ***Identification of Alcohol and Other Drug Services (IAD)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Removed CMS-DRGs from Table IAD-B.

Deleted CPT codes 90871, 99261-99263 from Table IAD-C.

Added CPT codes 96102, 96103, 96105, 96119, 96120, 96125 to Table IAD-D.

Deleted CPT code 90871 from Table IAD-D.

### **Description**

This measure summarizes the number and percentage of members with an alcohol and other drug (AOD) claim who received the following chemical dependency services during the measurement year.

Any services

Inpatient

Intensive outpatient or partial hospitalization

Outpatient or ED

### **Calculations**

#### **Product lines**

Report the following tables for each applicable product line.

Table IAD-1a	Total Medicaid
Table IAD-1b	Medicaid/Medicare Dual-Eligibles
Table IAD-1c	Medicaid—Disabled
Table IAD-1d	Medicaid—Other Low Income
Table IAD-2	Commercial—by Product or Combined HMO/POS
Table IAD-3	Medicare

Count members who received inpatient, intensive outpatient, partial hospitalization, outpatient and ED chemical dependency services in each column. Count members in each column only once, regardless of number of visits.

Count members in the *Any Services* column only if they had at least one inpatient, intensive outpatient, partial hospitalization, outpatient or ED claim/encounter during the measurement year.

For members who had more than one encounter, count only the first visit in the measurement year and report the member in the respective age category as of the date of service or discharge.

#### **Benefit**

Chemical dependency.



**Member months** For each product line, report all member months during the measurement year for members with the benefit. IDSS automatically produces member years data for the commercial and Medicare product lines. Refer to *Specific Instructions for Use of Services Tables* for more information.

Because some organizations may offer different benefits for inpatient and outpatient chemical dependency services, denominators in the columns of the member months table may vary. The denominator in the *Any* column should include all members with any chemical dependency benefit.

**Inpatient** Include inpatient care, including inpatient detoxification, at either a hospital or treatment facility with any diagnosis of chemical dependency.

Use one of the following criteria to identify inpatient services.

An inpatient facility code in conjunction with any diagnosis of chemical dependency (Table IAD-A), **or**

A code in Table IAD-B

Include discharges associated with residential care and rehabilitation.

**Table IAD-A: Codes to Identify Chemical Dependency Diagnosis**

ICD-9-CM Diagnosis
291-292, 303-304, 305.0, 305.2-305.9, 535.3, 571.1

**Table IAD-B: Codes to Identify Inpatient Services**

ICD-9-CM Procedure	MS—DRG
94.6x <i>WITH</i> an inpatient facility code	894-897

**Intensive outpatient and partial hospitalization** Report intensive outpatient and partial hospitalization claims/encounters (Table IAD-C) in conjunction with any chemical dependency diagnosis (Table IAD-A).  
Count services provided by physician and nonphysician practitioners.

Intensive outpatient and partial hospitalization are reported separate from outpatient and ED services because these programs represent a significant number of services rendered.

Exclude any services the health plan knows to be *inpatient* based on type of bill, place of service or location of service codes.

**Table IAD-C: Codes to Identify Intensive Outpatient and Partial Hospitalization Services**

HCPCS		UB Revenue	
Visits identified by the following HCPCS, UB revenue and CPT/POS codes may be with a mental health or non-mental health practitioner (i.e., the organization does not need to determine practitioner type).			
H0015, H0035, H2001, H2012, S0201, S9480		0905-0907, 0912, 0913	
CPT		WITH	POS
90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255			52, 53*

\*POS 53 identifies visits that occur in an outpatient, intensive outpatient or partial hospitalization setting. If the organization uses POS 53 for reporting, it must have a system to confirm the visit was in an intensive outpatient or partial hospitalization setting.

**Outpatient and ED** Report outpatient and ED claims/encounters (Table IAD-D) in conjunction with any chemical dependency diagnosis (Table IAD-A).

Count services provided by physicians and nonphysician practitioners.

Only include observation stays and ED visits that do not result in an inpatient stay.

**Table IAD-D: Codes to Identify Outpatient and ED Services**

CPT	HCPCS	UB Revenue
Visits identified by the following CPT, HCPCS, UB revenue and CPT/POS codes may be with a mental health or non-mental health practitioner (i.e., the organization does not need to determine practitioner type).		
90804-90815, 96101-96103, 96105, 96110, 96111, 96116, 96118-96120, 96125, 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99281-99285, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99408, 99409, 99411, 99412, 99420, 99510	G0155, G0176, G0177, G0396, G0397, H0001, H0002, H0004, H0005, H0007, H0012-H0014, H0016, H0020, H0022, H0031, H0034, H0036, H0037, H0039, H0040, H0049, H0050, H2000, H2010, H2011, H2013-H2020, H2035, H2036, M0064, S9475, S9484, S9485, T1006, T1012	045x, 0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0762, 077x, 0900-0904, 0911, 0914-0919, 0944, 0945, 0981-0983
CPT	WITH	POS
90801, 90802, 90845, 90847, 90849, 90853, 90857, 90862, 90870, 90875, 90876		03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 23, 33, 49, 50, 53*, 57, 71, 72

\* POS 53 identifies visits that occur in an outpatient, intensive outpatient or partial hospitalization setting. If the organization uses POS 53 for reporting, it must have a system to confirm the visit was in an outpatient setting.



**Table IAD-1/2/3: Identification of Alcohol and Other Drug Services**

Member Months (Any Services)				Member Months (Inpatient)		
Age	Male	Female	Total	Male	Female	Total
0-12	_____	_____	_____	_____	_____	_____
13-17	_____	_____	_____	_____	_____	_____
18-24	_____	_____	_____	_____	_____	_____
25-34	_____	_____	_____	_____	_____	_____
35-64	_____	_____	_____	_____	_____	_____
65+	_____	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____	_____
Member Months (Intensive Outpatient/Partial Hospitalization)				Member Months (Outpatient/ED)		
Age	Male	Female	Total	Male	Female	Total
0-12	_____	_____	_____	_____	_____	_____
13-17	_____	_____	_____	_____	_____	_____
18-24	_____	_____	_____	_____	_____	_____
25-34	_____	_____	_____	_____	_____	_____
35-64	_____	_____	_____	_____	_____	_____
65+	_____	_____	_____	_____	_____	_____
Unknown	_____	_____	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____	_____	_____

Age	Sex	Any Services		Inpatient		Intensive Outpatient/Partial Hospitalization		Outpatient/ED	
		Number	Percent	Number	Percent	Number	Percent	Number	Percent
0-12	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
13-17	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
18-24	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
25-34	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____

**Table IAD-1/2/3: Identification of Alcohol and Other Drug Services (continued)**

Age	Sex	Any Services		Inpatient		Intensive Outpatient/Partial Hospitalization		Outpatient/ED	
		Number	Percent	Number	Percent	Number	Percent	Number	Percent
35-64	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
65+	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Unkno wn	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Total	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____

---

## Outpatient Drug Utilization (ORX)

---

### SUMMARY OF CHANGES TO HEDIS 2010

---

No changes to this measure.

#### Description

This measure summarizes data on outpatient utilization of drug prescriptions, stratified by age, during measurement year. The following data are reported.

Total cost of prescriptions

Average cost of prescriptions PMPM

Total number of prescriptions

Average number of prescriptions PMPY

#### Calculations

**Product lines** Report the following tables for each applicable product line.

Table ORX-1a	Total Medicaid
Table ORX-1b	Medicaid/Medicare Dual-Eligibles
Table ORX-1c	Medicaid—Disabled
Table ORX-1d	Medicaid—Other Low Income
Table ORX-2	Commercial—by Product or Combined HMO/POS
Table ORX-3	Medicare

**Age** Age as of the date the prescription is dispensed.

**Benefit** Pharmacy.

**Member months** Report all member months for the measurement year for members with the benefit. Refer to *Specific Instructions for Use of Services Tables*.

**Prescription** One 30-day (or less) supply of pharmaceuticals.\* Supplies (e.g., syringes) do not count toward this measure.

*\*To calculate dispensing events for prescriptions longer than 30 days, divide the days supply by 30 and round up to convert. For example, a 100-day prescription is equal to 4 dispensing events ( $100/30 = 3.33$ , rounded up to 4).*

**Formulas** **Total cost of prescriptions** = Discounted ingredient cost + dispensing or professional fees + administrative fees – formulary or other rebates.

The plan may be responsible for part of the total prescription cost and the member may be responsible for the remainder of the total cost. The total cost of prescriptions may be alternatively calculated as:

Total cost of prescriptions = plan cost + member cost.

---

**Average total cost of prescriptions per member per month** = [Discounted ingredient costs (before member copayments or deductibles) + dispensing or professional fees + administrative fees – formulary or other rebates]/member months for members with a pharmacy benefit.

Alternatively, average total cost of prescriptions = [plan costs + member costs]/ member months for members with a pharmacy benefit. For example, the average wholesale price for prescription “X” is \$50. The plan negotiates a 20 percent discount with the pharmacy. There is a \$5 dispensing fee and member copay is \$4. Assuming no administrative fees or other rebates or formularies, the discounted ingredient cost is \$40 (\$50 average wholesale price less the 20 percent discount). The *total cost of prescriptions* is \$45 (\$40 discounted ingredient cost + \$5 dispensing fee). While the cost to the member is \$4 and the plan cost is \$41 (for a total of \$45), the breakdown of total prescription cost between the plan and the member is not reported.

**Average total number of prescriptions per member per year** = [Total number of prescriptions/member months for members with a pharmacy benefit] × 12 months.

**Note**

---

*Results of this measure might be affected by differences in pharmacy benefits across health plans.*

*A health plan that dispenses rebates on a lump-sum basis should average the rebates over the total number of prescriptions.*

**Table ORX-1/2/3: Outpatient Drug Utilization**

Age	Member Months
0-9	_____
10-17	_____
18-34	_____
35-49	_____
50-64	_____
65-74	_____
75-84	_____
85+	_____
Unknown	_____
<b>Total:</b>	_____

**Table ORX-1/2/3: Outpatient Drug Utilization (continued)**

<b>Age</b>	<b>Total Cost of Prescriptions</b>	<b>Average Cost of Prescriptions PMPM</b>	<b>Total Number of Prescriptions</b>	<b>Average Number of Prescriptions PMPY</b>
0-9	_____	_____	_____	_____
10-17	_____	_____	_____	_____
18-34	_____	_____	_____	_____
35-49	_____	_____	_____	_____
50-64	_____	_____	_____	_____
65-74	_____	_____	_____	_____
75-84	_____	_____	_____	_____
85+	_____	_____	_____	_____
Unknown	_____	_____	_____	_____
<b>Total:</b>	_____	_____	_____	_____



---

## ***Antibiotic Utilization (ABX)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

This measure summarizes the following data on outpatient utilization of antibiotic prescriptions during the measurement year, stratified by age and gender.

- Total number of antibiotic prescriptions
- Average number of antibiotic prescriptions per member per year (PMPY)
- Total days supplied for all antibiotic prescriptions
- Average days supplied per antibiotic prescription
- Total number of prescriptions for antibiotics of concern
- Average number of prescriptions PMPY for antibiotics of concern
- Percentage of antibiotics of concern for all antibiotic prescriptions
- Average number of antibiotics PMPY reported by drug class:
  - For selected “antibiotics of concern”
  - For all other antibiotics

**Note:** NCQA will provide a list of NDC codes for antibiotic medications on its Web site ([www.ncqa.org](http://www.ncqa.org)) by November 16, 2009.

#### **Measure Attributes**

<b>Product lines</b>	Report the following tables for each applicable product line. <ul style="list-style-type: none"><li>Table ABX-1a Total Medicaid</li><li>Table ABX-1b Medicaid/Medicare Dual-Eligibles</li><li>Table ABX-1c Medicaid—Disabled</li><li>Table ABX-1d Medicaid—Other Low Income</li><li>Table ABX-2 Commercial—by Product or Combined HMO/POS</li><li>Table ABX-3 Medicare</li></ul> Report the information in Tables ABX-1/2/3 (a–c) by age and sex.
<b>Age</b>	Age as of the date the prescription is dispensed.
<b>Benefit</b>	Pharmacy.
<b>Member months</b>	Report all member months for the measurement year for members with the benefit. IDSS automatically produces member years data for all product lines: Medicaid, commercial and Medicare. Refer to <i>Specific Instructions for Use of Services Tables</i> .
<b>Antibiotic prescription</b>	A dispensed antibiotic for any duration.

## Calculations

<b>Total number of antibiotic prescriptions</b>	Total number of all antibiotic prescriptions for the measurement year of any duration of the medication.
<b>Average number of antibiotic prescriptions PMPY</b>	Annual total number of antibiotic prescriptions PMPY = [Total number of antibiotic prescriptions in the year/member months for members with a pharmacy benefit] × 12 months.
<b>Total days supplied for all antibiotic prescriptions</b>	Count the number of days supplied for all antibiotic prescriptions during the measurement year. Organizations should identify the number of days supplied for each antibiotic prescription and sum the days for all antibiotic prescriptions during the measurement year.
<b>Average number of days supplied per antibiotic prescription</b>	Average number of days supplied per prescription = [Total days supplied for all antibiotics prescription in the year/Total number of antibiotic prescriptions in the year].

**Table ABX-A: Antibiotic Medications**

Description	Prescription		
Antibiotics of concern	amoxicillin-clavulanate azithromycin aztreonam clarithromycin cefaclor cefdinir cefditoren cefepime cefixime cefotaxime cefotetan cefoxitin	cefepodoxime cefprozil ceftazidime ceftibuten ceftizoxime ceftriaxone cefuroxime clindamycin chloramphenicol ciprofloxacin dalfopristin-quinupristin gatifloxacin	gemifloxacin levofloxacin lomefloxacin moxifloxacin loracarbef linezolid norfloxacin ofloxacin sparfloxacin telithromycin vancomycin
All other antibiotics	amikacin amoxicillin ampicillin ampicillin-sulbactam carbenicillin cefadroxil cefazolin cephalexin cephradine daptomycin doxycycline erythromycin erythromycin estolate erythromycin ethylsuccinate erythromycin lactobionate erythromycin stearate	erythromycin-sulfisoxazole fosfomycin gentamicin kanamycin lincomycin metronidazole minocycline nafcillin nitrofurantoin nitrofurantoin macrocrystals dicloxacillin oxacillin penicillin G benzathine penicillin G potassium penicillin G procaine penicillin G sodium	penicillin V potassium piperacillin piperacillin-tazobactam rifampin sulfadiazine sulfamethoxazole-trimethoprim sulfasalazine sulfisoxazole tetracycline ticarcillin ticarcillin-clavulanate streptomycin tobramycin trimethoprim

## Calculations for Antibiotics of Concern

**Total number of prescriptions for antibiotics of concern**

Total number of all prescriptions for antibiotics of concern during the measurement year. Table ABX-B contains all antibiotics of concern.

**Average number of prescriptions PMPY for antibiotics of concern**

Annual total number of prescriptions for antibiotics of concern per member per year = [Annual number of prescriptions for antibiotics of concern/member months for members with a pharmacy benefit] × 12 months.

**Percentage of antibiotics of concern of all antibiotic prescriptions**

Percentage of prescriptions for antibiotics of concern of all antibiotic prescriptions = [Total number of prescriptions for antibiotics of concern in the year/Total number of antibiotic prescriptions in the year].

**Table ABX-B: Antibiotics of Concern by NCQA Drug Class**

Description	Prescription		
Quinolone	ciprofloxacin gatifloxacin gemifloxacin	levofloxacin lomefloxacin moxifloxacin	norfloxacin ofloxacin sparfloxacin
Azithromycin and clarithromycin	azithromycin	clarithromycin	
Cephalosporin (second, third, fourth generation)	cefaclor cefdinir cefditoren cefepime cefixime cefotaxime	cefotetan cefoxitin cefepodoxime cefprozil ceftazidime ceftibuten	ceftizoxime ceftriaxone cefuroxime loracarbef
Amoxicillin/clavulanate	amoxicillin-clavulanate		
Ketolide	telithromycin		
Clindamycin	clindamycin		
Miscellaneous antibiotics of concern	aztreonam chloramphenicol	dalfopristin-quinupristin linezolid	vancomycin

## Calculations for Reporting by Drug Class

**Antibiotic utilization by drug class**

For each product line, report the utilization of antibiotic prescriptions by drug class in Tables ABX-1/2/3(b) and (c) for the following.

Antibiotics of concern

All other antibiotics

**Antibiotics of concern**

Report the utilization of antibiotics of concern by the following antibiotic drug classes in Table ABX-1/2/3(b).

Amoxicillin/clavulanate

Azithromycin and clarithromycin

Cephalosporin (includes second-, third- and fourth-generation cephalosporins)

Clindamycin

Ketolide  
 Quinolone  
 Miscellaneous antibiotics of concern

Refer to Table ABX-B for a list of antibiotics of concern and therapeutic classes.

**All other antibiotics** Report the utilization of all other antibiotics by the following antibiotic drug classes in Table ABX-1/2/3(c).

Absorbable sulfonamide  
 Aminoglycoside  
 Cephalosporin (includes first generation only)  
 Lincosamide (other than clindamycin)  
 Macrolide (other than azithromycin and clarithromycin)  
 Penicillin (other than amoxicillin/clavulanate)  
 Tetracycline  
 Miscellaneous antibiotics

Refer to Table ABX-C for a list of all other antibiotics of concern and therapeutic classes.

**Table ABX-C: All Other Antibiotics by NCQA Drug Class**

Description	Prescription	
Absorbable sulfonamide	sulfadiazine sulfamethoxazole-trimethoprim	sulfasalazine sulfisoxazole
Aminoglycoside	amikacin gentamicin	kanamycin streptomycin tobramycin
Cephalosporin (first generation)	cefadroxil cefazolin	cephalexin cephradine
Lincosamide (other than clindamycin)	lincomycin	
Macrolide (other than azithromycin and clarithromycin)	erythromycin erythromycin estolate erythromycin ethylsuccinate	erythromycin lactobionate erythromycin stearate erythromycin-sulfisoxazole
Penicillin (other than amoxicillin/clavulanate)	ampicillin ampicillin-sulbactam amoxicillin carbenicillin dicloxacillin nafcillin oxacillin penicillin G benzathine	penicillin G potassium penicillin G procaine penicillin G sodium penicillin V potassium piperacillin piperacillin-tazobactam ticarcillin ticarcillin-clavulanate
Tetracyclines	doxycycline	minocycline tetracycline
Miscellaneous antibiotics	daptomycin fosfomicin metronidazole nitrofurantoin	nitrofurantoin macrocrystals rifampin trimethoprim

**Table ABX-1/2/3: Plan Member Months**

Member Months			
Age	Male	Female	Total
0-9	_____	_____	_____
10-17	_____	_____	_____
18-34	_____	_____	_____
35-49	_____	_____	_____
50-64	_____	_____	_____
65-74	_____	_____	_____
75-84	_____	_____	_____
85+	_____	_____	_____
Unknown	_____	_____	_____
<b>Total:</b>	_____	_____	_____

**Table ABX-1/2/3(a): Antibiotic Utilization**

Age	Sex	Total Antibiotic Scripts	Average Scripts for Antibiotics PMPY	Total Days Supplied for All Antibiotic Scripts	Average Days Supplied per Antibiotic Scrip	Total Scripts for Antibiotics of Concern	Average Scripts for Antibiotics of Concern PMPY	% of Antibiotics of Concern of All Antibiotic Scripts
0-9	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____%
10-17	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____%
18-34	Male	_____	_____	_____	_____	_____	_____	_____%
	Female	_____	_____	_____	_____	_____	_____	_____%
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____%

**Table ABX-1/2/3(a): Antibiotic Utilization (continued)**

Age	Sex	Total Antibiotic Scripts	Average Scripts for Antibiotics PMPY	Total Days Supplied for All Antibiotic Scripts	Average Days Supplied per Antibiotic Scrip	Total Scripts for Antibiotics of Concern	Average Scripts for Antibiotics of Concern PMPY	% of Antibiotics of Concern of All Antibiotic Scripts
35-49	Male	_____	_____	_____	_____	_____	_____	_____ %
	Female	_____	_____	_____	_____	_____	_____	_____ %
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____ %
50-64	Male	_____	_____	_____	_____	_____	_____	_____ %
	Female	_____	_____	_____	_____	_____	_____	_____ %
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____ %
65-74	Male	_____	_____	_____	_____	_____	_____	_____ %
	Female	_____	_____	_____	_____	_____	_____	_____ %
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____ %
75-84	Male	_____	_____	_____	_____	_____	_____	_____ %
	Female	_____	_____	_____	_____	_____	_____	_____ %
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____ %
85+	Male	_____	_____	_____	_____	_____	_____	_____ %
	Female	_____	_____	_____	_____	_____	_____	_____ %
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____ %
Unknown	Male	_____	_____	_____	_____	_____	_____	_____ %
	Female	_____	_____	_____	_____	_____	_____	_____ %
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____ %
<b>Total</b>	Male	_____	_____	_____	_____	_____	_____	_____ %
	Female	_____	_____	_____	_____	_____	_____	_____ %
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____ %

**Table ABX-1/2/3(b): Antibiotics of Concern Utilization by Drug Class**

Age	Sex	Total Quinolone Scripts	Avg Scripts for Quinolone PMPY	Total Cephalosporin Scripts	Avg Scripts for Cephalosporin PMPY	Total Azithromycin & Clarithromycin Scripts	Avg Scripts for Azithromycin & Clarithromycin PMPY	Total Amoxicillin/Clavulanate Scripts	Avg Scripts PMPY for Amoxicillin/Clavulanate PMPY	Total Keto-lide Scripts	Avg Scripts for Keto-lide PMPY	Total Clindamycin Scripts	Avg Scripts for Clindamycin PMPY	Total Misc Antibiotics of Concern Scripts	Avg Scripts for Misc Antibiotics of Concern PMPY
0-9	Male														
	Female														
	<b>Total:</b>														
10-17	Male														
	Female														
	<b>Total:</b>														
18-34	Male														
	Female														
	<b>Total:</b>														
35-49	Male														
	Female														
	<b>Total:</b>														
50-64	Male														
	Female														
	<b>Total:</b>														
65-74	Male														
	Female														
	<b>Total:</b>														
75-84	Male														
	Female														
	<b>Total:</b>														

**Table ABX-1/2/3(b): Antibiotics of Concern Utilization by Drug Class (continued)**

Age	Sex	Total Quinolone Scripts	Avg Scripts for Quinolone PMPY	Total Cephalosporin Scripts	Avg Scripts for Cephalosporin PMPY	Total Azithromycin & Clarithromycin Scripts	Avg Scripts for Azithromycin & Clarithromycin PMPY	Total Amoxicillin/Clavulanate Scripts	Avg Scripts PMPY for Amoxicillin/Clavulanate PMPY	Total Keto-lide Scripts	Avg Scripts for Keto-lide PMPY	Total Clindamycin Scripts	Avg Scripts for Clindamycin PMPY	Total Misc Antibiotics of Concern Scripts	Avg Scripts for Misc Antibiotics of Concern PMPY
85+	Male	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
Unknown	Male	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
<b>Total:</b>	Male	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____



**Table ABX-1/2/3(c): All Other Antibiotic Utilization by Drug Class**

Age	Sex	Total Absorb-able sulfona-mide Scrips	Avg Scrips for Absorb-able sulfona-mide PMPY	Total Amino-glyco-side Scrips	Avg Scrips for Amino-glyco-side PMPY	Total 1st Gen Cephalo-spor-ins Scrips	Avg Scrips for 1st Gen Cephalo-spor-ins PMPY	Total Linco-samide Scrips	Avg Scrips for Linco-samide PMPY	Total Macro-lides (not azith., clar.) Scrips	Avg Scrips for Macro-lides (not azith., clar.) PMPY	Total Peni-cillin Scrips	Avg Scrips for Peni-cillin PMPY	Total Tetra-cycline Scrips	Avg Scrips for Tetra-cycline PMPY	Total Misc. Anti-biotics Scrips	Avg Scrips for Misc. Anti-biotics PMPY
0-9	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
10-17	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
18-34	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
35-49	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
50-64	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
65-74	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
75-84	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____

**Table ABX-1/2/3(c): All Other Antibiotic Utilization by Drug Class (continued)**

Age	Sex	Total Absorb-able sulfona-mide Scrips	Avg Scrips for Absorb-able sulfona-mide PMPY	Total Amino-glyco-side Scrips	Avg Scrips for Amino-glyco-side PMPY	Total 1st Gen Cephalo-spor-ins Scrips	Avg Scrips for 1st Gen Cephalo-spor-ins PMPY	Total Linco-samide Scrips	Avg Scrips for Linco-samide PMPY	Total Macro-lides (not azith., clar.) Scrips	Avg Scrips for Macro-lides (not azith., clar.) PMPY	Total Peni-cillin Scrips	Avg Scrips for Peni-cillin PMPY	Total Tetra-cycline Scrips	Avg Scrips for Tetra-cycline PMPY	Total Misc. Anti-biotics Scrips	Avg Scrips for Misc. Anti-biotics PMPY
85+	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
Un.	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot:</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
<b>Total</b>	M	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	F	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Tot.</b>	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____

---

## **Board Certification (BCR)**

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

Clarified that physicians listed in an organization's directory should be included.

#### **Description**

The percentage of the following physicians whose board certification is *active* as of December 31 of the measurement year.

Family medicine physicians	Pediatricians	Geriatricians
Internal medicine physicians	OB/GYN physicians	Other physician specialists

**Board certification** refers to the various specialty certification programs of the American Board of Medical Specialties and the American Osteopathic Association. The organization should report separately for each product as of December 31 of the measurement year.

**Product lines** Commercial, Medicaid, Medicare (report each product line separately).

**Physicians** This measure applies to independent physicians or group of physicians who provide care for members.

**Organizations must include:** Physicians who have an independent relationship with the organization. An **independent relationship** exists when the organization selects and directs its members to see a specific physician or group of physicians. An independent relationship is not synonymous with an "independent contract." Physicians may contract directly with the organization or indirectly (e.g., physicians contract with an IPA).

Physicians who are listed in the organization's directory.

Physicians who see members outside of the inpatient hospital setting or outside of free-standing facilities.

Physicians who are hospital based and who see members as a result of their independent relationship with the organization; for example:

Anesthesiologists with pain management practices

Hospital-based cardiologists

Hospital-based faculty (provided that they meet the criteria listed above)

**Organizations must exclude:** Physicians who practice exclusively within the inpatient hospital setting and who provide care for members only as a result of members being directed to the hospital; for example:

Pathologists ED physicians

Radiologists Chiropractors

Anesthesiologists Podiatrists

Neonatologists

Physicians who practice exclusively within free-standing facilities and who provide care for members only as a result of members being directed to the facility; for example:

- Mammography centers
- Urgent care centers
- Surgicenters

Dentists who do not provide care under the organization's medical benefits; for example:

- Endodontists
- Oral surgeons
- Periodontists

Dentists who provide primary dental care under a dental plan or rider.

**Categories** Table BCR-A indicates how to identify physicians.

**Table BCR-A: Identifying Physicians**

Product Line	Family Medicine	Internal Medicine	Pediatricians	OB/GYN	Geriatricians	Other Physician Specialists
Commercial	✓	✓	✓	✓	✓	✓
Medicaid	✓	✓	✓	✓	✓	✓
Medicare	✓	✓			✓	✓

## Definitions

**Family medicine physician**

A physician who provides preventive and diagnostic health care services for individuals and families. Report general practitioners in the *Family Medicine* category.

**Internal medicine physician**

A physician who provides long-term and comprehensive care and manages common and complex illness of adolescents, adults and the elderly.

**Pediatrician**

A physician who provides preventive and diagnostic health care services for infants, children and adolescents.

**OB/GYN physician**

A physician who provides medical and surgical care relating to the female reproductive system and associated disorders.

**Geriatrician**

A family medicine or internal medicine physician who has special knowledge of the aging process and special skills in the diagnostic, therapeutic, preventive and rehabilitative aspects of illness in the elderly.

**Other physician specialist**

Any other physician specialist or physician subspecialist not specified above.

---

## Calculation of Board Certification

### Number of physicians in each practice area

Refer to Table BCR-1/2/3. For each product line, identify the number of physicians (with active or inactive board certification) in each practice area, by type and number, with whom the organization contracted as of December 31 of the measurement year.

Physicians are assumed to practice in the clinical area or areas in which they are listed in the organization's *internal* directory or classification system. Physicians listed under more than one category should be counted as many times as they are listed and should be included in each area of practice. For example, a family medicine physician who also practices as a geriatrician should be reported in both the Family Medicine category and the Geriatrician category.

Physicians do not have to be listed in the organization's external provider directory to be included in the measure. Physicians associated with an entity (e.g., vendor) should only be counted if located in areas where the organization is licensed to operate.

### Board certification number

Report the number of physicians in each practice area with active board certification. For example, to be counted as a board-certified geriatrician, a physician must have a specialty certification in geriatric medicine.

A physician with recent board certification who has not completed a residency/fellowship may be counted as board certified.

Confirmation by the appropriate certifying body that a physician is eligible for, and has applied to, a board-certification program, may not be counted as board certification.

### Board certification percentage

For each type of physician, calculate the percentage whose board certification is active by dividing the board certification number by the number of physicians in each practice area.

First, determine the number of areas of specialization and board certification status for each physician; then determine how to count them in the denominator (i.e., number of physicians in each practice area) and numerator (i.e., number of active board-certified physicians) of the calculation.

*A physician with only one specialty who is not board certified in that specialty counts as 1 in the denominator and 0 in the numerator.*

*A physician with only one specialty whose board certification is active in that specialty counts as 1 in the denominator and 1 in the numerator.*

*A physician with more than one specialty counts as 1 in the denominator for each specialty. Count in the numerator the number of specialty areas in which the physician has active board certification.*

**Example** A physician listed under both hematology and medical oncology counts as 2 in the denominator for *Other Physician Specialists*.

A physician whose board certification is active in both hematology and medical oncology counts as 2 in the numerator.

A physician whose board certification is active in only one of these two areas counts as 1 in the numerator.

A physician whose board certification is not active in either area counts as 0 in the numerator.

---

**Note**

---

*The physician definitions for this measure are based on the American Board of Medical Specialties (ABMS) definitions for physician specialties.*

*The numbers in the column Number of Physicians in Each Practice Area may not be the same as the organization's actual number of physicians because some physicians may practice in more than one area and will be counted in the denominators of several percentages.*

**Table BCR-1/2/3: Board Certification**

Type of Physician	Number of Physicians in Each Practice Area	Active Board Certification	
		Number	Percentage
Family medicine			
Internal medicine			
Pediatricians			
OB/GYN			
Geriatricians			
Other physician specialists			

---

## ***Enrollment by Product Line (ENP)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

The total number of members enrolled in the product line, stratified by age and sex.

#### **Calculations**

**Product lines** Report the following tables for each applicable product line, stratified by age and sex.

Table ENP-1a	Total Medicaid
Table ENP-1b	Medicaid/Medicare Dual-Eligibles
Table ENP-1c	Medicaid—Disabled
Table ENP-1d	Medicaid—Other Low Income
Table ENP-2	Commercial—by Product or Combined HMO/POS
Table ENP-3	Medicare

**Member months** For each product line, report all member months for the measurement year. IDSS automatically produces member years data for the commercial and Medicare product lines. Refer to *Specific Instructions for Use of Services Tables* in *Guidelines for Use of Services Measures* for more information.

#### **Medicaid Beneficiary Category Assignment**

The organization assigns Medicaid members to beneficiary categories based on a state-provided list of all payment-rate categories used by that state and the organization in their contract. The state should use the algorithm provided below (described in Categories A–D) to assign each payment-rate category it uses to one of the three beneficiary categories and provide this categorization of rate categories to the organization. The organization should then report Medicaid members using the state's categories. The state should classify beneficiaries according to the hierarchy below, beginning with Category A.

This algorithm addresses variables most likely to influence utilization patterns.

The presence of a Medicare benefit

The presence of a disability

Whether or not there is a restricted benefits package

This last group is not reported separately because of its anticipated small numbers, but it is included in the total count of Medicaid members

---

## Category A

**Total Medicaid—  
Table ENP-1a** Include all Medicaid members enrolled in the organization who receive Medicaid benefits, including those who receive a restricted benefits package smaller in scope than the other Medicaid members enrolled in the same organization. A **restricted benefits package** meets one of the following criteria.

Pregnant women whose Medicaid eligibility is based on poverty-related coverage and whose Medicaid benefits are restricted to services related to pregnancy and other conditions that may complicate pregnancy, **or**

Other individuals whose benefits are limited (e.g., emergency services)

The organization should include individuals in either of these two groups in this category. Total Medicaid also includes the sum of Categories B–D.

Go to Category B if a member does not meet the criteria for Category A.

## Category B

**Medicaid/Medicare  
Eligible—  
Table ENP-1b** Include all Medicaid members (including children) entitled both to the state's full Medicaid benefit for which the organization has contracted and to Medicare Part A or B benefits.

Qualified Medicare Beneficiaries (QMB), other specified low-income Medicare beneficiaries, Qualified Disabled and Working Individuals (QDWI) and Qualified COBRA Continuation Beneficiaries whose Medicaid benefit is limited to the payment of a premium for Medicare or commercial coverage are not included in this category because these individuals do not receive the Medicaid benefit package.

Go to Category C if a member does not meet the criteria for Category B.

## Category C

**Disabled—  
Table ENP-1c** Include all Medicaid members who do not meet the criteria for Category B *and* who receive Medicaid benefits wholly or in part because of physical or mental disability. This category includes supplemental security income (SSI) beneficiaries, SSI-related beneficiaries and other disabled, medically needy beneficiaries.

Go to Category D if a Medicaid beneficiary does not meet the criteria for Category B and does not receive Medicaid based on a disability (Category C).

## Category D

**Other Low  
Income—  
Table ENP-1d** Include all non-disabled, non-Medicare, low-income Medicaid beneficiaries who do not meet the criteria for Category B or Category C.

## Note

---

*NCQA recognizes that most organizations do not serve Medicaid beneficiaries in all categories. Not many serve the few individuals with a restricted benefits package (see Category A).*



---

## Table Instructions

Use Table ENP-1/2/3 to report the organization's enrollment by product line for the most recent calendar year, based on member months.

**Medicaid  
(Tables 1a-1d)**

*Assign Medicaid beneficiaries to Categories A–D based on the definitions provided above.*

*Report by eligibility category the number of member months by age and sex, including subtotals.*

*Calculate the subtotal percentages within each eligibility category by dividing the total subtotal member months into total member months by sex (e.g., [X member months of enrolled Medicaid disabled males, 0–19/Y member months for all Medicaid disabled males, 0–90+ and age unknown] x 100 = Z percent of member months for Medicaid disabled males, 0–19 years of all male Medicaid disabled member months).*

**Commercial  
(Table 2)**

*Report by commercial product line the number of member months by age and sex, including subtotals.*

*Calculate the subtotal percentages within the commercial product line by dividing the total subtotal member months into total member months by sex (e.g., [X member months of enrolled commercial product males, 0–19/Y member months for all commercial product males, 0–90+ and age unknown] x 100 = Z percent of member months for commercial product males, 0–19 years of age of all male commercial product member months).*

**Medicare  
(Table 3)**

*Report by Medicare product line the number of member months by age and sex, including subtotals.*

*Calculate the subtotal percentages within the Medicare product line by dividing the total subtotal member months into total member months by sex (e.g., [X member months of enrolled Medicare males 0-19/Y member months for all Medicare males, 0–90+ and age unknown] x 100 = Z percent of member months for Medicare males, 0–19 years of age of all male Medicare member months).*

**Table ENP-1/2/3: Member Months of Enrollment by Product Line**

Age	Male	Female	Total
<1	_____	_____	_____
1-4	_____	_____	_____
5-9	_____	_____	_____
10-14	_____	_____	_____
15-17	_____	_____	_____
18-19	_____	_____	_____
<b>0-19 Subtotal:</b>	_____	_____	_____
<b>0-19 Subtotal (%):</b>	_____ %	_____ %	_____ %
20-24	_____	_____	_____
25-29	_____	_____	_____
30-34	_____	_____	_____
35-39	_____	_____	_____
40-44	_____	_____	_____
<b>20-44 Subtotal:</b>	_____	_____	_____
<b>20-44 Subtotal (%):</b>	_____ %	_____ %	_____ %
45-49	_____	_____	_____
50-54	_____	_____	_____
55-59	_____	_____	_____
60-64	_____	_____	_____
<b>45-64 Subtotal:</b>	_____	_____	_____
<b>45-64 Subtotal (%):</b>	_____ %	_____ %	_____ %
65-69	_____	_____	_____
70-74	_____	_____	_____
75-79	_____	_____	_____
80-84	_____	_____	_____
85-89	_____	_____	_____
≥90	_____	_____	_____
<b>≥65 Subtotal:</b>	_____	_____	_____
<b>≥65 Subtotal (%):</b>	_____ %	_____ %	_____ %
Age unknown	_____	_____	_____
<b>Total:</b>	_____	_____	_____

## Enrollment by State (EBS)

### SUMMARY OF CHANGES TO HEDIS 2010

No changes to this measure.

#### Description

The number of members enrolled as of December 31 of the measurement year, by state.

**Product lines**            Commercial, Medicaid, Medicare (report each product line separately).

**Anchor Date**            December 31 of the measurement year.

#### Calculation

Calculate enrollment by state using the address on record for members on December 31 of the measurement year, to be determined according to the organization's administrative processes. Report by categories (states and territories) listed in Table EBS-1/2/3. If the member's address is unknown or does not match, report as "Other." If a child's address is not captured, the organization may use the address of the policyholder, parent or caretaker.

Report on total unduplicated membership as of December 31 of the measurement year. If the organization assigns a new member number to members who disenroll and reenroll during the measurement year, it must develop a system to avoid double-counting members.

**Table EBS-1/2/3: Member Enrollment by State**

State	Number	State	Number	State	Number
Alabama	_____	Michigan	_____	Utah	_____
Alaska	_____	Minnesota	_____	Vermont	_____
Arizona	_____	Mississippi	_____	Virginia	_____
Arkansas	_____	Missouri	_____	Washington	_____
California	_____	Montana	_____	West Virginia	_____
Colorado	_____	Nebraska	_____	Wisconsin	_____
Connecticut	_____	Nevada	_____	Wyoming	_____
Delaware	_____	New Hampshire	_____	American Samoa	_____
District of Columbia	_____	New Jersey	_____	Fed. Sts. of Micronesia	_____
Florida	_____	New Mexico	_____	Guam	_____
Georgia	_____	New York	_____	Cmnwlth. of N. Marianas	_____
Hawaii	_____	North Carolina	_____	Puerto Rico	_____
Idaho	_____	North Dakota	_____	Virgin Islands	_____
Illinois	_____	Ohio	_____	Other	_____
Indiana	_____	Oklahoma	_____	<b>Total:</b>	_____
Iowa	_____	Oregon	_____		
Kansas	_____	Pennsylvania	_____		
Kentucky	_____	Rhode Island	_____		
Louisiana	_____	South Carolina	_____		
Maine	_____	South Dakota	_____		
Maryland	_____	Tennessee	_____		
Massachusetts	_____	Texas	_____		

---

## ***Race/Ethnicity Diversity of Membership (RDM)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

An unduplicated count and percentage of members enrolled any time during the measurement year, by race and ethnicity.

**Product lines** Medicaid, Medicare (report each product line separately).

#### **Calculations**

**Table instructions** Report the number and percentage of members by race/ethnicity stratified by gender for the product population. If a member's race or ethnicity is unknown or unavailable from the state agency or CMS, report as "Unknown."

Report on total unduplicated membership during the measurement year. If the organization assigns a new member number to members who disenroll and reenroll during the measurement year, it must develop a system to prevent double counting members.

**Data source** Obtain race and ethnicity data from enrollment information furnished by state Medicaid agencies or by CMS, or supplemented through the organization's own direct data collection from members (e.g., surveys, health risk assessments, disease management registries) or through other available indirect methods (e.g., surname analysis, geocoding). When using CMS as the data source, refer to Table RDM-A for a crosswalk of reporting categories for the RDM measure.

#### **Race Reporting Category Definitions**

**White** People whose origins are in any of the original peoples of Europe, the Middle East or North Africa; including people who indicated their race or races as "White" or wrote in entries such as Irish, German, Italian, Lebanese, Near Easterner, Arab or Polish.

**Black or African American** People whose origins are in any of the Black racial groups of Africa; including people who indicated their race or races as "Black, African Am., or Negro," or wrote in entries such as African American, Afro-American, Nigerian or Haitian.

**American Indian and Alaska Native** People whose origins are in any of the original peoples of North and South America (including Central America), and who maintain tribal affiliation or community attachment; including people who indicated their race or races by marking this category or writing in their principal or enrolled tribe, such as Rosebud, Sioux, Chippewa or Navajo.

**Asian** People who are Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese and "Other Asian," which may include people who are Burmese, Hmong, Pakistani, Thai or from two or more Asian subgroups.

**Native Hawaiian and Other Pacific Islander**

People whose origins are in any of the original peoples of Hawaii, Guam, Samoa or other Pacific Islands; including Carolinian, Fijian, Kosraean, Melanesian, Micronesian, Northern Mariana Islander, Palauan, Papua New Guinean, Ponapean (Pohnpelan), Polynesian, Solomon Islander, Tahitian, Tarawa Islander, Tokelauan, Tongan, Trukese (Chuukese) and Yapese.

**Some Other Race**

People whose race information has been collected but does not fit into any of the other seven race categories. This category includes people who may be Mulatto, Creole and Mestizo or another race not specified in the Census race categories.

**Two or More Races**

People with any combination of races, including "Some Other Race."

**Ethnicity reporting category: Hispanic or Latino**

People of Spanish, Mexican, Puerto Rican or Cuban origins.

**Note:** NCQA encourages collecting and reporting race and Hispanic ethnicity based on categories adapted from the official U.S. census forms established by the U.S. Department of Commerce, Bureau of the Census and defined by the Office of Management and Budget (OMB). Because CMS and state agencies may have varying classification schemes for race and ethnicity, refer to Table RDM-A for HEDIS reporting.

**Table RDM-A: CMS/HEDIS Crosswalk for Reporting Categories**

CMS Category	HEDIS Race	HEDIS Ethnicity
0 = Unknown	Unknown	Unknown
1 = White not Hispanic	White	Not Hispanic
2 = Black not Hispanic	Black	Not Hispanic
3 = Other	Some Other Race	Unknown
4 = Asian	Asian	Unknown
5 = Hispanic	Unknown	Hispanic
6 = North American Native	American Indian/AN	Unknown

**Table RDM-1/3: Race/Ethnicity Diversity of Membership**

<p><b>Data Source:</b> _____</p> <p>Values include NR, CMS, Health plan direct, Surname analysis/geo-coding, Multiple sources, Other</p> <p><b>Total unduplicated membership during the measurement year:</b></p> <p>Number of members: _____</p>
<p>The total unduplicated count of members in the organization is the denominator for calculating the percentages. Each cell represents the proportion of members of a specific race/ethnicity combination of the total unduplicated count of members in the organization.</p>
<p><b>Percentage of members with known race information</b> (sum all the race categories, except Unknown Race, and divide by the number of total unduplicated members during the measurement year): _____</p>
<p><b>Percentage of members with known ethnicity information</b> (sum all the ethnicity categories, except Unknown Ethnicity, and divide by the number of total unduplicated members during the measurement year): _____</p>

**Table RDM-1/3: Race/Ethnicity Diversity of Membership (continued)**

Race	Sex	Hispanic or Latino		Not Hispanic or Latino		Unknown Ethnicity		Total	
		Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage
White	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Black or African-American	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
American-Indian and Alaska Native	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Asian	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Native Hawaiian and Other Pacific Islander	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Some other race	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Two or more races	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Unknown	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	_____
Total	Male	_____	_____	_____	_____	_____	_____	_____	_____
	Female	_____	_____	_____	_____	_____	_____	_____	_____
	<b>Total:</b>	_____	_____	_____	_____	_____	_____	_____	100%

---

## ***Language Diversity of Membership (LDM)***

---

### **SUMMARY OF CHANGES TO HEDIS 2010**

---

No changes to this measure.

#### **Description**

An unduplicated count and percentage of Medicaid and Medicare members enrolled at any time during the measurement year by demand for language interpreter services and spoken language.

**Product lines** Medicaid, Medicare (report each product line separately).

#### **Calculations**

**Table instructions** Report the number and percentage of members by demand for language interpreter services and spoken language stratified by gender for each product population. If a member's interpreter service needs or spoken language is unknown or unavailable from the state agency or CMS, report as "Unknown."

Report total unduplicated membership during the measurement year. If the organization assigns a new member number to members who disenroll and reenroll during the measurement year, it must develop a system to prevent double-counting members.

**Data source** Obtain interpretation service needs and language spoken from enrollment information furnished by state Medicaid agencies or supplemented through data that the organization collected from its members (e.g., surveys, health risk assessments, disease management registries) or through indirect methods (e.g., surname analysis, geo-coding).

**Need/Want Interpreter** Identify individuals who need or want interpreter services; enter this information in Table LDM-1/3. This information should be reported by gender for the organization population.

**Data collection guidance for organizations and agencies.** This information can be gathered through a two-part question to beneficiaries/members:

*(Does the Medicaid or Medicare beneficiary) Do you need or want an interpreter to communicate with a doctor or health care practitioner?*

No

Yes

Unknown (if data are unavailable)

**Spoken Language** Indicate the language spoken by the member at home most of the time; enter this information in Table LDM-1/3. This information should be reported by gender for the organization population.

**Data collection guidance for organizations and agencies.** This information may be gathered through the second part of a two-part question:

*What language (does the beneficiary) do you speak most of the time at home?*

**Note**

The U.S. Census asks Does this person speak a language other than English at home?

**Table LDM-1/3: Language Diversity of Membership**

**Data source:** \_\_\_\_\_  
 Values include NR, CMS, Health plan direct, Surname analysis/geo-coding, Multiple sources, Other  
**Total unduplicated membership during the measurement year:**  
 Number of members \_\_\_\_\_  
 The total unduplicated count of members in the organization is the denominator for calculating the percentages. Each cell represents the proportion of members with identified demand for interpreter services and indicated spoken language of the total unduplicated count of members in the organization.

Demand for Language Interpretation Services	Sex	Number	Percentage
Need/Want an Interpreter    Yes	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
Need/Want an Interpreter    No	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
Need/Want an Interpreter    Unknown	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
<b>Total:</b> (This should sum to 100%)	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
<b>Percentage of members with known interpretation needs:</b> (Sum the Yes/No categories and divide by the number of total unduplicated members during the measurement year )			
English	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
Spanish (or Spanish Creole)	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
Other Indo-European Languages (e.g., French or French Creole, Italian, Portuguese or Portuguese Creole, German, Yiddish, Scandinavian languages, Greek, Russian, Polish, Serbo-Croatian, Armenian, Persian, Gujarathi, Hindi, Urdu)	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
Asian and Pacific Island Languages (e.g., Chinese, Japanese, Korean, Mon-Khmer, Cambodian, Miao, Hmong, Thai, Laotian, Vietnamese, Tagalog and Other Pacific Island languages)	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____



**Table LDM-1/3: Language Diversity of Membership (continued)**

Spoken Language at Home	Sex	Number	Percentage
Other Languages (e.g., Navajo, Other Native North American languages, Hungarian, Arabic, Hebrew, African languages)	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
Unknown	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
<b>Total:</b> (this should sum to 100%)	Male	_____	_____
	Female	_____	_____
	<b>Total:</b>	_____	_____
<b>Percentage of members with known spoken language:</b> (Sum all the language categories, except unknown and divide by the number of total unduplicated members during the measurement year)		_____	_____

**Note**

CMS does not provide language information on its Medicare beneficiaries. Medicare organizations should obtain language data through alternate sources, including surveys and case management and enrollment registries.

---